[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic syndrome\nNote: These terms are synonyms, and both terms refer to the same medical condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that can cause developmental delays, intellectual disability, and distinctive physical features. However, they are distinct conditions and have different underlying genetic causes.\nWeaver syndrome is caused by mutations in the PHLPP2 gene, which codes for a protein involved in the regulation of protein phosphatase 1 (PP1). PP1 is an enzyme that dephosphorylates proteins, which can affect various cellular processes, including cell signaling and protein synthesis. Weaver syndrome is characterized by developmental delays, intellectual disability, seizures, and distinctive physical features such as a small head, narrow eyes, and a flat nasal bridge.\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which codes for a protein involved in the regulation of chromatin remodeling and transcriptional elongation. Sotos syndrome is characterized by developmental delays, intellectual disability, growth retardation, and distinctive physical features such as a large head, coarse facial features, and a high-pitched voice.\nWhile both conditions can cause developmental delays and intellectual disability, the physical features and underlying genetic causes are distinct between Weaver syndrome and Sotos syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both genetic disorders associated with developmental delays and intellectual disability.\n2. Weaver syndrome is caused by mutations in the PHLPP2 gene.\n3. The protein phosphatase 1 (PP1) enzyme is involved in cellular processes affected by Weaver syndrome.\n4. Sotos syndrome is caused by mutations in the NSD1 gene.\n5. The physical features characteristic of Sotos syndrome include a large head, coarse facial features, and a high-pitched voice.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both genetic disorders associated with developmental delays and intellectual disability.",
      "Weaver syndrome is caused by mutations in the PHLPP2 gene.",
      "The protein phosphatase 1 (PP1) enzyme is involved in cellular processes affected by Weaver syndrome.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "The physical features characteristic of Sotos syndrome include a large head, coarse facial features, and a high-pitched voice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PHLPP2 gene.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junkunc et al., 2003) is a database of transcription factor binding site (TFBS) matrices for various organisms. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2003): This was the first release of the JASPAR database, containing TFBS matrices for 12 organisms, including humans, mice, and yeast.\n2. JASPAR Release 2 (2006): This release expanded the number of organisms covered to 30, and included new features such as the ability to search for TFBSs by sequence motif.\n3. JASPAR Release 3 (2010): This release included updates to the matrices for all organisms, as well as the addition of new organisms and new features such as the ability to download the matrices in a more compact format.\n4. JASPAR Release 4 (2012): This release included significant improvements to the matrices, including the use of new computational methods and the incorporation of new experimental data.\n5. JASPAR Release 5 (2015): This release included further updates to the matrices, as well as the addition of new features such as the ability to search for TFBSs in non-coding RNA sequences.\n6. JASPAR Release 6 (2018): This release included significant improvements to the matrices, including the use of new computational methods and the incorporation of new experimental data.\n7. JASPAR Release 7 (2020): This release included further updates to the matrices, as well as the addition of new features such as the ability to search for TFBSs in long non-coding RNA sequences.\n8. JASPAR Release 8 (2022): This is the latest release of the JASPAR database, which includes updates to the matrices and the addition of new organisms and features.\nIt's worth noting that JASPAR also releases specialized versions of the database, such as JASPAR-TFBS, which includes only the TFBS matrices, and JASPAR-ChIP-seq, which includes the ChIP-seq data for a subset of the TFs in the database.",
    "llama-2-7b-chat-hf_fact_raw": "1. The JASPAR database was first released in 2003.\n2. The second release of the JASPAR database in 2006 expanded the number of organisms covered to 30.\n3. JASPAR Release 3 in 2010 introduced the ability to download the matrices in a more compact format.\n4. JASPAR Release 5 in 2015 added the ability to search for transcription factor binding sites in non-coding RNA sequences.\n5. The latest release of the JASPAR database, Release 8, occurred in 2022.",
    "llama-2-7b-chat-hf_fact": [
      "The JASPAR database was first released in 2003.",
      "The second release of the JASPAR database in 2006 expanded the number of organisms covered to 30.",
      "JASPAR Release 3 in 2010 introduced the ability to download the matrices in a more compact format.",
      "JASPAR Release 5 in 2015 added the ability to search for transcription factor binding sites in non-coding RNA sequences.",
      "The latest release of the JASPAR database, Release 8, occurred in 2022."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The latest release of the JASPAR database as of my knowledge cutoff in early 2023 was Release 2020, not Release 8 in 2022.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KRAS-like protein 4 (KP4) gene in some viruses, including the human papillomavirus (HPV). The KP4 protein is a regulatory protein that plays a critical role in the viral life cycle, particularly in the process of viral DNA replication and transcription.\nThe KP4 protein is a transcriptional activator that binds to specific DNA sequences in the viral genome and regulates the expression of downstream genes involved in DNA replication and transcription. It is also involved in the regulation of viral latency, a state in which the virus is not actively replicating but can still persist in the host cells.\nIn addition, the KP4 protein has been shown to interact with host cell factors and modulate the immune response, potentially contributing to the evasion of the host immune system by the virus.\nOverall, the KP4 protein plays a crucial role in the regulation of HPV gene expression and the viral life cycle, and its dysregulation can contribute to the development of HPV-related diseases such as cervical cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KRAS-like protein 4 (KP4) gene in some viruses, including the human papillomavirus (HPV).\n2. KP4 protein plays a critical role in the process of viral DNA replication and transcription.\n3. It functions as a transcriptional activator that binds to specific DNA sequences in the viral genome.\n4. The KP4 protein is involved in the regulation of viral latency.\n5. The KP4 protein is known to interact with host cell factors and can modulate the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KRAS-like protein 4 (KP4) gene in some viruses, including the human papillomavirus (HPV).",
      "KP4 protein plays a critical role in the process of viral DNA replication and transcription.",
      "It functions as a transcriptional activator that binds to specific DNA sequences in the viral genome.",
      "The KP4 protein is involved in the regulation of viral latency.",
      "The KP4 protein is known to interact with host cell factors and can modulate the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by the KRAS-like protein 4 (KP4) gene in viruses including HPV. KP4, or Ustiloxin B, is actually a fungal toxin from Ustilaginoidea virens, and not a viral protein. HPV encodes proteins such as E6 and E7, which are critical in its pathology.\n2. FALSE [correction]: Since KP4 is not a viral protein, it does not play a role in the process of viral DNA replication and transcription. This would apply to viral proteins specific to a particular virus, such as HPV's E1 and E2 proteins which are involved in viral replication and transcription.\n3. FALSE [correction]: The KP4 does not function as a transcriptional activator for viruses since it is not a viral protein but a fungal toxin. In the context of viruses, different proteins, like the aforementioned E2 protein in HPV, would bind to specific DNA sequences.\n4. FALSE [correction]: Again, KP4 is a fungal toxin and not a viral protein, so it is not involved in the regulation of viral latency. Viral latency is associated with proteins from the specific viruses that have the ability to become latent, such as the herpes simplex virus.\n5. UNKNOWN: While this statement could potentially be true for some viral proteins, since KP4 is not associated with viruses, there is no known interaction of KP4 with host cell factors to modulate the immune response in the context of viral infection. Without more context, it's difficult to determine the interactions of KP4 with immune responses in its correct fungal context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-(5-Iodonaphthalene-1-yl)-2-thiazolyl]-2,6-diphenyl-aminocarbonyl-L-tyrosine methyl ester) is a synthetic thyroid hormone analog that has been used in both experimental and clinical studies.\nDITPA is a potent agonist of the thyroid hormone receptor (TR), with high affinity for the TRα subtype. It has been shown to activate various cellular pathways, including the PI3K/Akt signaling pathway, the MAPK/ERK pathway, and the JNK pathway, which are involved in various cellular processes such as cell proliferation, differentiation, and survival.\nIn experimental studies, DITPA has been used to investigate the role of thyroid hormones in various biological processes, including embryonic development, metabolism, and cancer. For example, DITPA has been shown to induce the expression of genes involved in glucose metabolism and to inhibit the growth of cancer cells.\nIn clinical studies, DITPA has been investigated as a potential therapeutic agent for the treatment of various diseases, including cancer, hypothyroidism, and infertility. However, its clinical use is limited due to its potent activity and potential side effects, such as cardiotoxicity and bone toxicity.\nIn summary, DITPA is a thyroid hormone analog that has been used in both experimental and clinical studies to investigate the role of thyroid hormones in various biological processes and to evaluate its potential as a therapeutic agent.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.\n2. It is a potent agonist of the thyroid hormone receptor (TR), especially the TRα subtype.\n3. DITPA has been used experimentally to investigate thyroid hormones' role in embryonic development, metabolism, and cancer.\n4. Clinical studies have explored DITPA's use as a treatment for diseases such as cancer, hypothyroidism, and infertility.\n5. The clinical use of DITPA is limited due to potential side effects like cardiotoxicity and bone toxicity.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.",
      "It is a potent agonist of the thyroid hormone receptor (TR), especially the TRα subtype.",
      "DITPA has been used experimentally to investigate thyroid hormones' role in embryonic development, metabolism, and cancer.",
      "Clinical studies have explored DITPA's use as a treatment for diseases such as cancer, hypothyroidism, and infertility.",
      "The clinical use of DITPA is limited due to potential side effects like cardiotoxicity and bone toxicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Clinical studies have explored DITPA's use as a treatment primarily for conditions like heart failure and high cholesterol; there is no widespread evidence of its use for cancer, hypothyroidism, and infertility.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (COmbinatorial UGer) is a bioinformatics tool used for the prediction of gene regulation from chromatin structure data. It is specifically designed to predict the combinatorial interactions between different types of chromatin modifications (such as histone modifications and DNA methylation) and their impact on gene expression. COUGER uses a machine learning approach to analyze the spatial proximity of different chromatin modifications and predict the regulatory effects of these interactions on gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for COmbinatorial UGer and is a bioinformatics tool.\n2. COUGER is used for the prediction of gene regulation from chromatin structure data.\n3. COUGER is designed to predict interactions between different types of chromatin modifications.\n4. Types of chromatin modifications include histone modifications and DNA methylation.\n5. COUGER utilizes a machine learning approach to analyze spatial proximity of chromatin modifications.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for COmbinatorial UGer and is a bioinformatics tool.",
      "COUGER is used for the prediction of gene regulation from chromatin structure data.",
      "COUGER is designed to predict interactions between different types of chromatin modifications.",
      "Types of chromatin modifications include histone modifications and DNA methylation.",
      "COUGER utilizes a machine learning approach to analyze spatial proximity of chromatin modifications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER stands for COmbinatorial Usage of Genomic REgulatory Elements and is a bioinformatics tool.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE \n5. UNKNOWN\n\nNote: While it is established that chromatin modifications include histone modifications and DNA methylation, the specific functionality and design of COUGER, as well as its use of machine learning, cannot be confirmed without specific reference to this tool. The acronym correction is based on common bioinformatics nomenclature, but without a specific reference to COUGER, the details about its usage and design are considered UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs for the treatment of TBE include:\n1. Antiviral medications: Ribavirin, a nucleoside analogue, is the most commonly used antiviral drug for the treatment of TBE. It has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n2. Corticosteroids: Corticosteroids, such as prednisone, are sometimes used to reduce inflammation in the brain and spinal cord.\n3. Immunoglobulins: Immunoglobulins, such as intravenous immunoglobulin (IVIG), may be used to treat TBE in severe cases. IVIG contains antibodies that can help to reduce the replication of the virus and modulate the immune response.\n4. Supportive care: Supportive care, such as rest, hydration, and pain management, is important for managing the symptoms of TBE and preventing complications.\nIt's important to note that the effectiveness of these drugs can vary depending on the severity and duration of the infection, as well as the individual patient's response to treatment. In some cases, a combination of drugs may be used to achieve the best outcome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is a nucleoside analogue antiviral drug used for the treatment of tick-borne encephalitis (TBE).\n2. Corticosteroids like prednisone are sometimes used to reduce inflammation in the brain and spinal cord in TBE patients.\n3. Intravenous immunoglobulin (IVIG) is used in severe cases of TBE treatment and contains antibodies to help reduce viral replication and modulate the immune response.\n4. Supportive care measures such as rest, hydration, and pain management are part of managing the symptoms of TBE.\n5. The effectiveness of drugs for TBE can vary based on the severity and duration of the infection and the patient's individual response to treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is a nucleoside analogue antiviral drug used for the treatment of tick-borne encephalitis (TBE).",
      "Corticosteroids like prednisone are sometimes used to reduce inflammation in the brain and spinal cord in TBE patients.",
      "Intravenous immunoglobulin (IVIG) is used in severe cases of TBE treatment and contains antibodies to help reduce viral replication and modulate the immune response.",
      "Supportive care measures such as rest, hydration, and pain management are part of managing the symptoms of TBE.",
      "The effectiveness of drugs for TBE can vary based on the severity and duration of the infection and the patient's individual response to treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The use of Ribavirin for the treatment of tick-borne encephalitis (TBE) is not well established and may vary by protocol and region. Without specific information from the passage about its use in TBE, this cannot be confirmed as true or false.\n2. TRUE: Corticosteroids like prednisone are sometimes used in TBE and other encephalitis cases to reduce inflammation in the brain and spinal cord.\n3. FALSE [correction]: Intravenous immunoglobulin (IVIG) is generally used for conditions related to immune deficiencies or to modulate the immune response. For TBE, there is not a widely accepted use of IVIG as a standard treatment and it is not specifically known to contain antibodies against the TBE virus.\n4. TRUE: Supportive care measures are typically part of managing the symptoms of many infectious diseases, including TBE.\n5. TRUE: The effectiveness of drugs for many diseases, including TBE, can indeed vary based on various factors including the severity and duration of the infection and the individual patient characteristics.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases available for DNA shape annotations. Some of the most popular ones include:\n1. ChromHMM: ChromHMM is a genome-scale model of chromatin structure and dynamics, which provides DNA shape annotations for various cell types and states.\n2. Topological Associated Domains (TADs): TADs are three-dimensional chromatin structures that are defined by the interactions between distant regulatory elements and gene promoters. The 3C (chromatin conformation capture) and 4C (chromatin conformation capture with histone modifications) techniques are used to identify TADs.\n3. High-throughput chromosome conformation capture (Hi-C): Hi-C is a technique that captures the three-dimensional interactions between different regions of the genome. The resulting data can be used to identify topological domains, chromatin loops, and other structural features of the genome.\n4. DNase-seq: DNase-seq is a technique that uses DNase I to cleave the DNA at specific regions of interest, and the resulting cleavage sites are used to infer the three-dimensional structure of the genome.\n5. FAIRE-seq: FAIRE-seq is a technique that uses formaldehyde to cross-link chromatin, and the resulting structure is used to identify regions of the genome that are more accessible or compact.\n6. Topological domains in the human genome (TDT): TDT is a computational method that identifies topological domains in the human genome based on the chromatin conformation data.\n7. 3D Genome Browser: The 3D Genome Browser is a web-based tool that provides a visual representation of the three-dimensional structure of the genome. It integrates data from various techniques, including Hi-C, DNase-seq, and FAIRE-seq.\n8. Genome-wide chromatin structure data (GW-ChIP-seq): GW-ChIP-seq is a technique that combines ChIP-seq with genome-wide chromatin conformation data to provide a comprehensive view of the chromatin structure.\n9. Chromatin structure in the human genome (H3K27ac): H3K27ac is a histone modification that is associated with active chromatin regions. The",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM provides DNA shape annotations for various cell types and states.\n2. Topological Associated Domains (TADs) are defined by interactions between distant regulatory elements and gene promoters.\n3. High-throughput chromosome conformation capture (Hi-C) is a technique that captures three-dimensional interactions between different regions of the genome.\n4. DNase-seq is a technique that uses DNase I to cleave DNA at specific regions, which are then used to infer the three-dimensional structure of the genome.\n5. The 3D Genome Browser is a web-based tool that provides a visual representation of the three-dimensional structure of the genome, integrating data from various techniques such as Hi-C and DNase-seq.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM provides DNA shape annotations for various cell types and states.",
      "Topological Associated Domains (TADs) are defined by interactions between distant regulatory elements and gene promoters.",
      "High-throughput chromosome conformation capture (Hi-C) is a technique that captures three-dimensional interactions between different regions of the genome.",
      "DNase-seq is a technique that uses DNase I to cleave DNA at specific regions, which are then used to infer the three-dimensional structure of the genome.",
      "The 3D Genome Browser is a web-based tool that provides a visual representation of the three-dimensional structure of the genome, integrating data from various techniques such as Hi-C and DNase-seq."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is a computational tool that is used to characterize the genome into different chromatin states based on histone modification data, not for providing DNA shape annotations.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DNase-seq is a technique that uses DNase I to cleave DNA at accessible regions, often associated with active transcription, to identify areas of the genome that are likely to be regulatory elements such as promoters and enhancers, but it does not infer the three-dimensional structure of the genome.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes the enzyme enzyme polycomb repressive complex 2 (PRC2), which plays a critical role in regulating gene expression by modifying histone H3 lysine 27 (H3K27) through histone methylation. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and congenital anomalies.\n2. Coffin-Lowry syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and congenital anomalies.\n3. Pallister-Hall syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and congenital anomalies.\n4. Beckwith-Wiedemann syndrome: This is a rare genetic disorder characterized by abdominal wall defects, visceromegaly, and an increased risk of developing embryonal tumors.\n5. Langer syndrome: This is a rare genetic disorder characterized by respiratory distress, growth retardation, and congenital anomalies.\n6. EZH2-mutant B cell malignancies: Mutations in the EZH2 gene have been found in various types of B cell malignancies, including diffuse large B cell lymphoma and follicular lymphoma.\nThese syndromes are caused by mutations in the EZH2 gene that disrupt its normal function, leading to altered gene expression and developmental abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. The EZH2 gene is responsible for encoding the enzyme polycomb repressive complex 2 (PRC2).\n2. Rubinstein-Taybi syndrome is associated with mutations in the EZH2 gene.\n3. Coffin-Lowry syndrome is associated with mutations in the EZH2 gene.\n4. Pallister-Hall syndrome is associated with mutations in the EZH2 gene.\n5. Mutations in the EZH2 gene have been found in various types of B cell malignancies, including diffuse large B cell lymphoma and follicular lymphoma.",
    "llama-2-7b-chat-hf_fact": [
      "The EZH2 gene is responsible for encoding the enzyme polycomb repressive complex 2 (PRC2).",
      "Rubinstein-Taybi syndrome is associated with mutations in the EZH2 gene.",
      "Coffin-Lowry syndrome is associated with mutations in the EZH2 gene.",
      "Pallister-Hall syndrome is associated with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene have been found in various types of B cell malignancies, including diffuse large B cell lymphoma and follicular lymphoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The EZH2 gene is responsible for encoding the enzymatic component of the complex called Enhancer of Zeste Homolog 2, which is part of the polycomb repressive complex 2 (PRC2), not the complex itself.\n2. TRUE\n3. FALSE [correction]: Coffin-Lowry syndrome is associated with mutations in the RPS6KA3 gene, not the EZH2 gene.\n4. FALSE [correction]: Pallister-Hall syndrome is associated with mutations in the GLI3 gene, not the EZH2 gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 is a well-known example of a protein that undergoes a dimer-to-tetramer transition. The p53 protein exists as both a dimer and a tetramer, and the transition between these two forms is regulated by various cellular signals and stressors.\n2. c-Myc: The c-Myc protein is a transcription factor that is involved in cellular proliferation, differentiation, and apoptosis. c-Myc exists as both a dimer and a tetramer, and the transition between these two forms is regulated by phosphorylation and ubiquitination.\n3. NF-κB: The NF-κB transcription factor is involved in the regulation of inflammation and immune responses. NF-κB exists as both a dimer and a tetramer, and the transition between these two forms is regulated by phosphorylation and binding to specific DNA sequences.\n4. STAT3: The STAT3 transcription factor is involved in the regulation of immune responses and inflammation. STAT3 exists as both a dimer and a tetramer, and the transition between these two forms is regulated by phosphorylation and binding to specific DNA sequences.\n5. FOXO1: The FOXO1 transcription factor is involved in the regulation of cellular metabolism, stress resistance, and longevity. FOXO1 exists as both a dimer and a tetramer, and the transition between these two forms is regulated by phosphorylation and binding to specific DNA sequences.\n6. CREB: The CREB transcription factor is involved in the regulation of gene expression in response to changes in cellular energy levels. CREB exists as both a dimer and a tetramer, and the transition between these two forms is regulated by phosphorylation and binding to specific DNA sequences.\n7. HIF1α: The HIF1α transcription factor is involved in the regulation of gene expression in response to changes in oxygen availability. HIF1α exists as both a dim",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein p53 can exist in both dimer and tetramer forms.\n2. The c-Myc protein undergoes a transition between dimer and tetramer states.\n3. NF-κB can exist as both a dimer and a tetramer.\n4. STAT3 exists as both a dimer and a tetramer.\n5. FOXO1 is a transcription factor that can transition between dimer and tetramer forms.",
    "llama-2-7b-chat-hf_fact": [
      "The protein p53 can exist in both dimer and tetramer forms.",
      "The c-Myc protein undergoes a transition between dimer and tetramer states.",
      "NF-κB can exist as both a dimer and a tetramer.",
      "STAT3 exists as both a dimer and a tetramer.",
      "FOXO1 is a transcription factor that can transition between dimer and tetramer forms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The protein p53 can exist in both dimer and tetramer forms, with the tetramer being the active form that can bind to DNA.\n2. FALSE [correction]: The c-Myc protein functions as a transcription factor and forms heterodimers with Max proteins but does not transition between dimer and tetramer states. c-Myc-Max heterodimers are the functional form that binds to DNA.\n3. FALSE [correction]: NF-κB typically exists as a dimer and does not form tetramers. It is a family of inducible transcription factors that play a key role in regulating the immune response to infection.\n4. TRUE: STAT3 can form dimers through reciprocal phosphotyrosine-SH2 domain interactions, and there is evidence for higher order oligomerization (including tetramers under certain conditions), although dimers are the most well-studied active form.\n5. UNKNOWN: The dimerization and oligomerization states of FOXO1 are less well-characterized in the literature, and it is known to function as a monomer or dimer. However, there is insufficient information readily available to confirm its ability to form a tetramer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is BCL-2 (B-cell lymphoma 2).",
    "llama-2-7b-chat-hf_fact_raw": "1. BCL-2 (B-cell lymphoma 2) is a protein that interacts with phospholamban (PLN).\n2. BCL-2 (B-cell lymphoma 2) is an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact": [
      "BCL-2 (B-cell lymphoma 2) is a protein that interacts with phospholamban (PLN).",
      "BCL-2 (B-cell lymphoma 2) is an anti-apoptotic protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2013 meta-analysis published in the Journal of the American Geriatrics Society pooled data from 17 randomized controlled trials involving over 15,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.77, 95% CI=0.65-0.90).\n2. A 2011 randomized controlled trial published in the Journal of Gerontology found that older adults who received vitamin D and calcium supplements had a lower risk of falls compared to those who received placebo (RR=0.57, 95% CI=0.39-0.85).\n3. A 2014 meta-analysis published in the journal Osteoporosis International found that vitamin D supplementation was associated with a reduced risk of falls in older adults (RR=0.73, 95% CI=0.63-0.85).\n4. A 2017 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults who received vitamin D and omega-3 supplements had a lower risk of falls compared to those who received placebo (RR=0.47, 95% CI=0.27-0.83).\nIt's worth noting that while these studies suggest a potential benefit of vitamin D supplementation in reducing the risk of falls in older adults, the evidence is not yet conclusive, and more research is needed to confirm these findings and establish the optimal dosage and duration of supplementation. Additionally, it's important to consult with a healthcare professional before starting any supplement regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 meta-analysis in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in the risk of falls among older adults with a relative risk (RR) of 0.77.\n2. A 2011 randomized controlled trial published in the Journal of Gerontology indicated that older adults receiving vitamin D and calcium supplements had a lower risk of falls compared to those receiving a placebo.\n3. A 2014 meta-analysis in the journal Osteoporosis International reported that vitamin D supplementation was linked to a reduced risk of falls in older adults.\n4. A 2017 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults taking vitamin D and omega-3 supplements had a lower risk of falls as compared to those taking a placebo.\n5. The aforementioned clinical trials involved over 15,000 older adults.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 meta-analysis in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in the risk of falls among older adults with a relative risk (RR) of 0.77.",
      "A 2011 randomized controlled trial published in the Journal of Gerontology indicated that older adults receiving vitamin D and calcium supplements had a lower risk of falls compared to those receiving a placebo.",
      "A 2014 meta-analysis in the journal Osteoporosis International reported that vitamin D supplementation was linked to a reduced risk of falls in older adults.",
      "A 2017 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults taking vitamin D and omega-3 supplements had a lower risk of falls as compared to those taking a placebo.",
      "The aforementioned clinical trials involved over 15,000 older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: A 2017 randomized controlled trial published in the Journal of the American Geriatrics Society found that vitamin D and calcium, not omega-3 supplements, reduced the risk of falls in older adults when compared to a placebo.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. Studies have shown that Jarid2 is a direct target of miR-155 and that miR-155 regulates Jarid2 expression in Th17 cells. Specifically, miR-155 has been shown to bind to the 3'UTR of the Jarid2 mRNA and inhibit its translation, leading to decreased Jarid2 protein expression and activity. This inhibition of Jarid2 by miR-155 has been implicated in the regulation of Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a direct target of miR-155 in Th17 cells.\n2. miR-155 regulates Jarid2 expression in Th17 cells.\n3. miR-155 binds to the 3'UTR of Jarid2 mRNA and inhibits its translation.\n4. The inhibition of Jarid2 by miR-155 leads to decreased Jarid2 protein expression and activity.\n5. The regulation of Th17 cell differentiation and function is influenced by the inhibition of Jarid2 by miR-155.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a direct target of miR-155 in Th17 cells.",
      "miR-155 regulates Jarid2 expression in Th17 cells.",
      "miR-155 binds to the 3'UTR of Jarid2 mRNA and inhibits its translation.",
      "The inhibition of Jarid2 by miR-155 leads to decreased Jarid2 protein expression and activity.",
      "The regulation of Th17 cell differentiation and function is influenced by the inhibition of Jarid2 by miR-155."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE (Assuming statement 2 is correct, miR-155 regulation of Jarid2 would typically result in decreased expression and activity of a target protein like Jarid2).\n5. TRUE (Assuming the previous statements are correct, it is known that miRNAs can influence cell differentiation and function by regulating the expression of specific target proteins).",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes: Hoxd-1 to Hoxd-9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine kinase that phosphorylates a variety of substrates, including other kinases, transcription factors, and structural proteins. The consensus motifs for phosphorylation by CK1 are:\n1. Ser/Thr-Pro-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the CK1 catalytic domain and is a common target site for CK1-mediated phosphorylation.\n2. Ser/Thr-Pro-X-X-X-X-X-X (where X is any amino acid)\nThis motif is also recognized by the CK1 catalytic domain and is involved in the regulation of various cellular processes, including cell signaling, gene expression, and protein degradation.\n3. Ser/Thr-Gly-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the CK1 catalytic domain and is involved in the regulation of protein-protein interactions and subcellular localization.\n4. Ser/Thr-Pro-X-X-X-X-X-X-X (where X is any amino acid)\nThis motif is recognized by the CK1 catalytic domain and is involved in the regulation of cellular processes such as cell growth, differentiation, and survival.\n5. Ser/Thr-Pro-X-X-X-X-X-X-X-X (where X is any amino acid)\nThis motif is recognized by the CK1 catalytic domain and is involved in the regulation of protein stability and degradation.\nIt's worth noting that these consensus motifs are not exhaustive and there may be other motifs that are recognized by CK1. Additionally, the specificity of CK1 for certain motifs can vary depending on the isoform of the enzyme and the substrate binding site.",
    "llama-2-7b-chat-hf_fact_raw": "1. CK1 is a serine/threonine kinase that phosphorylates different substrates.\n2. One of the consensus motifs for phosphorylation by CK1 is Ser/Thr-Pro-X-X-X-Ser/Thr, where X represents any amino acid.\n3. Another consensus motif for CK1 phosphorylation is Ser/Thr-Pro-X-X-X-X-X-X, where X is any amino acid.\n4. The motif Ser/Thr-Gly-X-X-X-Ser/Thr is recognized by CK1 and is involved in the regulation of protein-protein interactions and subcellular localization.\n5. CK1 is also known to recognize motifs like Ser/Thr-Pro-X-X-X-X-X-X-X and Ser/Thr-Pro-X-X-X-X-X-X-X-X, where X is any amino acid, involved in regulating cellular processes such as growth, differentiation, and survival, as well as protein stability and degradation.",
    "llama-2-7b-chat-hf_fact": [
      "CK1 is a serine/threonine kinase that phosphorylates different substrates.",
      "One of the consensus motifs for phosphorylation by CK1 is Ser/Thr-Pro-X-X-X-Ser/Thr, where X represents any amino acid.",
      "Another consensus motif for CK1 phosphorylation is Ser/Thr-Pro-X-X-X-X-X-X, where X is any amino acid.",
      "The motif Ser/Thr-Gly-X-X-X-Ser/Thr is recognized by CK1 and is involved in the regulation of protein-protein interactions and subcellular localization.",
      "CK1 is also known to recognize motifs like Ser/Thr-Pro-X-X-X-X-X-X-X and Ser/Thr-Pro-X-X-X-X-X-X-X-X, where X is any amino acid, involved in regulating cellular processes such as growth, differentiation, and survival, as well as protein stability and degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: CK1 (Casein Kinase 1) is indeed a serine/threonine-specific protein kinase that phosphorylates various substrates.\n2. TRUE: One of the consensus motifs for CK1 phosphorylation is Ser/Thr-Pro followed by any three amino acids and then another Ser/Thr, often denoted as Ser/Thr-Pro-X-X-X-Ser/Thr.\n3. UNKNOWN: Without specific scientific reference, it's not clear whether Ser/Thr-Pro followed by six X (any amino acid) residues is a consensus motif for CK1 phosphorylation or not.\n4. FALSE [correction]: The motif Ser/Thr-Gly-X-X-X-Ser/Thr is actually recognized by a different serine/threonine kinase, GSK3 (Glycogen Synthase Kinase 3), and not CK1. This motif is involved in the regulation of a number of cellular processes, including protein-protein interactions and protein stability.\n5. UNKNOWN: Specificity to motifs like Ser/Thr-Pro followed by seven or eight X (any amino acid) residues for CK1 is unclear without more detailed research or scientific references. Although CK1 does recognize certain Ser/Thr-Pro motifs and is involved in a wide array of cellular processes, the precise motifs given here are not clearly established in this response, and the extent of their relevance to CK1 specifically is undetermined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene and is involved in the biosynthesis of the neurotransmitter serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): This isoform is produced by the alternative splicing of the ASPH gene and inhibits the activity of matrix metalloproteinases (MMPs), which are involved in the breakdown of the extracellular matrix.\n3. Matrix metalloproteinase 9 (MMP9): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the breakdown of the extracellular matrix.\n4. Matrix metalloproteinase 2 (MMP2): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the breakdown of the extracellular matrix.\n5. Matrix metalloproteinase 14 (MMP14): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the breakdown of the extracellular matrix.\n6. Prostaglandin-endoperoxide synthase 2 (PGES2): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the production of prostaglandins, which are mediators of inflammation.\n7. Peroxisome proliferator-activated receptor gamma (PPARγ): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the regulation of glucose and lipid metabolism.\n8. Glucocorticoid receptor (GR): This isoform is produced by the alternative splicing of the ASPH gene and is involved in the regulation of glucocorticoid-mediated gene expression.\nThese isoforms are produced by different splicing patterns of the ASPH gene and each of them has a distinct function in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes an isoform known as aspartate beta-hydroxylase, which is involved in the biosynthesis of serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1) is an isoform encoded by the ASPH gene that inhibits matrix metalloproteinases.\n3. Matrix metalloproteinase 9 (MMP9), an isoform encoded by the ASPH gene, is involved in the breakdown of the extracellular matrix.\n4. The ASPH gene produces the isoform prostaglandin-endoperoxide synthase 2 (PGES2), which is involved in the production of prostaglandins.\n5. Peroxisome proliferator-activated receptor gamma (PPARγ) is an isoform produced by the ASPH gene and is involved in the regulation of glucose and lipid metabolism.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes an isoform known as aspartate beta-hydroxylase, which is involved in the biosynthesis of serotonin.",
      "Tissue inhibitor of metalloproteinases 1 (TIMP1) is an isoform encoded by the ASPH gene that inhibits matrix metalloproteinases.",
      "Matrix metalloproteinase 9 (MMP9), an isoform encoded by the ASPH gene, is involved in the breakdown of the extracellular matrix.",
      "The ASPH gene produces the isoform prostaglandin-endoperoxide synthase 2 (PGES2), which is involved in the production of prostaglandins.",
      "Peroxisome proliferator-activated receptor gamma (PPARγ) is an isoform produced by the ASPH gene and is involved in the regulation of glucose and lipid metabolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The ASPH gene encodes an enzyme known as aspartate beta-hydroxylase, but this enzyme is not involved in the biosynthesis of serotonin. Instead, it is involved in the posttranslational modification of certain proteins by hydroxylating aspartyl and asparaginyl residues.\n2. FALSE [correction]: Tissue inhibitor of metalloproteinases 1 (TIMP1) is not an isoform encoded by the ASPH gene. It is a separate protein that inhibits matrix metalloproteinases but is encoded by its own gene, TIMP1.\n3. FALSE [correction]: Matrix metalloproteinase 9 (MMP9) is not an isoform encoded by the ASPH gene. It is part of a family of proteases involved in the breakdown of the extracellular matrix, but it is encoded by the MMP9 gene.\n4. FALSE [correction]: The ASPH gene does not produce the isoform prostaglandin-endoperoxide synthase 2 (PGES2). PGES2 is involved in prostaglandin production but is encoded by the PTGS2 gene, not the ASPH gene.\n5. FALSE [correction]: Peroxisome proliferator-activated receptor gamma (PPARγ) is not an isoform produced by the ASPH gene. PPARγ is a nuclear receptor involved in the regulation of glucose and lipid metabolism, but it is encoded by the PPARG gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 28, 2014, for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 28, 2014.\n2. Empagliflozin is approved for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 28, 2014.",
      "Empagliflozin is approved for the treatment of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis results in a number of phenotypic changes, including:\n1. Increased sensitivity to oxidative stress: Lon1 plays a role in protecting against oxidative stress, and loss of the protein leads to increased sensitivity to hydrogen peroxide and other oxidizing agents.\n2. Enhanced cell death: Lon1 has been shown to inhibit programmed cell death (apoptosis) in Arabidopsis, and loss of the protein leads to increased cell death, particularly in response to stress.\n3. Altered root architecture: Lon1 is involved in regulating root growth and development, and loss of the protein leads to alterations in root architecture, including reduced root length and branching.\n4. Delayed seed germination: Lon1 has been shown to regulate seed germination in Arabidopsis, and loss of the protein leads to delayed seed germination.\n5. Affected flowering time: Lon1 has been shown to regulate flowering time in Arabidopsis, and loss of the protein leads to alterations in flowering time.\n6. Impaired nutrient uptake: Lon1 has been shown to play a role in regulating nutrient uptake and transport in Arabidopsis, and loss of the protein leads to impaired nutrient uptake and reduced plant growth.\n7. Altered hormone signaling: Lon1 has been shown to regulate hormone signaling in Arabidopsis, and loss of the protein leads to alterations in hormone signaling, including changes in auxin and cytokinin levels.\n8. Increased susceptibility to pathogens: Lon1 has been shown to play a role in regulating immune responses in Arabidopsis, and loss of the protein leads to increased susceptibility to pathogens.",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis leads to increased sensitivity to oxidative stress.\n2. Loss of Lon1 protein in Arabidopsis results in enhanced cell death, especially in response to stress.\n3. The absence of Lon1 protein impacts root growth and development in Arabidopsis, causing alterations in root architecture.\n4. Arabidopsis seeds lacking Lon1 protein experience delayed seed germination.\n5. Loss of Lon1 protein in Arabidopsis affects flowering time.",
    "llama-2-7b-chat-hf_fact": [
      "Loss of the protein Lon1 in Arabidopsis leads to increased sensitivity to oxidative stress.",
      "Loss of Lon1 protein in Arabidopsis results in enhanced cell death, especially in response to stress.",
      "The absence of Lon1 protein impacts root growth and development in Arabidopsis, causing alterations in root architecture.",
      "Arabidopsis seeds lacking Lon1 protein experience delayed seed germination.",
      "Loss of Lon1 protein in Arabidopsis affects flowering time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The loss of Lon1 protein in Arabidopsis has been associated with increased sensitivity to oxidative stress, as it is involved in the removal of damaged proteins and maintenance of mitochondrial function.\n2. TRUE: The loss of Lon1 can lead to enhanced cell death, as the protein is important for the regulation of the turnover of various proteins, and its absence can lead to the accumulation of dysfunctional proteins and cellular stress.\n3. TRUE: Alterations in root growth and development have been observed in plants with mutations affecting Lon1, suggesting that the protein plays a role in these processes, possibly through its involvement in the maintenance of mitochondrial function and overall cellular homeostasis.\n4. UNKNOWN: Without specific research or evidence provided about the impact of Lon1 on seed germination in Arabidopsis, it is difficult to confirm if this statement is true or false.\n5. UNKNOWN: Similarly, without specific information regarding the effect of Lon1 on flowering time in Arabidopsis, the truth of this statement cannot be ascertained.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H2A.Z exists in the yeast genome. H2A.Z is a variant of the H2A histone protein that is specifically involved in the formation of higher-order chromatin structures, such as nucleosomes and chromatin fibers, and plays a role in regulating gene expression and chromatin dynamics in various organisms, including yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H2A.Z exists in the yeast genome.\n2. H2A.Z is a variant of the H2A histone protein.\n3. H2A.Z is involved in the formation of higher-order chromatin structures, such as nucleosomes and chromatin fibers.\n4. H2A.Z plays a role in regulating gene expression and chromatin dynamics in various organisms, including yeast.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H2A.Z exists in the yeast genome.",
      "H2A.Z is a variant of the H2A histone protein.",
      "H2A.Z is involved in the formation of higher-order chromatin structures, such as nucleosomes and chromatin fibers.",
      "H2A.Z plays a role in regulating gene expression and chromatin dynamics in various organisms, including yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: A linker histone is typically referred to as H1. H2A.Z is a variant of the H2A histone protein, not a linker histone.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels. Studies have shown that consuming tomato juice can help reduce total cholesterol, LDL (bad) cholesterol, and triglycerides, while increasing HDL (good) cholesterol.\nOne study published in the Journal of Nutrition found that drinking 100 ml of tomato juice daily for 12 weeks reduced total cholesterol and LDL cholesterol by 5-6% in healthy adults. Another study published in the European Journal of Clinical Nutrition found that consuming 100 ml of tomato juice daily for 12 weeks reduced LDL cholesterol by 10% in patients with high cholesterol.\nThe cholesterol-lowering effects of tomato juice are thought to be due to the presence of lycopene, an antioxidant found in tomatoes. Lycopene has been shown to inhibit the absorption of dietary cholesterol in the gut, as well as reduce the activity of enzymes involved in cholesterol synthesis.\nIt's important to note that while these studies suggest that tomato juice may have cholesterol-lowering effects, more research is needed to confirm these findings and to determine the optimal dosage and duration of tomato juice consumption for cholesterol reduction. Additionally, it's important to consume tomato juice as part of a balanced diet and to talk to a healthcare provider before making any significant changes to your diet.",
    "llama-2-7b-chat-hf_fact_raw": "1. Consuming tomato juice can help reduce total cholesterol, LDL cholesterol, and triglycerides while increasing HDL cholesterol.\n2. A study in the Journal of Nutrition reported that drinking 100 ml of tomato juice daily for 12 weeks reduced total and LDL cholesterol by 5-6% in healthy adults.\n3. Another study in the European Journal of Clinical Nutrition showed that consuming 100 ml of tomato juice daily for 12 weeks reduced LDL cholesterol by 10% in patients with high cholesterol.\n4. The cholesterol-lowering effects of tomato juice are thought to be due to the presence of lycopene.\n5. Lycopene is an antioxidant that can inhibit the absorption of dietary cholesterol in the gut and reduce the activity of enzymes involved in cholesterol synthesis.",
    "llama-2-7b-chat-hf_fact": [
      "Consuming tomato juice can help reduce total cholesterol, LDL cholesterol, and triglycerides while increasing HDL cholesterol.",
      "A study in the Journal of Nutrition reported that drinking 100 ml of tomato juice daily for 12 weeks reduced total and LDL cholesterol by 5-6% in healthy adults.",
      "Another study in the European Journal of Clinical Nutrition showed that consuming 100 ml of tomato juice daily for 12 weeks reduced LDL cholesterol by 10% in patients with high cholesterol.",
      "The cholesterol-lowering effects of tomato juice are thought to be due to the presence of lycopene.",
      "Lycopene is an antioxidant that can inhibit the absorption of dietary cholesterol in the gut and reduce the activity of enzymes involved in cholesterol synthesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There is evidence to suggest that consuming tomato juice can impact cholesterol levels due to various components it contains, such as lycopene.\n2. UNKNOWN: Without access to the specific study published in the Journal of Nutrition, the exact findings and validity of the statement cannot be determined. Thus, without being able to verify the specified reduction in cholesterol levels, the truth of this statement remains unknown.\n3. UNKNOWN: Like statement 2, without access to the specific study from the European Journal of Clinical Nutrition, it is not possible to confirm the findings stated. Consequently, the truth of the 10% reduction in LDL cholesterol remains unknown.\n4. TRUE: Lycopene, a compound found in tomatoes, has been widely studied and is thought to have various health benefits, including potential effects on cholesterol levels, though the exact mechanisms and extent of its impact require further research.\n5. UNKNOWN: While lycopene is an antioxidant and there are studies suggesting it may have a role in cholesterol metabolism, this statement is very specific about how lycopene inhibits dietary cholesterol absorption and reduces enzyme activity. Without specific references to studies that confirm each part of this mechanism, the precise truth of these details remains undetermined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are molecular chaperones that play a crucial role in protein folding and degradation, but they also have been shown to affect mRNA stability.\nHsp70 has been shown to bind to mRNA and protect it from degradation by the 5' exonuclease of the RNA-exosome complex. This can lead to an increase in mRNA stability and translation efficiency. Additionally, Hsp70 has been shown to regulate the localization and activity of the RNA-binding protein Musashi, which is involved in mRNA stability and translation.\nHsp110, on the other hand, has been shown to interact with the RNA-binding protein FUS (fused in sarcoma) and regulate its activity. FUS is involved in the regulation of mRNA stability and translation, and Hsp110 has been shown to modulate FUS activity by preventing its aggregation and promoting its proper localization.\nIn summary, Hsp70 and Hsp110 both play a role in regulating mRNA stability by interacting with RNA-binding proteins and modulating their activity, leading to changes in mRNA stability and translation efficiency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are molecular chaperones that have a role in protein folding and degradation.\n2. Hsp70 can bind to mRNA and protect it from degradation by the 5' exonuclease of the RNA-exosome complex.\n3. The interaction of Hsp70 with mRNA can lead to an increase in mRNA stability and translation efficiency.\n4. Hsp70 can regulate the localization and activity of the RNA-binding protein Musashi, which is involved in mRNA stability and translation.\n5. Hsp110 can interact with the RNA-binding protein FUS and regulate its activity, which is involved in mRNA stability and translation.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are molecular chaperones that have a role in protein folding and degradation.",
      "Hsp70 can bind to mRNA and protect it from degradation by the 5' exonuclease of the RNA-exosome complex.",
      "The interaction of Hsp70 with mRNA can lead to an increase in mRNA stability and translation efficiency.",
      "Hsp70 can regulate the localization and activity of the RNA-binding protein Musashi, which is involved in mRNA stability and translation.",
      "Hsp110 can interact with the RNA-binding protein FUS and regulate its activity, which is involved in mRNA stability and translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Hsp70 and Hsp110 are indeed molecular chaperones that play roles in protein folding, and they can also assist with the prevention of protein aggregation and aid in cellular stress responses. They are not classically associated with degradation processes like proteases are, but they help maintain protein quality which can indirectly influence degradation if proteins are misfolded.\n\n2. FALSE [correction]: While Hsp70 has a variety of functions, there is no direct evidence to suggest that it binds to mRNA to protect it from degradation by the 5' exonuclease of the RNA-exosome complex. Hsp70 primarily functions in protein folding and stabilization.\n\n3. TRUE: It is known that some molecular chaperones, including members of the Hsp70 family, can interact with mRNA and protect it from degradation, which can lead to increased mRNA stability and, potentially, translation efficiency.\n\n4. UNKNOWN: The regulation of Musashi by Hsp70 is specific and would require citation of specific scientific literature to confirm its accuracy. Without such evidence, this statement remains uncertain.\n\n5. TRUE: Hsp110, as part of its wide range of functions, can potentially interact with various RNA-binding proteins such as FUS. These interactions can have implications for mRNA stability and translation, as alterations in the activity of RNA-binding proteins like FUS are known to affect these processes. However, the specifics of the interaction between Hsp110 and FUS and the exact regulatory mechanisms involved would need to be supported by scientific research for a definitive statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism. In skeletal muscle, there are three types of deiodinases:\n1. Deiodinase type 1 (D1): found primarily in the liver, brain, and heart, but also present in skeletal muscle, where it is involved in the conversion of T4 to T3.\n2. Deiodinase type 2 (D2): found primarily in the brain, but also present in skeletal muscle, where it is involved in the conversion of T4 to reverse T3 (rT3).\n3. Deiodinase type 3 (D3): found primarily in the thyroid gland, but also present in other tissues, including skeletal muscle, where it is involved in the conversion of T4 and T3 to their active forms.\nSo, to answer your question, deiodinases present in skeletal muscle are D1, D2, and D3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and is involved in the conversion of T4 to T3.\n2. Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 to reverse T3 (rT3).\n3. Deiodinase type 3 (D3) is present in skeletal muscle and is involved in the conversion of T4 and T3 to their active forms.\n4. In addition to skeletal muscle, D1 is primarily found in the liver, brain, and heart.\n5. D2 is primarily found in the brain, while D3 is primarily found in the thyroid gland.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and is involved in the conversion of T4 to T3.",
      "Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 to reverse T3 (rT3).",
      "Deiodinase type 3 (D3) is present in skeletal muscle and is involved in the conversion of T4 and T3 to their active forms.",
      "In addition to skeletal muscle, D1 is primarily found in the liver, brain, and heart.",
      "D2 is primarily found in the brain, while D3 is primarily found in the thyroid gland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 2 (D2), not type 1 (D1), is present in skeletal muscle and is involved in the conversion of T4 to T3.\n2. FALSE [correction]: Deiodinase type 2 (D2) is not primarily involved in the conversion of T4 to reverse T3 (rT3); instead, it converts T4 to the active form of thyroid hormone, T3.\n3. FALSE [correction]: Deiodinase type 3 (D3) is involved in the inactivation of thyroid hormones by converting T4 to reverse T3 (rT3) and T3 to 3,3'-diiodothyronine (T2), not their active forms.\n4. TRUE\n5. FALSE [correction]: D2 is primarily found in the brain, but also in the pituitary gland and brown adipose tissue among other tissues. D3 is primarily found in the placenta and the central nervous system during fetal development, as well as in other tissues like the skin, but not predominantly in the thyroid gland.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a group of enzymes that play a role in the regulation of inflammation. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1: Also known as interleukin-1 beta (IL-1β) converting enzyme (ICE), caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3: Also known as caspase-8, this enzyme is involved in the regulation of apoptosis and inflammation. It plays a role in the activation of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).\n3. Caspase-7: This enzyme is involved in the regulation of apoptosis and inflammation, and is activated in response to DNA damage and viral infection.\n4. Caspase-9: Also known as caspase-3-like protease, this enzyme is involved in the regulation of apoptosis and inflammation. It plays a role in the activation of the pro-inflammatory cytokine interleukin-12 (IL-12).\n5. Caspase-12: Also known as caspase-4, this enzyme is involved in the regulation of inflammation and apoptosis. It plays a role in the activation of the pro-inflammatory cytokine TNF-α.\n6. Caspase-13: This enzyme is involved in the regulation of inflammation and apoptosis, and is activated in response to DNA damage and viral infection.\nThese are some of the examples of inflammatory caspase proteins, there are more and each one has its specific function and activation pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).\n2. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n3. Caspase-3, also known as caspase-8, is involved in the regulation of apoptosis and inflammation.\n4. Caspase-7 is activated in response to DNA damage and viral infection.\n5. Caspase-9, also known as caspase-3-like protease, is involved in the regulation of apoptosis and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).",
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
      "Caspase-3, also known as caspase-8, is involved in the regulation of apoptosis and inflammation.",
      "Caspase-7 is activated in response to DNA damage and viral infection.",
      "Caspase-9, also known as caspase-3-like protease, is involved in the regulation of apoptosis and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β, but not TNF-α. TNF-α is processed by different enzymes.\n3. FALSE [correction]: Caspase-3 and caspase-8 are different proteins. Caspase-3 is involved in the execution phase of apoptosis, while caspase-8 is involved in initiating apoptosis via the extrinsic pathway.\n4. UNKNOWN (the statement about caspase-7 activation in response to DNA damage and viral infection is not clearly false, but commonly known triggers include activation by caspase-3 or -9 during apoptosis; without specific context or reference, the statement's accuracy regarding DNA damage and viral infection response is difficult to assess)\n5. FALSE [correction]: Caspase-9, known for its role in the intrinsic pathway of apoptosis, is not also known as caspase-3-like protease. It is an initiator caspase that, when activated, leads to the activation of effector caspases such as caspase-3.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between the aurora B kinase and the polycomb protein Ring1B. Both aurora B kinase and Ring1B are involved in the regulation of chromatin dynamics and gene expression, particularly during the cell cycle and cell division.\nAurora B kinase is a key regulator of the spindle checkpoint, which ensures that chromosomes are properly aligned and separated during cell division. Aurora B kinase phosphorylates and stabilizes the protein polyvinylated insulin-like growth factor-binding protein 3 (PIGBP3), which in turn recruits and activates the polycomb repressive complex 2 (PRC2). PRC2 is responsible for the trimethylation of histone H3 lysine 27 (H3K27me3), a repressive mark that silences gene expression by compacting chromatin.\nRing1B is a member of the polycomb repressive complex 2 (PRC2) and is involved in the monoubiquitination of histone H2A (H2Aub1), which is a mark that also represses gene expression by compacting chromatin. Ring1B also interacts with and is phosphorylated by aurora B kinase, which can affect its activity and localization.\nIn summary, aurora B kinase and Ring1B are connected through their roles in regulating chromatin dynamics and gene expression, and their interactions may play a role in ensuring proper cell division and maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and the polycomb protein Ring1B are both involved in the regulation of chromatin dynamics and gene expression.\n2. Aurora B kinase plays a role in the spindle checkpoint of cell division.\n3. Aurora B kinase phosphorylates and stabilizes PIGBP3, which recruits and activates the polycomb repressive complex 2 (PRC2).\n4. PRC2 is responsible for the trimethylation of histone H3 lysine 27 (H3K27me3), a mark associated with gene silencing.\n5. Ring1B, a member of PRC2, is involved in the monoubiquitination of histone H2A and interacts with aurora B kinase.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and the polycomb protein Ring1B are both involved in the regulation of chromatin dynamics and gene expression.",
      "Aurora B kinase plays a role in the spindle checkpoint of cell division.",
      "Aurora B kinase phosphorylates and stabilizes PIGBP3, which recruits and activates the polycomb repressive complex 2 (PRC2).",
      "PRC2 is responsible for the trimethylation of histone H3 lysine 27 (H3K27me3), a mark associated with gene silencing.",
      "Ring1B, a member of PRC2, is involved in the monoubiquitination of histone H2A and interacts with aurora B kinase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Aurora B kinase and the polycomb protein Ring1B are indeed both involved in the regulation of chromatin dynamics and gene expression, albeit through different mechanisms and complexes.\n2. TRUE: Aurora B kinase is a key player in cell division, where it contributes to the regulation of the spindle checkpoint, ensuring proper chromosome alignment and segregation.\n3. FALSE [correction]: Aurora B kinase does not phosphorylate and stabilize PIGBP3, as PIGBP3 is not a recognized protein in the literature concerning Aurora B kinase. Instead, Aurora B kinase phosphorylates histone H3 and other proteins involved in chromatin structure and function.\n4. TRUE: PRC2 is indeed responsible for the trimethylation of histone H3 lysine 27 (H3K27me3), which is a mark associated with gene silencing.\n5. TRUE: Ring1B is a component of PRC1, not PRC2, and it is involved in the monoubiquitination of histone H2A lysine 119 (H2AK119ub). While there is limited information on the direct interaction between Ring1B and Aurora B kinase, they do function in related pathways involving chromatin modification and gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are sequences that are not part of the standard donor or acceptor splice site consensus sequences, but are nevertheless recognized by the spliceosome and can facilitate splicing. Some of the most frequent non-canonical sequence motifs found in vertebrates include:\n1. GU-rich sequences: Non-canonical donor splice sites often have a GU-rich sequence, which can be recognized by the spliceosome and lead to the inclusion of intronic sequences in the final mRNA transcript.\n2. AG-rich sequences: Non-canonical acceptor splice sites often have an AG-rich sequence, which can be recognized by the spliceosome and lead to the inclusion of cryptic exons or the skipping of exons.\n3. TG dinucleotides: Non-canonical acceptor splice sites can also have TG dinucleotides, which can be recognized by the spliceosome and lead to the inclusion of cryptic exons or the skipping of exons.\n4. Internal sequences: Non-canonical splice sites can also be located within introns, rather than at the 5' or 3' ends of introns. These internal sequences can be recognized by the spliceosome and lead to the inclusion of cryptic exons or the skipping of exons.\n5. Repeats: Non-canonical splice sites can also be located in repetitive sequences, such as Alu elements or other transposable elements. These repeats can be recognized by the spliceosome and lead to the inclusion of cryptic exons or the skipping of exons.\nIt's worth noting that the frequency and specificity of non-canonical splice sites can vary widely across different species and even within the same species, and can be influenced by a variety of factors, including gene expression levels, cell type, and developmental stage.",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical donor splice sites in vertebrates are often characterized by GU-rich sequences.\n2. Non-canonical acceptor splice sites in vertebrates frequently exhibit AG-rich sequences.\n3. TG dinucleotides can be a feature of non-canonical acceptor splice sites in vertebrates.\n4. Non-canonical splice sites can sometimes be located within introns of vertebrate genes.\n5. Repeats such as Alu elements can serve as non-canonical splice sites in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical donor splice sites in vertebrates are often characterized by GU-rich sequences.",
      "Non-canonical acceptor splice sites in vertebrates frequently exhibit AG-rich sequences.",
      "TG dinucleotides can be a feature of non-canonical acceptor splice sites in vertebrates.",
      "Non-canonical splice sites can sometimes be located within introns of vertebrate genes.",
      "Repeats such as Alu elements can serve as non-canonical splice sites in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: Non-canonical splice sites are typically located at the ends of introns, not within introns. Canonical splice sites are used in the majority of splicing events and are located at the exon-intron boundaries, but non-canonical splice sites can also occur at these boundaries when they deviate from the canonical sequences.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The activation of mTOR (mechanistic target of rapamycin) signaling pathway results in the acetylation of S6K1 (serine/arginine protein kinase 1).",
    "llama-2-7b-chat-hf_fact_raw": "1. The activation of the mTOR signaling pathway results in the acetylation of S6K1.\n2. S6K1 stands for serine/arginine protein kinase 1.",
    "llama-2-7b-chat-hf_fact": [
      "The activation of the mTOR signaling pathway results in the acetylation of S6K1.",
      "S6K1 stands for serine/arginine protein kinase 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: S6K1 stands for S6 kinase, a component of the mTOR signaling pathway, not serine/arginine protein kinase 1.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of the calcium channel Cav2.2, which is involved in the regulation of neuronal excitability and synaptic transmission. Mutations in the CACNA1A gene lead to a decrease in the function of these calcium channels, resulting in the characteristic episodic ataxia symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene is responsible for encoding a subunit of the calcium channel Cav2.2.\n3. Cav2.2 is involved in the regulation of neuronal excitability and synaptic transmission.\n4. Mutations in the CACNA1A gene lead to decreased function of these calcium channels.\n5. The decreased function of calcium channels due to CACNA1A gene mutations results in episodic ataxia symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene is responsible for encoding a subunit of the calcium channel Cav2.2.",
      "Cav2.2 is involved in the regulation of neuronal excitability and synaptic transmission.",
      "Mutations in the CACNA1A gene lead to decreased function of these calcium channels.",
      "The decreased function of calcium channels due to CACNA1A gene mutations results in episodic ataxia symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Episodic ataxia type 6 (EA6) is indeed caused by mutations in the CACNA1A gene.\n\n2. FALSE [correction]: The CACNA1A gene encodes the alpha-1A subunit of the voltage-dependent P/Q-type calcium channel, not the Cav2.2, which is the N-type calcium channel encoded by the CACNA1B gene.\n\n3. TRUE: The P/Q-type calcium channels (Cav2.1), for which the CACNA1A gene encodes a subunit, are involved in the regulation of neuronal excitability and synaptic transmission.\n\n4. TRUE: Mutations in the CACNA1A gene can indeed lead to decreased (or sometimes altered) function of these P/Q-type calcium channels.\n\n5. TRUE: The decreased or altered function of P/Q-type calcium channels caused by mutations in the CACNA1A gene can result in symptoms of episodic ataxia, such as episodic ataxia type 6.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to DNA, and they play a role in various cellular processes, including gene regulation and chromatin modification.\nIn animals, chromomethylases are involved in the regulation of gene expression, particularly in the context of development and cell differentiation. For example, some chromomethylases are involved in the silencing of gene expression during cell differentiation, while others are involved in the activation of gene expression during embryonic development.\nThere are several types of chromomethylases present in animal genomes, including:\n1. DNA methyltransferases (DNMTs): These enzymes are responsible for adding a methyl group to the cytosine residue of a CpG dinucleotide, leading to the repression of gene transcription.\n2. HMTs (histone methyltransferases): These enzymes are responsible for adding a methyl group to histone proteins, leading to changes in chromatin structure and gene expression.\n3. SETDB1 (Esetin): This enzyme is responsible for adding a methyl group to histone H3 lysine 9 (H3K9), leading to the repression of gene transcription.\n4. SUV39H1 (Suv39h1): This enzyme is responsible for adding a methyl group to histone H3 lysine 27 (H3K27), leading to the repression of gene transcription.\n5. KMT1A (Lysine-specific methyltransferase 1A): This enzyme is responsible for adding a methyl group to lysine residues on histone proteins, leading to changes in chromatin structure and gene expression.\nOverall, chromomethylases play a crucial role in the regulation of gene expression and chromatin structure in animal genomes, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to DNA and are present in animal genomes.\n2. In animals, chromomethylases are involved in regulation of gene expression, particularly during development and cell differentiation.\n3. DNA methyltransferases (DNMTs) add a methyl group to the cytosine residue of a CpG dinucleotide, leading to the repression of gene transcription.\n4. HMTs (histone methyltransferases) add a methyl group to histone proteins, leading to changes in chromatin structure and gene expression.\n5. Dysregulation of chromomethylases has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to DNA and are present in animal genomes.",
      "In animals, chromomethylases are involved in regulation of gene expression, particularly during development and cell differentiation.",
      "DNA methyltransferases (DNMTs) add a methyl group to the cytosine residue of a CpG dinucleotide, leading to the repression of gene transcription.",
      "HMTs (histone methyltransferases) add a methyl group to histone proteins, leading to changes in chromatin structure and gene expression.",
      "Dysregulation of chromomethylases has been implicated in various diseases, including cancer and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that add a methyl group to DNA and are known to be present in plant genomes, not animal genomes.\n2. FALSE [correction]: Since chromomethylases are not present in animal genomes, they are not involved in the regulation of gene expression in animals during development and cell differentiation. Rather, other types of DNA methyltransferases perform this function in animals.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Dysregulation of DNA methyltransferases, not chromomethylases (since they are not present in animal genomes), has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most popular ones:\n1. TRANSFAC: This package provides a comprehensive collection of transcription factor binding sites (TFBS) and their corresponding binding affinities. It also includes a tool for predicting TFBS in a given DNA sequence.\n2. TFBSpred: This package uses a machine learning approach to predict TFBS in a given DNA sequence. It can be used to identify potential TFBS in a query sequence and to predict their binding affinities.\n3. ChIPseek: This package provides a tool for identifying potential TFBS in a given DNA sequence based on ChIP-seq data. It can be used to predict TFBS that are enriched in regions of the genome that are bound by a specific transcription factor.\n4. TFBS-Tools: This package provides a collection of tools for analyzing TFBS in a given DNA sequence. It includes tools for predicting TFBS, identifying potential binding sites, and analyzing the binding affinities of transcription factors.\n5. RIFT: This package provides a tool for predicting TFBS in a given DNA sequence based on the RIFT (Repeats-in-Fragments) algorithm. It can be used to identify potential TFBS in a query sequence and to predict their binding affinities.\n6. TFProfiler: This package provides a tool for analyzing the binding affinities of transcription factors in a given DNA sequence. It can be used to predict TFBS and to identify potential binding sites.\n7. TFSEARCH: This package provides a tool for searching for TFBS in a given DNA sequence. It can be used to identify potential TFBS and to predict their binding affinities.\n8. GTF-utils: This package provides a collection of tools for working with GTF (Genomic Feature) files, which contain information about transcription factor binding sites and other genomic features. It can be used to analyze TFBS in a given DNA sequence and to identify potential binding sites.\n9. TRANSFAC-gold: This package provides a comprehensive collection of transcription factor binding sites (TFBS) and their corresponding binding affinities",
    "llama-2-7b-chat-hf_fact_raw": "1. TRANSFAC is a package in R/Bioconductor that provides a collection of transcription factor binding sites and their binding affinities and includes a tool for predicting TFBS in DNA sequences.\n2. TFBSpred is a package in R/Bioconductor that uses a machine learning approach to predict transcription factor binding sites and binding affinities in DNA sequences.\n3. ChIPseek is a package in R/Bioconductor that provides tools for identifying potential transcription factor binding sites using ChIP-seq data.\n4. TFBS-Tools is a package in R/Bioconductor that offers a collection of tools for analyzing transcription factor binding sites in DNA sequences.\n5. RIFT is a package in R/Bioconductor that predicts transcription factor binding sites using the Repeats-in-Fragments algorithm.",
    "llama-2-7b-chat-hf_fact": [
      "TRANSFAC is a package in R/Bioconductor that provides a collection of transcription factor binding sites and their binding affinities and includes a tool for predicting TFBS in DNA sequences.",
      "TFBSpred is a package in R/Bioconductor that uses a machine learning approach to predict transcription factor binding sites and binding affinities in DNA sequences.",
      "ChIPseek is a package in R/Bioconductor that provides tools for identifying potential transcription factor binding sites using ChIP-seq data.",
      "TFBS-Tools is a package in R/Bioconductor that offers a collection of tools for analyzing transcription factor binding sites in DNA sequences.",
      "RIFT is a package in R/Bioconductor that predicts transcription factor binding sites using the Repeats-in-Fragments algorithm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TRANSFAC is not a package in R/Bioconductor but rather a proprietary database of transcription factors, their binding sites, and regulatory sequences. A package that provides similar functionalities in R/Bioconductor is TFBSTools.\n2. UNKNOWN: There is no package named TFBSpred specifically referenced in the Bioconductor documentation or commonly known R packages at the time of the knowledge cutoff. It could be a hypothetical package or a mistake in the naming.\n3. FALSE [correction]: ChIPseeker is an R/Bioconductor package that provides tools for annotating ChIP-seq data and identifying potential transcription factor binding sites, not ChIPseek.\n4. UNKNOWN: While there are multiple packages in R/Bioconductor that provide tools for analyzing transcription factor binding sites (such as TFBSTools), the exact name TFBS-Tools does not correspond to any specific, widely recognized package at the time of the knowledge cutoff.\n5. UNKNOWN: The RIFT package is not a known R/Bioconductor package specifically linked to the prediction of transcription factor binding sites using a \"Repeats-in-Fragments\" algorithm as of the knowledge cutoff. This could be a fictional package, a new development post-knowledge cutoff, or an error in the name.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Effects of resistance training on muscle mass, strength, and functional capacity in older adults: a systematic review and meta-analysis\" (2019) - This study published in the Journal of the American Medical Directors Association found that resistance training can help prevent sarcopenia by increasing muscle mass, strength, and functional capacity in older adults.\n2. \"Dietary protein intake and sarcopenia: a systematic review and meta-analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that adequate protein intake is important for preventing sarcopenia, particularly in older adults who are malnourished or have chronic diseases.\n3. \"Effects of omega-3 fatty acid supplementation on muscle function and quality of life in older adults: a systematic review and meta-analysis\" (2020) - This study published in the Journal of the American Geriatrics Society found that omega-3 fatty acid supplementation may help improve muscle function and quality of life in older adults, which can help prevent sarcopenia.\n4. \"The effects of yoga on sarcopenia in older adults: a systematic review\" (2020) - This study published in the Journal of Aging and Physical Activity found that yoga may help prevent sarcopenia by improving muscle mass, strength, and functional capacity in older adults.\n5. \"Effects of resistance training and aerobic exercise on muscle mass, strength, and functional capacity in older adults: a systematic review and meta-analysis\" (2019) - This study published in the Journal of Aging and Physical Activity found that both resistance training and aerobic exercise can help prevent sarcopenia by increasing muscle mass, strength, and functional capacity in older adults.\n6. \"The effects of Tai Chi on sarcopenia in older adults: a systematic review\" (2020) - This study published in the Journal of Aging and Physical Activity found that Tai Chi may help prevent sarcopenia by improving muscle mass, strength, and functional capacity in older adults.\n7",
    "llama-2-7b-chat-hf_fact_raw": "1. A study found that resistance training can help prevent sarcopenia in older adults by increasing muscle mass, strength, and functional capacity, according to the Journal of the American Medical Directors Association in 2019.\n2. Adequate protein intake is important for preventing sarcopenia, particularly in malnourished or chronically ill older adults, as noted in a study published in the Journal of the American Geriatrics Society in 2019.\n3. Omega-3 fatty acid supplementation may improve muscle function and quality of life in older adults, potentially helping to prevent sarcopenia, based on a study in the Journal of the American Geriatrics Society in 2020.\n4. Yoga may help prevent sarcopenia by improving muscle mass, strength, and functional capacity in older adults, according to a study published in the Journal of Aging and Physical Activity in 2020.\n5. A study published in the Journal of Aging and Physical Activity in 2019 found that both resistance training and aerobic exercise can help prevent sarcopenia by increasing muscle mass, strength, and functional capacity in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "A study found that resistance training can help prevent sarcopenia in older adults by increasing muscle mass, strength, and functional capacity, according to the Journal of the American Medical Directors Association in 2019.",
      "Adequate protein intake is important for preventing sarcopenia, particularly in malnourished or chronically ill older adults, as noted in a study published in the Journal of the American Geriatrics Society in 2019.",
      "Omega-3 fatty acid supplementation may improve muscle function and quality of life in older adults, potentially helping to prevent sarcopenia, based on a study in the Journal of the American Geriatrics Society in 2020.",
      "Yoga may help prevent sarcopenia by improving muscle mass, strength, and functional capacity in older adults, according to a study published in the Journal of Aging and Physical Activity in 2020.",
      "A study published in the Journal of Aging and Physical Activity in 2019 found that both resistance training and aerobic exercise can help prevent sarcopenia by increasing muscle mass, strength, and functional capacity in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Structure Prediction (Membrane-PSP) database: This database contains a collection of structural and functional information on membrane proteins, including their molecular recognition features.\n2. The Protein Data Bank (PDB): The PDB is a comprehensive database of 3D structures of proteins, including membrane proteins, and provides information on their molecular recognition features.\n3. The Membrane Protein Structural Database (Membrane-SP): This database contains structural information on membrane proteins, including their molecular recognition features, and provides tools for searching and analyzing the data.\n4. The Membrane Protein Interaction Database (MPI-DB): This database contains information on the interactions between membrane proteins and other molecules, including ligands, substrates, and other proteins, and provides tools for searching and analyzing the data.\n5. The Membrane Protein Functional Site Database (Membrane-FSD): This database contains information on the functional sites of membrane proteins, including their binding sites, active sites, and other functional regions, and provides tools for searching and analyzing the data.\n6. The Membrane Protein-Ligand Interaction Database (MPI-DB): This database contains information on the interactions between membrane proteins and ligands, including small molecules, peptides, and other ligands, and provides tools for searching and analyzing the data.\n7. The Membrane Protein-Protein Interaction Database (MPI-DB): This database contains information on the interactions between membrane proteins and other proteins, including other membrane proteins, cytoplasmic proteins, and viral proteins, and provides tools for searching and analyzing the data.\n8. The Membrane Protein-Nucleic Acid Interaction Database (MPI-DB): This database contains information on the interactions between membrane proteins and nucleic acids, including DNA and RNA, and provides tools for searching and analyzing the data.\nThese databases provide valuable information on the molecular recognition features of membrane proteins, which can be used to better understand their structure, function, and",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Structure Prediction (Membrane-PSP) database contains structural and functional information on membrane proteins.\n2. The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Structural Database (Membrane-SP) provides structural information on membrane proteins.\n4. The Membrane Protein Interaction Database (MPI-DB) includes information on the interactions between membrane proteins and other molecules.\n5. The Membrane Protein Functional Site Database (Membrane-FSD) contains information on the functional sites of membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Structure Prediction (Membrane-PSP) database contains structural and functional information on membrane proteins.",
      "The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Structural Database (Membrane-SP) provides structural information on membrane proteins.",
      "The Membrane Protein Interaction Database (MPI-DB) includes information on the interactions between membrane proteins and other molecules.",
      "The Membrane Protein Functional Site Database (Membrane-FSD) contains information on the functional sites of membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: While there isn't a database specifically named \"Membrane Protein Structure Prediction (Membrane-PSP)\", it is plausible that a database could exist which contains structural and functional information on membrane proteins. However, without more context or specific reference to a known database, this statement can't be definitively checked against known databases.\n\n2. TRUE: The Protein Data Bank (PDB) is indeed a comprehensive database that contains 3D structures of biological macromolecules, including proteins and nucleic acids, which would cover membrane proteins as well.\n\n3. UNKNOWN: There is no widely-recognized database known as the \"Membrane Protein Structural Database (Membrane-SP)\" specifically. It's possible that the statement refers to a specific database, but without further context, the existence of such a database can't be verified.\n\n4. UNKNOWN: Similarly to the previous statement, the \"Membrane Protein Interaction Database (MPI-DB)\" is not a known standard database in the scientific community. While there are databases that include information on protein interactions, without specific context, the existence of a database with this exact name is uncertain.\n\n5. UNKNOWN: The \"Membrane Protein Functional Site Database (Membrane-FSD)\" is not a known database in the public domain, and while databases exist that include information on protein functional sites, it is unclear if this is a real database or not without further information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys, with the liver being the primary site of metabolism. The kidneys play a secondary role in metabolism, with the majority of the drug being eliminated in the urine. The kidneys are responsible for metabolizing approximately 50-60% of the drug, while the liver metabolizes the remaining 40-50%.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by both the liver and kidneys.\n2. The liver is the primary site of metabolism for rivaroxaban.\n3. The kidneys play a secondary role in the metabolism of rivaroxaban.\n4. Approximately 50-60% of rivaroxaban is metabolized by the kidneys.\n5. The remaining 40-50% of rivaroxaban is metabolized by the liver.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by both the liver and kidneys.",
      "The liver is the primary site of metabolism for rivaroxaban.",
      "The kidneys play a secondary role in the metabolism of rivaroxaban.",
      "Approximately 50-60% of rivaroxaban is metabolized by the kidneys.",
      "The remaining 40-50% of rivaroxaban is metabolized by the liver."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Approximately 50-60% of a dose of rivaroxaban is excreted by the kidneys, but this refers to renal excretion, not metabolism. The kidneys are not primarily responsible for the metabolism of rivaroxaban; they are primarily involved in its elimination.\n5. FALSE [correction]: The remaining 40-50% of rivaroxaban is excreted unchanged by the kidneys, not metabolized by the liver. The liver is involved in the metabolism of the fraction that is not excreted unchanged by the kidneys.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRα2 is a transcriptional repressor that regulates the expression of several genes in the heart. Some of the genes known to be regulated by TRα2 in the heart include:\n1. Atrial natriuretic factor (ANF): TRα2 binds to the ANF promoter and represses its transcription, leading to decreased ANF production and attenuated natriuretic function.\n2. Beta-myosin heavy chain (MHCβ): TRα2 binds to the MHCβ promoter and represses its transcription, leading to decreased MHCβ expression and altered cardiac contractility.\n3. Brain natriuretic peptide (BNP): TRα2 binds to the BNP promoter and represses its transcription, leading to decreased BNP production and attenuated natriuretic function.\n4. Connective tissue growth factor (CTGF): TRα2 binds to the CTGF promoter and represses its transcription, leading to decreased CTGF expression and fibrosis in the heart.\n5. Hypoxia-inducible factor (HIF): TRα2 binds to the HIF promoter and represses its transcription, leading to decreased HIF expression and adaptation to hypoxic conditions in the heart.\n6. Keratin 2 (KRT2): TRα2 binds to the KRT2 promoter and represses its transcription, leading to decreased KRT2 expression and altered cardiac structure.\n7. Keratin 17 (KRT17): TRα2 binds to the KRT17 promoter and represses its transcription, leading to decreased KRT17 expression and altered cardiac structure.\n8. Matrix metalloproteinase (MMP): TRα2 binds to the MMP promoter and represses its transcription, leading to decreased MMP expression and altered extracellular matrix remodeling in the heart.\n9. Nuclear factor of kappa light chain enhancer in B cells (NF-κB): TRα2 binds to the NF-κB promoter and represses its transcription, leading to decreased NF-κB expression and attenuated inflammation in",
    "llama-2-7b-chat-hf_fact_raw": "1. TRα2 regulates the expression of the atrial natriuretic factor (ANF) gene in the heart by binding to its promoter and repressing transcription.\n2. TRα2 regulates the expression of the beta-myosin heavy chain (MHCβ) gene in the heart by binding to its promoter and repressing transcription.\n3. TRα2 regulates the expression of the brain natriuretic peptide (BNP) gene in the heart by binding to its promoter and repressing transcription.\n4. TRα2 regulates the expression of the connective tissue growth factor (CTGF) gene in the heart by binding to its promoter and repressing transcription.\n5. TRα2 regulates the expression of the hypoxia-inducible factor (HIF) gene in the heart by binding to its promoter and repressing transcription.",
    "llama-2-7b-chat-hf_fact": [
      "TRα2 regulates the expression of the atrial natriuretic factor (ANF) gene in the heart by binding to its promoter and repressing transcription.",
      "TRα2 regulates the expression of the beta-myosin heavy chain (MHCβ) gene in the heart by binding to its promoter and repressing transcription.",
      "TRα2 regulates the expression of the brain natriuretic peptide (BNP) gene in the heart by binding to its promoter and repressing transcription.",
      "TRα2 regulates the expression of the connective tissue growth factor (CTGF) gene in the heart by binding to its promoter and repressing transcription.",
      "TRα2 regulates the expression of the hypoxia-inducible factor (HIF) gene in the heart by binding to its promoter and repressing transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - TRα2 (thyroid hormone receptor alpha 2), which does not bind thyroid hormone, has been shown to act as a transcriptional repressor. It can bind to the promoter regions of certain genes, such as atrial natriuretic factor (ANF), and repress their transcription in cardiac tissue.\n2. UNKNOWN - While thyroid hormone receptors, including TRα isoforms, are known to regulate the expression of certain cardiac genes, detailed information about the specific regulation of beta-myosin heavy chain (MHCβ) gene by TRα2 through binding to its promoter and repressing its transcription is not provided in the statement. Therefore, without specific scientific literature or data to confirm this statement, it is considered unknown.\n3. UNKNOWN - Similar to the statement above, while TRα2 might play a role in cardiac gene regulation, the exact nature of its interaction with the brain natriuretic peptide (BNP) gene promoter and the transcriptional repression of this gene is not mentioned in the statement. We would need specific scientific evidence to substantiate this claim.\n4. UNKNOWN - The statement about TRα2 specifically regulating the connective tissue growth factor (CTGF) gene by binding to its promoter and repressing transcription in the heart is not something that can be substantiated without specific evidence from scientific research, which is not provided. It remains an unknown claim.\n5. UNKNOWN - The role of TRα2 in regulating the hypoxia-inducible factor (HIF) gene through promoter binding and transcription repression in the heart is unclear without further specific scientific evidence. Therefore, this statement is also unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed Central's \"Ask a Biologist\": This system uses natural language processing (NLP) to answer user questions based on the content of biomedical articles in PubMed Central, a free digital archive of biomedical literature.\n2. IBM Watson for Oncology: This system is a cloud-based platform that uses machine learning and NLP to analyze cancer-related data and provide personalized treatment recommendations to oncologists.\n3. Google's \"Google Genomics\": This system provides a suite of tools for analyzing and interpreting genomic data, including a question answering feature that allows users to ask questions about specific genes or genomic regions and receive answers based on the system's analysis of relevant scientific literature.\n4. Microsoft's \"Drug Discovery and Development Platform\": This system uses machine learning and NLP to analyze large datasets of biomedical literature and identify potential drug targets and lead compounds.\n5. BioMed Central's \"BioMed Central's Question Answering System\": This system uses NLP to answer user questions based on the content of biomedical articles in BioMed Central's collection of open access journals.\n6. \"BioQA\": This is a biomedical question answering system that uses NLP to answer questions about gene function, protein structure, and other biomedical concepts.\n7. \"BioASQ\": This is a biomedical question answering system that uses NLP to answer questions about gene function, protein structure, and other biomedical concepts, and also includes a benchmarking dataset for evaluating the performance of biomedical question answering systems.\n8. \"BioCreative II\": This is a biomedical question answering system that uses NLP to answer questions about gene function, protein structure, and other biomedical concepts, and also includes a benchmarking dataset for evaluating the performance of biomedical question answering systems.\n9. \"Bio-IRIS\": This is a biomedical question answering system that uses NLP to answer questions about gene function, protein structure, and other biomedical concepts, and also includes a benchmarking dataset for evaluating the performance of biomedical question answering systems.\n10. \"Open Biomedical Answers\": This is a biomedical question answering system that uses NLP to answer questions",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central has a system called \"Ask a Biologist\" that uses natural language processing to answer questions based on biomedical articles.\n2. IBM Watson for Oncology is a system that provides personalized cancer treatment recommendations using machine learning and natural language processing.\n3. Google's \"Google Genomics\" offers a question answering feature for genomic data interpretation.\n4. Microsoft has a \"Drug Discovery and Development Platform\" that identifies potential drug targets using machine learning and natural language processing.\n5. BioMed Central offers a question answering system that responds to inquiries using their collection of open access journals.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central has a system called \"Ask a Biologist\" that uses natural language processing to answer questions based on biomedical articles.",
      "IBM Watson for Oncology is a system that provides personalized cancer treatment recommendations using machine learning and natural language processing.",
      "Google's \"Google Genomics\" offers a question answering feature for genomic data interpretation.",
      "Microsoft has a \"Drug Discovery and Development Platform\" that identifies potential drug targets using machine learning and natural language processing.",
      "BioMed Central offers a question answering system that responds to inquiries using their collection of open access journals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: \"Ask a Biologist\" is not a feature of PubMed Central; rather, it is a separate educational resource designed to answer biology-related questions. PubMed Central is a free digital archive of biomedical and life sciences journal literature.\n2. TRUE\n3. FALSE [correction]: Google does have an initiative called \"Google Genomics\" (or \"Google Cloud Life Sciences\") that provides tools and services to store, process, and explore genomic data. However, it does not specifically offer a question-answering feature for genomic data interpretation.\n4. TRUE\n5. FALSE [correction]: BioMed Central is a publisher of open-access journals, but there is no indication that it offers a specific question-answering system that responds to inquiries using their collection of journals.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the bethanechol pathway is NF-κB (nuclear factor kappa B).",
    "llama-2-7b-chat-hf_fact_raw": "1. NF-κB (nuclear factor kappa B) is a transcription factor.\n2. NF-κB activates the betalain pathway.",
    "llama-2-7b-chat-hf_fact": [
      "NF-κB (nuclear factor kappa B) is a transcription factor.",
      "NF-κB activates the betalain pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: NF-κB is a transcription factor that is involved in regulating the expression of genes important for immune and inflammatory responses, among other functions. The betalain pathway, responsible for the production of betalains (pigments found in certain plants), is not typically regulated by NF-κB.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses typically involve the enrichment of phosphorylated peptides from protein samples before analysis. There are several technologies that are commonly used for phosphopeptide enrichment, including:\n1. Immunoaffinity purification (IAP): This method uses antibodies specific to phosphorylated peptides to capture and isolate them from the sample.\n2. Enzymatic digestion: This method involves breaking down the proteins in the sample into smaller peptides using enzymes, and then separating the phosphorylated peptides from the non-phosphorylated peptides using techniques such as gel electrophoresis or HPLC.\n3. Chemical capture: This method uses chemical probes that selectively bind to phosphorylated peptides, allowing them to be isolated from the rest of the sample.\n4. IMAC (Immobilized metal affinity chromatography): This method uses metal ions (e.g. Ni2+ or Co2+) immobilized on a resin to capture phosphorylated peptides.\n5. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to capture phosphorylated peptides based on their charge and size.\n6. Hydrophilic interaction liquid chromatography (HILIC): This method separates phosphorylated peptides based on their hydrophilicity, allowing for their enrichment.\n7. Reversed-phase HPLC: This method separates phosphorylated peptides based on their hydrophobicity, allowing for their enrichment.\n8. Microscale thermophoresis (MST): This method uses changes in the temperature-dependent diffusion of peptides to separate and enrich phosphorylated peptides.\n9. Electrospray ionization (ESI): This method uses a high-voltage electrical field to ionize and separate phosphorylated peptides from non-phosphorylated peptides in a liquid sample.\n10. Orbitrap: This method uses an ion trap mass spectrometer to isolate and analyze phosphorylated peptides based",
    "llama-2-7b-chat-hf_fact_raw": "1. Immunoaffinity purification (IAP) is a method used to capture and isolate phosphorylated peptides using antibodies specific to them.\n2. Enzymatic digestion involves breaking down proteins into smaller peptides, then using techniques like gel electrophoresis or HPLC to separate phosphorylated peptides.\n3. Immobilized metal affinity chromatography (IMAC) captures phosphorylated peptides using metal ions immobilized on a resin.\n4. Titanium dioxide (TiO2) is used in a method to capture phosphorylated peptides based on their charge and size.\n5. Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides for enrichment based on their hydrophilicity.",
    "llama-2-7b-chat-hf_fact": [
      "Immunoaffinity purification (IAP) is a method used to capture and isolate phosphorylated peptides using antibodies specific to them.",
      "Enzymatic digestion involves breaking down proteins into smaller peptides, then using techniques like gel electrophoresis or HPLC to separate phosphorylated peptides.",
      "Immobilized metal affinity chromatography (IMAC) captures phosphorylated peptides using metal ions immobilized on a resin.",
      "Titanium dioxide (TiO2) is used in a method to capture phosphorylated peptides based on their charge and size.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides for enrichment based on their hydrophilicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Immunoaffinity purification (IAP) is a method used to capture and isolate proteins or peptides by using antibodies specific to the protein or peptide of interest, not specifically to phosphorylated peptides unless the antibody is specific to a phosphorylated epitope.\n2. FALSE [correction]: Enzymatic digestion does break down proteins into smaller peptides, but it is not a technique used for separating phosphorylated peptides. Techniques like gel electrophoresis or HPLC are used after digestion to separate peptides, but digestion alone does not target phosphorylated peptides.\n3. TRUE\n4. FALSE [correction]: Titanium dioxide (TiO2) is used to capture phosphorylated peptides based on their affinity for titanium dioxide, which specifically binds to phosphorylated residues due to their interaction with the metal oxide, not based on charge and size.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of a genetic disorder called Limb-girdle muscular dystrophy (LGMD).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and is characterized by the sudden onset of symptoms such as pain, swelling, and inflammation in the thyroid gland. While the exact cause of subacute thyroiditis is not fully understood, some studies have suggested that certain viruses may play a role in its development.\nSome of the viruses that have been linked to subacute thyroiditis include:\n1. Viruses of the enterovirus family: Enteroviruses, such as coxsackievirus and echovirus, have been isolated from the thyroid glands of patients with subacute thyroiditis. These viruses are common causes of viral infections in the body and can cause a range of symptoms, including fever, headache, and muscle pain.\n2. Herpesviruses: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have also been implicated in the development of subacute thyroiditis. These viruses can remain dormant in the thyroid gland for years before reactivating and causing inflammation.\n3. Adenoviruses: Adenoviruses are another group of viruses that have been linked to subacute thyroiditis. These viruses are known to cause a range of respiratory, gastrointestinal, and other infections.\nIt is important to note that the exact role of viruses in the development of subacute thyroiditis is still being studied, and more research is needed to fully understand the relationship between viruses and this condition. However, in some cases, viral infections may trigger an autoimmune response, leading to inflammation and damage to the thyroid gland.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.\n2. Some studies have suggested that certain viruses may contribute to the development of subacute thyroiditis.\n3. Enteroviruses, such as coxsackievirus and echovirus, have been isolated from the thyroid glands of patients with subacute thyroiditis.\n4. Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis.\n5. Adenoviruses have been linked to subacute thyroiditis and are known to cause a variety of infections.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.",
      "Some studies have suggested that certain viruses may contribute to the development of subacute thyroiditis.",
      "Enteroviruses, such as coxsackievirus and echovirus, have been isolated from the thyroid glands of patients with subacute thyroiditis.",
      "Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis.",
      "Adenoviruses have been linked to subacute thyroiditis and are known to cause a variety of infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no widespread evidence to support that enteroviruses like coxsackievirus and echovirus have been isolated from the thyroid glands of patients with subacute thyroiditis.\n4. UNKNOWN: While there may be discussions in the medical community about the association of herpesviruses with thyroiditis, without specific context or evidence, the direct relationship between herpesviruses and subacute thyroiditis remains unclear.\n5. UNKNOWN: Adenoviruses are known to cause a variety of infections, but without proper context or studies, it is difficult to confirm their link specifically to subacute thyroiditis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in the EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor EIF2, leading to the suppression of global protein synthesis. STAT3 is a transcription factor that is activated in response to various signals, including cytokines and growth factors, and plays a role in regulating cellular processes such as inflammation, immune response, and cell survival. Studies have shown that EIF2AK2 and STAT3 interact and collaborate to regulate autophagy, with EIF2AK2-mediated suppression of translation leading to the activation of STAT3 and the induction of autophagy.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in the EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 is also known as Eukaryotic Translation Initiation Factor 2-Associated Kinase 2.\n3. EIF2AK2 phosphorylates and inhibits the translation initiation factor EIF2.\n4. Activation of STAT3 occurs in response to various signals, including cytokines and growth factors.\n5. Studies have shown an interaction between EIF2AK2 and STAT3 in the regulation of autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in the EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 is also known as Eukaryotic Translation Initiation Factor 2-Associated Kinase 2.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor EIF2.",
      "Activation of STAT3 occurs in response to various signals, including cytokines and growth factors.",
      "Studies have shown an interaction between EIF2AK2 and STAT3 in the regulation of autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nGiven the scientific nature of these statements, verification would require referencing current scientific literature or databases to confirm their accuracy. Without specific references to such literature, statements 1 and 5 can only be classified as UNKNOWN because while they may be accurate, we cannot determine their truthfulness without additional context. Statements 2, 3, and 4 are generally accepted scientific facts, with EIF2AK2 being a known kinase and STAT3 being a transcription factor activated by various signals.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for the analysis of genomic data, particularly for the identification of structural variations in genomes. It can be used for a variety of purposes, including:\n1. Genome assembly: Theatre can be used to improve the quality of genome assemblies by incorporating information from mate-pair reads and other types of genomic data.\n2. Structural variation detection: Theatre can identify structural variations in genomes, including insertions, deletions, and translocations, by analyzing the patterns of DNA sequence reads.\n3. Variant calling: Theatre can be used to identify genetic variants, including single nucleotide polymorphisms (SNPs), insertions, deletions, and other types of mutations, by analyzing the patterns of DNA sequence reads.\n4. Genetic map construction: Theatre can be used to construct genetic maps by identifying the locations of genetic markers and their distances from each other.\n5. Genome annotation: Theatre can be used to annotate genomes by identifying the locations of functional elements, such as genes, regulatory elements, and repetitive sequences.\n6. Comparative genomics: Theatre can be used to compare genomes from different species or strains to identify differences and similarities in their genomic structures.\n7. Epigenomics: Theatre can be used to study the epigenetic modifications in genomes, such as DNA methylation and histone modification, and how they affect gene expression.\n8. RNA analysis: Theatre can be used to analyze the transcriptome and identify differentially expressed genes, alternative splicing events, and other features of RNA structure and function.\n9. Genome engineering: Theatre can be used to design and construct genomes with specific features or modifications, such as gene knockouts or gene fusions.\n10. Personalized medicine: Theatre can be used to analyze genomic data from individual patients to identify genetic variations that may be associated with specific diseases or conditions, and to develop personalized treatment strategies.\nOverall, Theatre is a powerful tool for analyzing genomic data and can be used in a variety of applications, from basic research to clinical diagnostics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for analyzing genomic data.\n2. Theatre can improve the quality of genome assemblies through the incorporation of data from mate-pair reads.\n3. Theatre is capable of identifying structural variations in genomes, like insertions, deletions, and translocations.\n4. The tool can be used to construct genetic maps by locating genetic markers and measuring their distances from each other.\n5. Theatre can annotate genomes by identifying functional elements such as genes, regulatory elements, and repetitive sequences.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for analyzing genomic data.",
      "Theatre can improve the quality of genome assemblies through the incorporation of data from mate-pair reads.",
      "Theatre is capable of identifying structural variations in genomes, like insertions, deletions, and translocations.",
      "The tool can be used to construct genetic maps by locating genetic markers and measuring their distances from each other.",
      "Theatre can annotate genomes by identifying functional elements such as genes, regulatory elements, and repetitive sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific information about a software tool named \"Theatre\" related to genomic data analysis, it is not possible to verify the accuracy of these statements. The tool's capabilities would need to be confirmed by official documentation or a credible source. If \"Theatre\" is a fictional or hypothetical tool, these statements cannot be evaluated for truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, the general complexity of the algorithm is O(n^2), where n is the length of the shorter sequence.\nThe basic idea of the Smith-Waterman algorithm is to compute the similarity between two sequences by computing the dot product of the two sequences and then finding the maximum value of this dot product over a sliding window of size w. The execution time of this step is O(n), since we need to compute the dot product of the two sequences for each position in the window.\nThe total execution time of the Smith-Waterman algorithm is therefore O(n^2), since we need to compute the dot product of the two sequences for each position in the window, and the window size w is typically a fixed constant.\nIt's worth noting that there are some optimizations that can be made to the Smith-Waterman algorithm to reduce the execution time, such as using a sliding window of size w-1 instead of w, or using a precomputed matrix of similarity values. However, these optimizations only reduce the execution time by a constant factor, and the overall complexity of the algorithm remains O(n^2).",
    "llama-2-7b-chat-hf_fact_raw": "1. The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The algorithm computes the similarity between two sequences by calculating the dot product.\n3. The maximum value of the dot product is found over a sliding window of size w.\n4. The execution time for calculating the dot product in the Smith-Waterman algorithm is O(n).\n5. Optimizations to the Smith-Waterman algorithm can reduce execution time by a constant factor but do not change the overall complexity of O(n^2).",
    "llama-2-7b-chat-hf_fact": [
      "The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The algorithm computes the similarity between two sequences by calculating the dot product.",
      "The maximum value of the dot product is found over a sliding window of size w.",
      "The execution time for calculating the dot product in the Smith-Waterman algorithm is O(n).",
      "Optimizations to the Smith-Waterman algorithm can reduce execution time by a constant factor but do not change the overall complexity of O(n^2)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Smith-Waterman algorithm computes sequence similarity by using dynamic programming to calculate score matrices based on match, mismatch, and gap penalties, not by calculating the dot product.\n3. FALSE [correction]: The concept of a sliding window of size w and finding the maximum value of the dot product is more akin to local sequence alignment or string-matching algorithms but not applicable to the Smith-Waterman algorithm as described.\n4. FALSE [correction]: The execution time for any step in the Smith-Waterman algorithm is dependent on the complexity of the algorithm itself, which is O(n^2). The calculation of any intermediate step (such as updating the score matrix) will contribute to the overall complexity and does not have a separate, independent time complexity.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of proteins. Specifically, it is a member of the SLC16A1 subfamily, which is also known as the vesicular monoamine transporter (VMAT) family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of proteins.\n2. FLVCR1 is part of the SLC16A1 subfamily.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of proteins.",
      "FLVCR1 is part of the SLC16A1 subfamily."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 is part of the SLC49 family, not SLC16A1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1, a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis, has been shown to interact with several proteins using the biotinylation tagging approach. Some of the known interacting partners of GATA-1 include:\n1. p300/CBP-associated factor (PCAF): A histone acetyltransferase that is involved in regulating chromatin remodeling and gene expression.\n2. GATA-binding protein 1 (GATA-1): A transcription factor that is a homolog of GATA-1 and also plays a role in regulating erythroid gene expression.\n3. KAT2A (lysine acetyltransferase 2A): A histone acetyltransferase that is involved in regulating chromatin structure and gene expression.\n4. PML (promyelocytic leukemia protein): A protein that is involved in regulating the response to DNA damage and the development of the immune system.\n5. CBX3 (chromodomain-helicase-DNA-binding protein 3): A protein that is involved in regulating chromatin structure and gene expression during erythropoiesis.\n6. BTK (bruton's tyrosine kinase): A protein that is involved in regulating B cell signaling and the development of the immune system.\n7. ATF2 (activating transcription factor 2): A transcription factor that is involved in regulating the response to DNA damage and the development of the immune system.\n8. NF-κB (nuclear factor kappa B): A transcription factor that is involved in regulating the response to stress and inflammation.\n9. c-Myc (v-myc avian myelocytomatosis viral oncogene homolog): A transcription factor that is involved in regulating cell growth and proliferation.\n10. HIF1A (hypoxia-inducible factor 1-alpha): A transcription factor that is involved in regulating the response to hypoxia and the development of the immune system.\nThese interactions are thought to play a role in regulating the expression of genes involved in erythropo",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with p300/CBP-associated factor (PCAF), which is a histone acetyltransferase.\n2. GATA-1 interacts with GATA-binding protein 1 (GATA-1), a transcription factor and homolog of itself.\n3. GATA-1 interacts with KAT2A (lysine acetyltransferase 2A), another histone acetyltransferase.\n4. GATA-1 interacts with PML (promyelocytic leukemia protein), which is involved in regulating the DNA damage response.\n5. GATA-1 interacts with CBX3 (chromodomain-helicase-DNA-binding protein 3), which plays a role in chromatin structure regulation.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with p300/CBP-associated factor (PCAF), which is a histone acetyltransferase.",
      "GATA-1 interacts with GATA-binding protein 1 (GATA-1), a transcription factor and homolog of itself.",
      "GATA-1 interacts with KAT2A (lysine acetyltransferase 2A), another histone acetyltransferase.",
      "GATA-1 interacts with PML (promyelocytic leukemia protein), which is involved in regulating the DNA damage response.",
      "GATA-1 interacts with CBX3 (chromodomain-helicase-DNA-binding protein 3), which plays a role in chromatin structure regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE – GATA-1 is known to interact with various cofactors, including histone acetyltransferases like p300/CBP-associated factor (PCAF).\n\n2. TRUE – Although it seems unusual, it is not impossible for a protein to interact with itself or its isoforms in biology. This is known as homodimerization, and it is a common process in the function of many transcription factors. Since GATA-1 is a transcription factor that can form homodimers, the statement is considered true.\n\n3. TRUE – GATA-1 can interact with various enzymes including lysine acetyltransferases like KAT2A, which are involved in modifying histones and influencing gene transcription.\n\n4. TRUE – GATA-1 is known to interact with PML. The interaction between GATA-1 and PML has been studied in the context of acute promyelocytic leukemia, where PML-RARA fusion protein involves both proteins.\n\n5. UNKNOWN – While CBX3 is a chromobox protein involved in heterochromatin formation and gene silencing, the specific interaction between GATA-1 and CBX3 is not well documented and requires specific literature to confirm whether this interaction actually takes place.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 interacting with the GATA1 transcription factor leads to the recruitment of GATA1 to specific DNA sequences and the activation of transcription. GATA1 is a transcription factor that plays a crucial role in the regulation of gene expression in erythroid cells, and TAF10 helps to facilitate its interaction with DNA and the initiation of transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interaction with the GATA1 transcription factor results in the recruitment of GATA1 to specific DNA sequences.\n2. The interaction between TAF10 and GATA1 leads to the activation of transcription.\n3. GATA1 is a transcription factor involved in regulating gene expression in erythroid cells.\n4. TAF10 facilitates the interaction of GATA1 with DNA.\n5. TAF10 aids in the initiation of transcription with GATA1.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interaction with the GATA1 transcription factor results in the recruitment of GATA1 to specific DNA sequences.",
      "The interaction between TAF10 and GATA1 leads to the activation of transcription.",
      "GATA1 is a transcription factor involved in regulating gene expression in erythroid cells.",
      "TAF10 facilitates the interaction of GATA1 with DNA.",
      "TAF10 aids in the initiation of transcription with GATA1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific references to scientific literature or a relevant text passage to corroborate the details about the interactions between TAF10 and GATA1, their effects on transcription, and the specific role of TAF10 in facilitating GATA1's interaction with DNA, I cannot determine the accuracy of statements 1, 2, 4, and 5. However, statement 3 is widely known and accepted in the field of biology; GATA1 is indeed a transcription factor known to be involved in the regulation of gene expression in erythroid cells (precursor cells to red blood cells).",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers make more informed decisions about pain management by providing them with relevant information, data, and clinical guidelines. Some examples of DSS for chronic pain management include:\n1. Chronic Pain Management Decision Support System (CPMDSS): This system was developed by the Agency for Healthcare Research and Quality (AHRQ) and provides healthcare providers with evidence-based recommendations for managing chronic pain.\n2. Pain Management Collaborative (PMC): This is a web-based DSS that provides healthcare providers with tools and resources to improve pain management practices.\n3. Pain Care Collaborative (PCC): This DSS is designed to help healthcare providers develop and implement comprehensive pain management plans for patients.\n4. Chronic Pain Management Clinical Decision Support (CPMDSS): This system provides healthcare providers with evidence-based recommendations for managing chronic pain, including guidelines for medication use and non-pharmacological interventions.\n5. Pain Management Guidelines Pocket Guide: This is a mobile app that provides healthcare providers with quick access to evidence-based guidelines for pain management.\n6. Pain Management Decision Support System (PMDSS): This system provides healthcare providers with real-time decision support for pain management, including information on medication options, dosing, and potential side effects.\n7. Chronic Pain Management Algorithm: This is an algorithm-based DSS that provides healthcare providers with a step-by-step approach to managing chronic pain, including recommendations for medication and non-pharmacological interventions.\n8. Pain Management Workflow: This DSS is designed to help healthcare providers streamline their pain management workflow by providing them with tools and resources to manage patient appointments, track progress, and communicate with other healthcare providers.\n9. Pain Management Coordinated Care Plan: This DSS provides healthcare providers with a coordinated care plan for managing chronic pain, including recommendations for medication, non-pharmacological interventions, and follow-up care.\n10. Pain Management Patient Education: This D",
    "llama-2-7b-chat-hf_fact_raw": "1. The Chronic Pain Management Decision Support System (CPMDSS) was developed by the Agency for Healthcare Research and Quality (AHRQ).\n2. The Pain Management Collaborative (PMC) is a web-based decision support system available for chronic pain management.\n3. Chronic Pain Management Clinical Decision Support (CPMDSS) provides healthcare providers with evidence-based recommendations for managing chronic pain.\n4. The Pain Management Guidelines Pocket Guide is a mobile app that offers evidence-based guidelines for pain management to healthcare providers.\n5. The Pain Management Decision Support System (PMDSS) offers real-time decision support for pain management, including medication options and dosing.",
    "llama-2-7b-chat-hf_fact": [
      "The Chronic Pain Management Decision Support System (CPMDSS) was developed by the Agency for Healthcare Research and Quality (AHRQ).",
      "The Pain Management Collaborative (PMC) is a web-based decision support system available for chronic pain management.",
      "Chronic Pain Management Clinical Decision Support (CPMDSS) provides healthcare providers with evidence-based recommendations for managing chronic pain.",
      "The Pain Management Guidelines Pocket Guide is a mobile app that offers evidence-based guidelines for pain management to healthcare providers.",
      "The Pain Management Decision Support System (PMDSS) offers real-time decision support for pain management, including medication options and dosing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is too specific without context, and while AHRQ does develop various tools and resources for health care, it is not possible to verify whether they developed the Chronic Pain Management Decision Support System (CPMDSS) without additional information.\n2. UNKNOWN: Again, the statement is specific, and without additional context, it cannot be confirmed if the Pain Management Collaborative (PMC) refers to a web-based decision support system for chronic pain management. This requires direct evidence or a reliable source to establish its truthfulness.\n3. TRUE: Although I cannot confirm the specific functionality of CPMDSS without direct evidence, it is reasonable to assume that a Clinical Decision Support System designed for chronic pain management would provide healthcare providers with evidence-based recommendations, as this is generally the purpose of such systems.\n4. UNKNOWN: The Pain Management Guidelines Pocket Guide could exist as a mobile app, but it's not possible to verify the truth of this statement without concrete evidence.\n5. UNKNOWN: The PMDSS may offer real-time decision support including medication options and dosing, but there is no way to confirm this specific information without additional context or sources. Generally, decision support systems do offer such features, but the details of the PMDSS are not provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a secreted protein that is primarily localized to the cytoplasm and nucleus of cells, but it can also be found in the extracellular space, particularly in the context of angiogenesis (the formation of new blood vessels).",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a secreted protein.\n2. Angiogenin is primarily localized to the cytoplasm and nucleus of cells.\n3. Angiogenin can also be found in the extracellular space.\n4. Angiogenin plays a role in angiogenesis, which is the formation of new blood vessels.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a secreted protein.",
      "Angiogenin is primarily localized to the cytoplasm and nucleus of cells.",
      "Angiogenin can also be found in the extracellular space.",
      "Angiogenin plays a role in angiogenesis, which is the formation of new blood vessels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that specifically inhibits the activity of the cardiac ion channel KCNQ1, which is involved in the regulation of the cardiac action potential duration and refractoriness. This inhibition of KCNQ1 by ranolazine can lead to the activation of G-protein coupled receptor signaling pathways, such as the Gαq/Gβ1 pathway, which can increase the activity of protein kinases such as PKC and PKG, and thereby affect kinase signaling activation in the heart.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine specifically inhibits the activity of the cardiac ion channel KCNQ1.\n2. KCNQ1 is involved in the regulation of the cardiac action potential duration and refractoriness.\n3. Inhibition of KCNQ1 by ranolazine can lead to the activation of G-protein coupled receptor signaling pathways.\n4. Activation of G-protein coupled receptor signaling pathways by ranolazine can increase the activity of protein kinases such as PKC and PKG.\n5. Ranolazine can affect kinase signaling activation in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine specifically inhibits the activity of the cardiac ion channel KCNQ1.",
      "KCNQ1 is involved in the regulation of the cardiac action potential duration and refractoriness.",
      "Inhibition of KCNQ1 by ranolazine can lead to the activation of G-protein coupled receptor signaling pathways.",
      "Activation of G-protein coupled receptor signaling pathways by ranolazine can increase the activity of protein kinases such as PKC and PKG.",
      "Ranolazine can affect kinase signaling activation in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine primarily acts by inhibiting the late sodium current (I_Na) in cardiac cells, not by specifically inhibiting the activity of the cardiac ion channel KCNQ1.\n2. TRUE\n3. FALSE [correction]: Inhibition of the KCNQ1 channel affects the repolarization phase of the cardiac action potential, but there is no direct evidence that ranolazine’s inhibition of KCNQ1 leads to activation of G-protein coupled receptor signaling pathways.\n4. UNKNOWN: While G-protein coupled receptor signaling can indeed modulate the activity of protein kinases such as PKC and PKG, because statement 3 is false, this statement's accuracy depends on the unrelated effects of ranolazine on G-protein coupled receptors, which is not commonly described.\n5. TRUE: Ranolazine does affect the activity of kinases indirectly through its primary action on sodium currents, which can lead to reduced calcium overload and thus have an impact on kinase signaling in the heart.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is constitutively expressed in many bacteria, its activity is regulated in response to changes in the growth environment. For example, during stationary phase, the levels of Vsr activity are increased in response to the buildup of DNA damage and the need for repair. Additionally, the expression of Vsr is also regulated by transcriptional factors that are activated during different stages of growth, such as the LytM transcriptional regulator in E. coli.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease expression is not entirely independent of the growth phase of bacteria.\n2. Vsr endonuclease activity is regulated in response to changes in the growth environment.\n3. Vsr activity levels are increased during the stationary phase in response to the buildup of DNA damage and the need for repair.\n4. The expression of Vsr endonuclease is regulated by transcriptional factors.\n5. The LytM transcriptional regulator in E. coli is involved in regulating the expression of Vsr endonuclease.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease expression is not entirely independent of the growth phase of bacteria.",
      "Vsr endonuclease activity is regulated in response to changes in the growth environment.",
      "Vsr activity levels are increased during the stationary phase in response to the buildup of DNA damage and the need for repair.",
      "The expression of Vsr endonuclease is regulated by transcriptional factors.",
      "The LytM transcriptional regulator in E. coli is involved in regulating the expression of Vsr endonuclease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Vsr endonuclease expression has been shown to vary with the bacterial growth phase, not being entirely independent of it.\n2. TRUE - Endonuclease activity, such as that of Vsr, is generally subject to regulation based on changes in the environment, including nutrient availability and cell density, as part of the global response to stress.\n3. UNKNOWN - Without specific information about Vsr endonuclease, it is unclear whether its levels increase during the stationary phase in response to DNA damage. This may vary depending on the organism and specific conditions.\n4. TRUE - The expression of many endonucleases, including Vsr, is typically regulated by transcription factors as part of the overall regulation of DNA repair and replication systems.\n5. FALSE [correction]: The LytM transcriptional regulator is known for being involved in cell wall metabolism, particularly in the regulation of murein hydrolases in bacteria like Staphylococcus aureus. It is not typically associated with the regulation of endonucleases like Vsr in E. coli. In E. coli, the LexA protein is involved in regulating the expression of Vsr endonuclease as part of the SOS response to DNA damage.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: TMHMM is a widely used tool for predicting the transmembrane helices in a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n2. TopPred: TopPred is another popular tool for predicting the topology of transmembrane proteins. It uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices and their orientation.\n3. PredictProtein: PredictProtein is a web server that can be used to predict the structure and function of proteins, including their transmembrane topology. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n4. PHD: PHD is a tool for predicting the transmembrane helices in a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n5. Transmembrane Predictor: Transmembrane Predictor is a tool for predicting the transmembrane helices in a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n6. TM-align: TM-align is a tool for aligning multiple transmembrane protein structures to predict the transmembrane helices and their orientation. It can be used to predict the transmembrane topology of a protein sequence.\n7. TM-Suite: TM-Suite is a tool for predicting the transmembrane topology of a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n8. ProbCons: ProbCons is a tool for predicting the transmembrane topology of a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n9. TM-PSSM: TM-PSSM is a tool for predicting the transmembrane topology of a protein sequence. It uses a combination of sequence analysis and structural information to predict the transmembrane helices and their orientation.\n10",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a computational tool used for predicting transmembrane helices in protein sequences.\n2. TopPred uses sequence analysis and machine learning algorithms to predict the topology of transmembrane proteins.\n3. PredictProtein is a web server designed to predict protein structure and function, including transmembrane topology.\n4. PHD is a tool that predicts transmembrane helices in a protein sequence by utilizing sequence analysis and structural information.\n5. TM-align is a computational tool used for aligning multiple transmembrane protein structures to predict transmembrane helices and their orientations.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a computational tool used for predicting transmembrane helices in protein sequences.",
      "TopPred uses sequence analysis and machine learning algorithms to predict the topology of transmembrane proteins.",
      "PredictProtein is a web server designed to predict protein structure and function, including transmembrane topology.",
      "PHD is a tool that predicts transmembrane helices in a protein sequence by utilizing sequence analysis and structural information.",
      "TM-align is a computational tool used for aligning multiple transmembrane protein structures to predict transmembrane helices and their orientations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: TM-align is a computational tool used for aligning protein structures, but it does not specifically predict transmembrane helices and their orientations. It is designed for general protein structure alignment, not exclusively for transmembrane proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used for the classification of intellectual disability (ID) disorders, specifically for those that are caused by mutations in genes involved in neurotransmitter signaling and synaptic function. The Galassi classification system is a way of categorizing ID disorders based on the underlying genetic cause, with the goal of identifying specific genetic mutations that may be responsible for the disorder. The classification system was developed by Dr. Robert Galassi and colleagues and is also known as the Galassi syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used for the classification of intellectual disability disorders.\n2. It categorizes ID disorders based on the underlying genetic cause.\n3. The classification system aims to identify specific genetic mutations responsible for the disorder.\n4. The system was developed by Dr. Robert Galassi and colleagues.\n5. Galassi classification specifically addresses mutations in genes involved in neurotransmitter signaling and synaptic function.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used for the classification of intellectual disability disorders.",
      "It categorizes ID disorders based on the underlying genetic cause.",
      "The classification system aims to identify specific genetic mutations responsible for the disorder.",
      "The system was developed by Dr. Robert Galassi and colleagues.",
      "Galassi classification specifically addresses mutations in genes involved in neurotransmitter signaling and synaptic function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is not used for the classification of intellectual disability disorders. It is actually used for the classification of meniscal cysts associated with tears in the knee.\n2. FALSE [correction]: Since Galassi classification is not for intellectual disability (ID) disorders but meniscal cysts, it does not categorize ID disorders based on the underlying genetic cause.\n3. FALSE [correction]: Since the premise of Galassi classification is incorrect as it does not pertain to intellectual disability, it does not aim to identify specific genetic mutations responsible for ID disorder.\n4. UNKNOWN: Without further context on the development of the Galassi classification for meniscal cysts, I cannot verify whether it was developed by Dr. Robert Galassi and colleagues. More research would be needed to confirm the contributors to this classification system.\n5. FALSE [correction]: As the Galassi classification pertains to meniscal cysts in the knee, it does not specifically address mutations in genes involved in neurotransmitter signaling and synaptic function.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder characterized by a combination of distinctive clinical features. Here are some of the common features of Shapiro syndrome:\n1. Intellectual disability: Individuals with Shapiro syndrome typically have mild to severe intellectual disability, which can range from mild cognitive impairment to profound intellectual disability.\n2. Distinctive facial features: People with Shapiro syndrome often have distinctive facial features, including a small head, narrow eyes, a flat nasal bridge, and a short, upturned nose.\n3. Growth retardation: Children with Shapiro syndrome tend to be short stature and have a delayed growth rate.\n4. Congenital anomalies: Some individuals with Shapiro syndrome may be born with congenital anomalies, such as heart defects, cleft palate, or other structural abnormalities.\n5. Immune system dysfunction: Shapiro syndrome is associated with immune system dysfunction, including a deficiency in the immune system's ability to fight infections.\n6. Increased risk of infections: Individuals with Shapiro syndrome are at increased risk of developing infections, particularly respiratory infections, due to their impaired immune system.\n7. Autoimmune disorders: Some people with Shapiro syndrome may develop autoimmune disorders, such as type 1 diabetes or thyroiditis, due to the dysregulation of the immune system.\n8. Cognitive impairment: In addition to intellectual disability, individuals with Shapiro syndrome may also experience cognitive impairment, including difficulty with memory, attention, and problem-solving.\n9. Speech and language difficulties: Shapiro syndrome can also cause speech and language difficulties, including articulation problems and difficulty with communication.\n10. Seizures: Some individuals with Shapiro syndrome may experience seizures, which can be a result of the underlying genetic mutation or a complication of the disorder.\nIt's important to note that the severity and range of symptoms can vary widely among",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by intellectual disability, which can range from mild cognitive impairment to profound intellectual disability.\n2. Individuals with Shapiro syndrome often have distinctive facial features, such as a small head, narrow eyes, a flat nasal bridge, and a short, upturned nose.\n3. Growth retardation is common in children with Shapiro syndrome, often resulting in short stature and delayed growth rate.\n4. Congenital anomalies, including heart defects and cleft palate, may be present in individuals with Shapiro syndrome.\n5. Shapiro syndrome is associated with immune system dysfunction and an increased risk of infections.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by intellectual disability, which can range from mild cognitive impairment to profound intellectual disability.",
      "Individuals with Shapiro syndrome often have distinctive facial features, such as a small head, narrow eyes, a flat nasal bridge, and a short, upturned nose.",
      "Growth retardation is common in children with Shapiro syndrome, often resulting in short stature and delayed growth rate.",
      "Congenital anomalies, including heart defects and cleft palate, may be present in individuals with Shapiro syndrome.",
      "Shapiro syndrome is associated with immune system dysfunction and an increased risk of infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of spontaneous periodic hypothermia, hyperhidrosis, and agenesis of the corpus callosum. It does not typically include intellectual disability as a characteristic feature.\n2. FALSE [correction]: The distinctive facial features described are not typically associated with Shapiro syndrome. They may be indicative of a different condition.\n3. FALSE [correction]: Growth retardation and resulting short stature are not common characteristics of Shapiro syndrome.\n4. FALSE [correction]: Congenital anomalies such as heart defects and cleft palate are not typically associated with Shapiro syndrome.\n5. FALSE [correction]: Shapiro syndrome is not commonly associated with immune system dysfunction or an increased risk of infections.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1 gene) mutations have been linked to Charcot-Marie-Tooth disease (CMT), a group of genetic disorders that affect the peripheral nervous system, including the feet, legs, and hands. CMT is characterized by progressive muscle weakness, atrophy, and loss of sensation in the affected limbs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within BRAG1 are linked to Charcot-Marie-Tooth disease (CMT).\n2. Charcot-Marie-Tooth disease affects the peripheral nervous system.\n3. CMT is characterized by progressive muscle weakness.\n4. CMT can cause atrophy in the affected limbs.\n5. CMT leads to a loss of sensation in the feet, legs, and hands.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within BRAG1 are linked to Charcot-Marie-Tooth disease (CMT).",
      "Charcot-Marie-Tooth disease affects the peripheral nervous system.",
      "CMT is characterized by progressive muscle weakness.",
      "CMT can cause atrophy in the affected limbs.",
      "CMT leads to a loss of sensation in the feet, legs, and hands."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in a number of genes are linked to Charcot-Marie-Tooth disease; one well-known gene is PMP22, not BRAG1.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor (PP1SI).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, in Bacillus subtilis involves the upregulation of mutation rates in response to nutrient limitation during stationary phase. This is thought to be mediated by several mechanisms, including:\n1. Increased DNA damage: Under nutrient-limited conditions, the DNA damage response is activated, leading to an increase in mutation rates.\n2. Decreased DNA repair: The expression of DNA repair genes is reduced during stationary phase, leading to a decrease in the ability to repair DNA damage, which can increase mutation rates.\n3. Increased error-prone DNA repair: Some DNA repair pathways in B. subtilis are error-prone, leading to an increase in mutations during stationary phase.\n4. Increased expression of mutator genes: Some genes involved in DNA mutation and repair are upregulated during stationary phase, leading to an increase in mutation rates.\n5. Increased recombination: Recombination events can also increase during stationary phase, leading to an increase in mutation rates.\n6. Increased expression of genes involved in DNA replication and repair: Some genes involved in DNA replication and repair are upregulated during stationary phase, leading to an increase in the rate of DNA synthesis and repair, and thus an increase in mutation rates.\n7. Increased oxidative stress: Stationary phase is often associated with increased levels of reactive oxygen species (ROS), which can damage DNA and lead to mutations.\n8. Increased protein degradation: During stationary phase, the expression of genes involved in protein degradation is upregulated, which can lead to the degradation of proteins that are important for DNA repair and mutation avoidance, leading to an increase in mutation rates.\nThese mechanisms work together to increase the mutation rate in B. subtilis during stationary phase, allowing the organism to adapt to changing environmental conditions and maintain its fitness.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis upregulates mutation rates in response to nutrient limitation during the stationary phase.\n2. DNA damage response is activated under nutrient-limited conditions in Bacillus subtilis leading to increased mutation rates.\n3. The expression of DNA repair genes is reduced during the stationary phase in Bacillus subtilis, decreasing the ability to repair DNA damage.\n4. Certain DNA repair pathways in Bacillus subtilis are error-prone, leading to increased mutations during the stationary phase.\n5. Recombination events can increase during the stationary phase in Bacillus subtilis, leading to increased mutation rates.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis upregulates mutation rates in response to nutrient limitation during the stationary phase.",
      "DNA damage response is activated under nutrient-limited conditions in Bacillus subtilis leading to increased mutation rates.",
      "The expression of DNA repair genes is reduced during the stationary phase in Bacillus subtilis, decreasing the ability to repair DNA damage.",
      "Certain DNA repair pathways in Bacillus subtilis are error-prone, leading to increased mutations during the stationary phase.",
      "Recombination events can increase during the stationary phase in Bacillus subtilis, leading to increased mutation rates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Bacillus subtilis has been observed to upregulate mutation rates in response to stressful conditions such as nutrient limitation during the stationary phase as an adaptive response to potentially generate beneficial mutations.\n2. TRUE: Under nutrient-limited conditions in Bacillus subtilis, the DNA damage response can be activated, which can contribute to increased mutation rates.\n3. FALSE [correction]: While the general concept that a reduction in DNA repair gene expression could lead to decreased ability to repair DNA damage is logically sound, in Bacillus subtilis, the expression of DNA repair genes during the stationary phase can actually increase or be part of a complex regulatory network that does not simply reduce repair capacity. DNA repair systems are generally upregulated in response to increased damage or stress.\n4. TRUE: Certain DNA repair pathways in Bacillus subtilis are error-prone (such as the SOS response), which can lead to increased mutations during times of stress, including the stationary phase.\n5. TRUE: Recombination events can indeed increase during the stationary phase in Bacillus subtilis, and this can lead to increased mutation rates as part of the stress response mechanism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucismatosis or erucistic eruption, is a rare skin condition characterized by the appearance of small, itchy, fluid-filled blisters on the skin. The exact cause of erucism is not fully understood, but it is believed to be associated with certain triggers, such as:\n1. Allergies: Some people may develop erucism in response to certain allergens, such as certain foods, insect bites, or environmental triggers.\n2. Skin irritation: Exposure to harsh chemicals, detergents, or other irritants can cause erucism in some individuals.\n3. Certain medications: Some medications, such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood pressure medications, can cause erucism as a side effect.\n4. Hormonal changes: Hormonal fluctuations, such as those that occur during pregnancy or menstruation, can lead to the development of erucism.\n5. Genetic predisposition: Some people may be more susceptible to developing erucism due to genetic factors.\nIt's important to note that erucism can occur spontaneously without any identifiable cause in some cases. If you are experiencing symptoms of erucism, it's important to consult with a healthcare professional to determine the underlying cause and appropriate treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a rare skin condition characterized by small, itchy, fluid-filled blisters on the skin.\n2. The exact cause of erucism is not fully understood.\n3. Allergies are believed to be a potential trigger of erucism.\n4. Exposure to harsh chemicals, detergents, or other irritants can cause erucism in some individuals.\n5. Some medications, including antibiotics, NSAIDs, and blood pressure medications, can cause erucism as a side effect.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a rare skin condition characterized by small, itchy, fluid-filled blisters on the skin.",
      "The exact cause of erucism is not fully understood.",
      "Allergies are believed to be a potential trigger of erucism.",
      "Exposure to harsh chemicals, detergents, or other irritants can cause erucism in some individuals.",
      "Some medications, including antibiotics, NSAIDs, and blood pressure medications, can cause erucism as a side effect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not a skin condition; it is the term for irritation and skin reactions caused by contact with the hairs or bristles of certain caterpillars.\n2. TRUE\n3. FALSE [correction]: Since erucism is caused by contact with certain caterpillars, it is not triggered by allergies, but rather an irritant reaction to the caterpillar bristles.\n4. FALSE [correction]: Erucism is specifically caused by caterpillar hairs, not by exposure to harsh chemicals, detergents, or other irritants which might cause other types of dermatitis.\n5. FALSE [correction]: Medications including antibiotics, NSAIDs, and blood pressure medications can cause various side effects, but erucism is not related to medication side effects; it is related to contact with certain caterpillars.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of medical conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to lower blood pressure in patients with hypertension.\n2. Heart failure: Hydrochlorothiazide can help reduce fluid buildup and improve breathing in patients with heart failure.\n3. Edema (swelling): Hydrochlorothiazide is used to treat edema (swelling) caused by fluid buildup in the body.\n4. Nephrotic syndrome: Hydrochlorothiazide can help reduce proteinuria (excess protein in the urine) in patients with nephrotic syndrome.\n5. Kidney disease: Hydrochlorothiazide can help improve urine output and reduce fluid buildup in the body in patients with chronic kidney disease.\n6. Liver disease: Hydrochlorothiazide can help reduce fluid buildup in the body in patients with liver disease.\n7. Angiotensin-converting enzyme (ACE) inhibitors: Hydrochlorothiazide can be used in combination with ACE inhibitors to treat high blood pressure and heart failure.\n8. Renal impairment: Hydrochlorothiazide can help reduce fluid buildup in the body in patients with renal impairment.\n9. Hyperlipidemia (high cholesterol): Hydrochlorothiazide can help reduce cholesterol levels in the blood in patients with hyperlipidemia.\nIt is important to note that hydrochlorothiazide may have other uses not listed here. Always consult with a healthcare professional for medical advice and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide can help reduce fluid buildup and improve breathing in patients with heart failure.\n3. Hydrochlorothiazide is used to treat edema (swelling) caused by fluid buildup in the body.\n4. Hydrochlorothiazide can help reduce proteinuria (excess protein in the urine) in patients with nephrotic syndrome.\n5. Hydrochlorothiazide can help improve urine output and reduce fluid buildup in patients with chronic kidney disease.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide can help reduce fluid buildup and improve breathing in patients with heart failure.",
      "Hydrochlorothiazide is used to treat edema (swelling) caused by fluid buildup in the body.",
      "Hydrochlorothiazide can help reduce proteinuria (excess protein in the urine) in patients with nephrotic syndrome.",
      "Hydrochlorothiazide can help improve urine output and reduce fluid buildup in patients with chronic kidney disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to treat proteinuria in patients with nephrotic syndrome. Instead, medications such as ACE inhibitors or ARBs are commonly used.\n5. FALSE [correction]: While hydrochlorothiazide may increase urine output, it is generally not used to treat chronic kidney disease because it can further impair kidney function. Treatment for fluid buildup in CKD typically involves other types of diuretics or treatment modalities.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials, such as silicone, have been used to create devices that can be implanted in the body to support the urethra and help prevent urinary incontinence. These devices, known as midurethral slings or pelvic floor reconstruction, are typically used to treat stress urinary incontinence (SUI), which is the most common type of urinary incontinence.\nThe silicon-based devices are designed to lift and support the urethra, reducing the likelihood of urine leakage during physical activity or other movements. They are typically made of a soft, flexible material that can be easily inserted through a small incision in the abdomen and positioned around the urethra.\nStudies have shown that silicon-based midurethral slings can be effective in reducing the symptoms of SUI, with a success rate of up to 80-90% in some studies. However, as with any surgical procedure, there are potential risks and complications associated with the use of silicon-based devices, such as infection, bleeding, and erosion of the device into the surrounding tissue.\nIt's important to note that silicon-based devices are not the only option for treating urinary incontinence, and other treatments such as pelvic floor exercises, bladder training, and medications may be recommended before or in addition to surgical interventions. It's important to consult with a healthcare provider to determine the best course of treatment for individual cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been used to create devices that can be implanted in the body to support the urethra and help prevent urinary incontinence.\n2. These devices, known as midurethral slings or pelvic floor reconstruction, are typically used to treat stress urinary incontinence.\n3. The silicon-based devices are typically inserted through a small incision in the abdomen and positioned around the urethra.\n4. Studies have shown that silicon-based midurethral slings can have a success rate of up to 80-90% in reducing symptoms of stress urinary incontinence.\n5. There are potential risks and complications associated with the use of silicon-based devices for urinary incontinence, such as infection, bleeding, and erosion into the surrounding tissue.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been used to create devices that can be implanted in the body to support the urethra and help prevent urinary incontinence.",
      "These devices, known as midurethral slings or pelvic floor reconstruction, are typically used to treat stress urinary incontinence.",
      "The silicon-based devices are typically inserted through a small incision in the abdomen and positioned around the urethra.",
      "Studies have shown that silicon-based midurethral slings can have a success rate of up to 80-90% in reducing symptoms of stress urinary incontinence.",
      "There are potential risks and complications associated with the use of silicon-based devices for urinary incontinence, such as infection, bleeding, and erosion into the surrounding tissue."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicon-based materials are not typically used for implants in the body due to their biocompatibility issues; instead, silicone, which is a different material, has been used for devices like midurethral slings.\n2. TRUE\n3. FALSE [correction]: Midurethral slings are typically inserted through a vaginal incision, not an incision in the abdomen.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a suggested association between the lunar cycle (the cycle of the moon) and the risk of rupture of intracranial aneurysms. Some studies have found that the risk of rupture of intracranial aneurysms increases during the full moon and new moon phases of the lunar cycle.\nOne study published in the Journal of Neurosurgery found that the risk of rupture of intracranial aneurysms was significantly higher during the full moon phase compared to other phases of the lunar cycle. Another study published in the Journal of Stroke and Cerebrovascular Diseases found similar results, with a higher risk of rupture during the full moon and new moon phases.\nThe exact mechanism by which the lunar cycle may affect the rupture risk of intracranial aneurysms is not fully understood, but several theories have been proposed. One theory is that the increased blood pressure and flow during the full moon phase may put additional stress on the weakened walls of an aneurysm, leading to rupture. Another theory is that the hormonal changes that occur during the menstrual cycle in women may play a role in the association between the lunar cycle and aneurysm rupture.\nIt is important to note that these studies were small and had limited sample sizes, so more research is needed to confirm these findings and establish a clear association between the lunar cycle and rupture risk of intracranial aneurysms. Additionally, the risk of rupture of intracranial aneurysms can vary widely among individuals, and other factors such as genetics, age, and medical history also play a significant role in determining an individual's risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies suggest that the risk of rupture of intracranial aneurysms increases during the full moon and new moon phases of the lunar cycle.\n2. A study published in the Journal of Neurosurgery found that the risk of rupture of intracranial aneurysms was higher during the full moon phase.\n3. Another study in the Journal of Stroke and Cerebrovascular Diseases found a higher risk of rupture during the full moon and new moon phases.\n4. One proposed theory for the association between the lunar cycle and aneurysm rupture risk is the increased blood pressure and flow during the full moon phase, which may put additional stress on aneurysms.\n5. The risk of rupture of intracranial aneurysms can be influenced by factors such as genetics, age, and medical history.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies suggest that the risk of rupture of intracranial aneurysms increases during the full moon and new moon phases of the lunar cycle.",
      "A study published in the Journal of Neurosurgery found that the risk of rupture of intracranial aneurysms was higher during the full moon phase.",
      "Another study in the Journal of Stroke and Cerebrovascular Diseases found a higher risk of rupture during the full moon and new moon phases.",
      "One proposed theory for the association between the lunar cycle and aneurysm rupture risk is the increased blood pressure and flow during the full moon phase, which may put additional stress on aneurysms.",
      "The risk of rupture of intracranial aneurysms can be influenced by factors such as genetics, age, and medical history."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific studies to refer to, the veracity of this statement cannot be confirmed.\n2. UNKNOWN: Without access to the specific article in the Journal of Neurosurgery, the statement's accuracy cannot be verified.\n3. UNKNOWN: Similar to statement 2, without access to the specific study published in the Journal of Stroke and Cerebrovascular Diseases, it is not possible to confirm this statement's accuracy.\n4. UNKNOWN: Although this theory could be proposed by some research, without specific references, it's not possible to confirm its truthfulness or the acceptance of this theory within the scientific community.\n5. TRUE: It is well-established in medical literature that the risk of rupture of intracranial aneurysms is influenced by a variety of factors, including genetics, age, and patient medical history.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein (also known as ELAVL1) regulates the splicing process in cells. HuR is a RNA-binding protein that plays a critical role in the regulation of pre-mRNA splicing, particularly in the splicing of exon-exon junctions. It binds to specific sequences in the pre-mRNA and facilitates the splicing reaction by positioning the spliceosome at the correct location on the RNA molecule. HuR also regulates the expression of alternative splice variants, and its dysregulation has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein, also known as ELAVL1, regulates the splicing process in cells.\n2. HuR is a RNA-binding protein.\n3. HuR plays a role in the regulation of pre-mRNA splicing, particularly at exon-exon junctions.\n4. HuR binds to specific sequences in the pre-mRNA to facilitate the positioning of the spliceosome.\n5. Dysregulation of HuR has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein, also known as ELAVL1, regulates the splicing process in cells.",
      "HuR is a RNA-binding protein.",
      "HuR plays a role in the regulation of pre-mRNA splicing, particularly at exon-exon junctions.",
      "HuR binds to specific sequences in the pre-mRNA to facilitate the positioning of the spliceosome.",
      "Dysregulation of HuR has been implicated in a variety of diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein, also known as ELAVL1, is involved in the regulation of mRNA stability and translation, not the splicing process.\n2. TRUE\n3. FALSE [correction]: HuR is involved in the regulation of mRNA stability and translation, not specifically in the regulation of pre-mRNA splicing at exon-exon junctions.\n4. UNKNOWN: Without specific information on HuR's interaction with pre-mRNA at exon-exon junctions to facilitate spliceosome positioning, it's hard to determine the validity of this statement.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (ProT) is a small protein that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of ProT, also known as ProT-CT, has been shown to have several functional roles:\n1. Cell cycle regulation: ProT-CT inhibits the activity of cyclin-dependent kinases (CDKs), which are key regulators of the cell cycle, particularly in the G1/S phase transition. This inhibition leads to a decrease in cell proliferation and an increase in cell cycle arrest.\n2. Apoptosis: ProT-CT has been shown to induce apoptosis in various cell types, including cancer cells, by activating caspases and inhibiting the anti-apoptotic protein Bcl-xL.\n3. DNA repair: ProT-CT has been shown to stimulate the activity of the DNA repair enzyme, OGG1, which helps to maintain genome stability by repairing oxidative DNA damage.\n4. Autophagy: ProT-CT has been shown to induce autophagy, a process by which cells degrade and recycle damaged or dysfunctional organelles and proteins, which helps to maintain cellular homeostasis.\n5. Neuroprotection: ProT-CT has been shown to protect neurons against oxidative stress and excitotoxicity, which can contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's.\nIn summary, ProT-CT has a wide range of functional roles in various cellular processes, including cell cycle regulation, apoptosis, DNA repair, autophagy, and neuroprotection. Its dysregulation has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of Prothymosin alpha, ProT-CT, inhibits the activity of cyclin-dependent kinases (CDKs).\n2. ProT-CT induces apoptosis in various cell types by activating caspases and inhibiting the protein Bcl-xL.\n3. ProT-CT stimulates the activity of the DNA repair enzyme OGG1.\n4. ProT-CT can induce autophagy in cells.\n5. ProT-CT has been shown to have neuroprotective effects against oxidative stress and excitotoxicity.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of Prothymosin alpha, ProT-CT, inhibits the activity of cyclin-dependent kinases (CDKs).",
      "ProT-CT induces apoptosis in various cell types by activating caspases and inhibiting the protein Bcl-xL.",
      "ProT-CT stimulates the activity of the DNA repair enzyme OGG1.",
      "ProT-CT can induce autophagy in cells.",
      "ProT-CT has been shown to have neuroprotective effects against oxidative stress and excitotoxicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nExplanation:\nThere is limited public knowledge, as of my last update in 2023, explaining the specific biological functions of the Prothymosin alpha (ProT) and its c-terminal peptide, ProT-CT. These statements would require very specific and advanced knowledge in the field of molecular biology and the latest scientific research findings. Some of them may have been addressed in scientific studies, but without the context or the actual studies at hand, the verification of some of the statements is not possible.\n\nStatement 2 is true as it is a known role of ProT-CT to induce apoptosis through the activation of caspases and inhibition of anti-apoptotic proteins like Bcl-xL.\n\nStatement 3 is true because ProT-CT is known to activate the DNA repair enzyme OGG1, which plays a role in the base excision repair pathway.\n\nStatement 5 is true as there have been studies showing that ProT-CT has neuroprotective effects against oxidative stress.\n\nFor statements 1 and 4, while there might be research that addresses these points, a lack of specific references in the question makes it difficult to confirm their veracity, hence the response of \"UNKNOWN\". These would need to be checked against the latest scientific literature for accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRQARRP. This sequence is located in the N-terminal region of the cystatin C protein and is responsible for the formation of fibrillar aggregates.",
    "llama-2-7b-chat-hf_fact_raw": "1. The amino acid sequence RRQARRP plays a pivotal role in human cystatin C fibrillization.\n2. The sequence RRQARRP is located in the N-terminal region of the cystatin C protein.\n3. This sequence is responsible for the formation of fibrillar aggregates in cystatin C.",
    "llama-2-7b-chat-hf_fact": [
      "The amino acid sequence RRQARRP plays a pivotal role in human cystatin C fibrillization.",
      "The sequence RRQARRP is located in the N-terminal region of the cystatin C protein.",
      "This sequence is responsible for the formation of fibrillar aggregates in cystatin C."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The sequence RRQARRP is located at positions 57-63 of human cystatin C, which is not in the N-terminal region but rather in the central part of the protein.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor-1 alpha) increases after the administration of the cytoprotective prodrug ethyol (amifostine). HIF-1α is a transcription factor that plays a critical role in response to hypoxia, and its activation is a key mechanism by which ethyol provides cytoprotection. Ethyol is converted to the active compound ethylene oxide in the body, which can induce the expression of HIF-1α and other genes involved in adaptive responses to hypoxia, such as glucose metabolism and angiogenesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).\n2. HIF-1α is a transcription factor that plays a critical role in response to hypoxia.\n3. The activation of HIF-1α is a key mechanism by which amifostine (ethyol) provides cytoprotection.\n4. Amifostine (ethyol) is converted to the active compound ethylene oxide in the body.\n5. Ethylene oxide can induce the expression of HIF-1α and other genes involved in adaptive responses to hypoxia.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).",
      "HIF-1α is a transcription factor that plays a critical role in response to hypoxia.",
      "The activation of HIF-1α is a key mechanism by which amifostine (ethyol) provides cytoprotection.",
      "Amifostine (ethyol) is converted to the active compound ethylene oxide in the body.",
      "Ethylene oxide can induce the expression of HIF-1α and other genes involved in adaptive responses to hypoxia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Amifostine (ethyol) is dephosphorylated to the active compound WR-1065 in the body, not ethylene oxide.\n5. FALSE [correction]: It is the active metabolite of amifostine, WR-1065, that may induce the expression of HIF-1α and other genes involved in adaptive responses to hypoxia, not ethylene oxide. Ethylene oxide is a different compound and is primarily known as an industrial sterilizing agent, not for its role in gene expression related to hypoxia.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3. H3K4me3 is a repressive mark that is associated with the activation of genes and is often found at the promoters of actively expressed genes. Set7 is a key enzyme involved in the establishment and maintenance of these marks, and plays a role in regulating gene expression during various cellular processes, including cell proliferation, differentiation, and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3.\n3. H3K4me3 is associated with the activation of genes.\n4. H3K4me3 marks are often found at the promoters of actively expressed genes.\n5. Set7 plays a role in regulating gene expression during various cellular processes including cell proliferation, differentiation, and development.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3.",
      "H3K4me3 is associated with the activation of genes.",
      "H3K4me3 marks are often found at the promoters of actively expressed genes.",
      "Set7 plays a role in regulating gene expression during various cellular processes including cell proliferation, differentiation, and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 deposits histone 3 lysine 4 monomethylation (H3K4me1) marks on histone H3, not trimethylation (H3K4me3).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "DNAJC11 encodes a protein that is predominantly localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is predominantly localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is predominantly localized to the mitochondria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe localization of a protein encoded by a specific gene can be determined through scientific research, but without the specific context or study referencing the protein DNAJC11, I cannot confirm the accuracy of the statement. Therefore, without additional context or citation from relevant scientific literature, the localization of the protein encoded by the gene DNAJC11 remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UEs) are often depleted among copy number variants (CNVs). CNVs are genomic regions that contain duplications or deletions of DNA sequences, and they can affect the expression of nearby genes. UEs are a class of genomic elements that are characterized by high conservation across species and are thought to play important roles in regulating gene expression and other cellular processes.\nStudies have shown that UEs are enriched in regions of the genome that are less prone to CNVs, such as gene bodies and regulatory regions. This is because CNVs are more likely to occur in regions of the genome that are less conserved and have a lower evolutionary pressure to maintain their sequence fidelity. As a result, UEs are less likely to be disrupted by CNVs, which can lead to changes in gene expression and other cellular processes.\nIn contrast, regions of the genome that are more prone to CNVs, such as repetitive DNA sequences, are more likely to have UEs that are disrupted by CNVs. This can lead to changes in the expression of nearby genes and other cellular processes.\nOverall, the depletion of UEs among CNVs suggests that these elements play important roles in maintaining the stability of gene expression and other cellular processes, and that their disruption by CNVs can have significant consequences for cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UEs) are often depleted among copy number variants (CNVs).\n2. Copy number variants (CNVs) can contain duplications or deletions of DNA sequences.\n3. Ultraconserved elements (UEs) are highly conserved across species.\n4. Studies indicate that UEs are enriched in regions of the genome less prone to CNVs, such as gene bodies and regulatory regions.\n5. UEs tend to be less disrupted by CNVs, which are more likely to occur in less conserved regions of the genome.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UEs) are often depleted among copy number variants (CNVs).",
      "Copy number variants (CNVs) can contain duplications or deletions of DNA sequences.",
      "Ultraconserved elements (UEs) are highly conserved across species.",
      "Studies indicate that UEs are enriched in regions of the genome less prone to CNVs, such as gene bodies and regulatory regions.",
      "UEs tend to be less disrupted by CNVs, which are more likely to occur in less conserved regions of the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UEs) are typically regions in the genome that are resistant to change and thus tend to be depleted among copy number variants (CNVs), which are structural variations in the genome that can involve duplication or deletion of DNA sequences.\n2. TRUE: Copy number variants (CNVs) are indeed genomic alterations that can result in the cell having an abnormal number of copies of one or more sections of the DNA, including both duplications and deletions of those sequences.\n3. TRUE: Ultraconserved elements (UEs) are known to be sequences that are highly conserved across different species, suggesting that they have important functions and are subject to strong evolutionary constraints.\n4. FALSE [correction]: Studies indicate that UEs are depleted in regions of the genome that are prone to CNVs. This suggests that UEs are typically found in more stable regions of the genome, such as gene bodies and regulatory regions, which contradicts the original statement.\n5. TRUE: UEs tend to be less disrupted by CNVs precisely because they are often found in regions of the genome that are highly conserved and less subject to structural variations like CNVs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has1 (Haspin) is a protein kinase that plays a critical role in regulating the progression of mitosis by phosphorylating and inhibiting the activity of the separin protein. The substrate of Has1 during mitosis is separin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase is a protein kinase that regulates the progression of mitosis.\n2. Haspin kinase phosphorylates and inhibits the activity of the separin protein during mitosis.\n3. The substrate of Haspin kinase during mitosis is separin.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase is a protein kinase that regulates the progression of mitosis.",
      "Haspin kinase phosphorylates and inhibits the activity of the separin protein during mitosis.",
      "The substrate of Haspin kinase during mitosis is separin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin kinase does not phosphorylate and inhibit separin. Haspin kinase phosphorylates histone H3 to regulate chromosome segregation during mitosis.\n3. FALSE [correction]: The substrate of Haspin kinase during mitosis is histone H3, not separin.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other viruses. They do not have a protein coat or capsid and do not infect cells by penetrating the cell membrane. Instead, they replicate by infecting the host plant's RNA-dependent RNA polymerase, which is an enzyme that synthesizes RNA from other RNA templates.\nThe mechanism of viroid replication involves the following steps:\n1. Infection: Viroids infect the host plant by entering the cell through the plasma membrane. Once inside the cell, they bind to the RNA-dependent RNA polymerase and prevent it from functioning properly.\n2. RNA synthesis: The bound RNA-dependent RNA polymerase continues to synthesize RNA, but instead of using messenger RNA (mRNA) as a template, it uses the viroid RNA as a template. This results in the synthesis of additional viroid RNA, which accumulates in the cytoplasm of the infected cell.\n3. Replication: The viroid RNA is replicated by the host cell's RNA-dependent RNA polymerase, producing more viroid RNA. This process is continuous, resulting in a rapid increase in the amount of viroid RNA in the infected cell.\n4. Transmission: The newly synthesized viroid RNA is transmitted to other cells through a process called cytoplasmic streaming, which is the movement of cytoplasm from one cell to another. This allows the viroid to spread from cell to cell, infecting new cells and perpetuating the infection.\n5. Symptoms: The accumulation of viroid RNA in the cytoplasm of infected cells can cause a variety of symptoms, including stunted growth, yellowing of leaves, and distortion of leaf shapes. These symptoms are usually seen in plants that are sensitive to viroid infection.\nOverall, the mechanism of viroid replication is a complex process that involves the infection of host cells, the synthesis of additional viroid RNA, and the transmission of this RNA to other cells. This unique mechanism of replication allows viroids to infect a wide range of plant species and to cause significant",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that lack a protein coat or capsid.\n2. Viroids replicate by infecting the host plant's RNA-dependent RNA polymerase, an enzyme that normally synthesizes RNA from RNA templates.\n3. Once inside a host plant cell, viroids use their own RNA as a template for replication by the plant's RNA-dependent RNA polymerase.\n4. New viroid RNA is transmitted to other cells through cytoplasmic streaming, enabling the viroid to spread to new cells within the plant.\n5. Infected cells can exhibit symptoms such as stunted growth, yellowing of leaves, and distortion of leaf shapes due to the accumulation of viroid RNA.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that lack a protein coat or capsid.",
      "Viroids replicate by infecting the host plant's RNA-dependent RNA polymerase, an enzyme that normally synthesizes RNA from RNA templates.",
      "Once inside a host plant cell, viroids use their own RNA as a template for replication by the plant's RNA-dependent RNA polymerase.",
      "New viroid RNA is transmitted to other cells through cytoplasmic streaming, enabling the viroid to spread to new cells within the plant.",
      "Infected cells can exhibit symptoms such as stunted growth, yellowing of leaves, and distortion of leaf shapes due to the accumulation of viroid RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids replicate by hijacking the host plant's RNA polymerase, which is normally an RNA-dependent DNA polymerase that synthesizes DNA from RNA templates during transcription. The host polymerase mistakenly accepts the viroid RNA as a template, leading to replication.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Studies have shown that levels of fibronectin in the blood of DMD patients are significantly lower than in healthy individuals, which could potentially be used as a diagnostic marker for the disease. Additionally, fibronectin levels have been found to correlate with disease severity and progression in DMD patients, making it a promising biomarker for monitoring disease progression and response to treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy.\n2. Studies suggest that levels of fibronectin in the blood of patients with Duchenne muscular dystrophy are significantly lower than in healthy individuals.\n3. Fibronectin levels may serve as a diagnostic marker for Duchenne muscular dystrophy.\n4. There is a correlation between fibronectin levels and disease severity in patients with Duchenne muscular dystrophy.\n5. Fibronectin levels may be used to monitor disease progression and response to treatment in Duchenne muscular dystrophy patients.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy.",
      "Studies suggest that levels of fibronectin in the blood of patients with Duchenne muscular dystrophy are significantly lower than in healthy individuals.",
      "Fibronectin levels may serve as a diagnostic marker for Duchenne muscular dystrophy.",
      "There is a correlation between fibronectin levels and disease severity in patients with Duchenne muscular dystrophy.",
      "Fibronectin levels may be used to monitor disease progression and response to treatment in Duchenne muscular dystrophy patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Fibronectin has been identified in various studies as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n\n2. FALSE [correction]: Studies suggest that levels of fibronectin in the blood of patients with Duchenne muscular dystrophy are significantly higher, not lower, than in healthy individuals.\n\n3. TRUE - The presence of fibronectin in higher levels in patients with DMD compared to healthy individuals suggests that it may serve as a diagnostic marker for the disease.\n\n4. TRUE - There have been findings that indicate a correlation between fibronectin levels and disease severity in patients with Duchenne muscular dystrophy, making it a potential biomarker for assessing severity.\n\n5. UNKNOWN - While fibronectin levels have been identified as a potential biomarker, without specific study references, it is not possible to confidently state whether they can be used to monitor disease progression and response to treatment in Duchenne muscular dystrophy patients. More research may be needed to substantiate this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is an epigenomic data server that contains data from several major epigenome projects, including:\n1. ENCODE (ENCyclopedia Of DNA Elements): The Encyclopedia of DNA Elements (ENCODE) project is a large-scale effort to map all of the functional elements in the human genome.\n2. Roadmap Epigenomics Project: The Roadmap Epigenomics Project is a collaborative effort to map the epigenetic landscape of multiple organisms, including humans, mice, and fruit flies.\n3. NIH Roadmap Epigenomics Mapping Centers: The NIH Roadmap Epigenomics Mapping Centers are a set of collaborative research projects that aim to map the epigenetic marks on a large scale across different tissues and cell types.\n4. Epigenome-wide Association Study (EWAS): EWAS is a type of study that aims to identify genome-wide associations between epigenetic marks and specific diseases or traits.\n5. Human Epigenome Atlas (HEA): The Human Epigenome Atlas is a project that aims to create a comprehensive atlas of epigenetic marks across different human tissues and cell types.\n6. Mouse Epigenome Project: The Mouse Epigenome Project is a large-scale effort to map the epigenetic landscape of the mouse genome.\n7. Fruit Fly Epigenomics Project: The Fruit Fly Epigenomics Project is a collaborative effort to map the epigenetic marks in the Drosophila melanogaster genome.\n8. Arabidopsis Epigenomics Project: The Arabidopsis Epigenomics Project is a large-scale effort to map the epigenetic marks in the Arabidopsis thaliana genome.\n9. Yeast Epigenomics Project: The Yeast Epigenomics Project is a collaborative effort to map the epigenetic marks in the Saccharomyces cerevisiae genome.\n10. ChIP-seq and DNase-seq projects: These projects are focused on mapping the binding sites of transcription factors and other proteins that regulate gene expression, as well as the sites of DNA fragmentation in different cell types.\nThese projects are just a few examples of the major epigenome projects that are contained in the DeepBlue ep",
    "llama-2-7b-chat-hf_fact_raw": "1. The ENCODE project aims to map all functional elements in the human genome.\n2. The Roadmap Epigenomics Project maps the epigenetic landscape of multiple organisms, including humans, mice, and fruit flies.\n3. The NIH Roadmap Epigenomics Mapping Centers are collaborative research projects aimed at mapping epigenetic marks across different tissues and cell types.\n4. Epigenome-wide Association Studies (EWAS) aim to identify associations between epigenetic marks and specific diseases or traits.\n5. The Human Epigenome Atlas project aims to create a comprehensive atlas of epigenetic marks across different human tissues and cell types.",
    "llama-2-7b-chat-hf_fact": [
      "The ENCODE project aims to map all functional elements in the human genome.",
      "The Roadmap Epigenomics Project maps the epigenetic landscape of multiple organisms, including humans, mice, and fruit flies.",
      "The NIH Roadmap Epigenomics Mapping Centers are collaborative research projects aimed at mapping epigenetic marks across different tissues and cell types.",
      "Epigenome-wide Association Studies (EWAS) aim to identify associations between epigenetic marks and specific diseases or traits.",
      "The Human Epigenome Atlas project aims to create a comprehensive atlas of epigenetic marks across different human tissues and cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Roadmap Epigenomics Project focuses specifically on human epigenetic changes and does not include mapping the epigenetic landscape of mice or fruit flies.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is called \"CodonUsage\". It is a software tool developed by the University of California, San Diego, that uses SOMs to visualize and analyze the codon usage patterns in a given DNA sequence.",
    "llama-2-7b-chat-hf_fact_raw": "1. The tool called \"CodonUsage\" employs self-organizing maps for analyzing synonymous codon usage.\n2. The \"CodonUsage\" software tool was developed by the University of California, San Diego.\n3. The \"CodonUsage\" tool uses self-organizing maps to visualize codon usage patterns in DNA sequences.\n4. The \"CodonUsage\" tool analyzes codon usage patterns.",
    "llama-2-7b-chat-hf_fact": [
      "The tool called \"CodonUsage\" employs self-organizing maps for analyzing synonymous codon usage.",
      "The \"CodonUsage\" software tool was developed by the University of California, San Diego.",
      "The \"CodonUsage\" tool uses self-organizing maps to visualize codon usage patterns in DNA sequences.",
      "The \"CodonUsage\" tool analyzes codon usage patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Mitotic Inhibitor Database for Yeast 1) is a database that contains information on the effects of small molecules on the mitotic progression of yeast cells. It is a useful tool for identifying potential drugs that target specific checkpoints in the cell cycle and for studying the mechanisms of mitotic regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 stands for Mitotic Inhibitor Database for Yeast 1.\n2. MINDY-1 is a database containing information on small molecules affecting mitotic progression in yeast cells.\n3. MINDY-1 can be used for identifying potential drugs targeting specific checkpoints in the cell cycle.\n4. MINDY-1 aids in the study of mitotic regulation mechanisms.\n",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 stands for Mitotic Inhibitor Database for Yeast 1.",
      "MINDY-1 is a database containing information on small molecules affecting mitotic progression in yeast cells.",
      "MINDY-1 can be used for identifying potential drugs targeting specific checkpoints in the cell cycle.",
      "MINDY-1 aids in the study of mitotic regulation mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n\nRationale:\n1. Without additional context about the acronym MINDY-1, it is difficult to verify this statement. There is no widely recognized database or entity known as MINDY-1 in scientific literature based on my last update.\n2. Similar to statement 1, without explicit information about MINDY-1's content, it is not possible to confirm or deny the accuracy of this statement.\n3. Assuming MINDY-1 is indeed a database for small molecules affecting mitotic progression, it would logically be used for identifying potential drugs targeting specific checkpoints in the cell cycle.\n4. If MINDY-1 contains information on small molecules affecting mitosis in yeast cells, it would aid in the study of mitotic regulation mechanisms, as that would be part of its function.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBayes: A Bayesian phylogenetic software package that can be used to infer the evolutionary history of conserved genomic regions.\n2. PhastCons: A program that predicts the degree of conservation of a given genomic region based on the phylogenetic relationships among the organisms being compared.\n3. CONSER: A database and software package that provides information on the conservation of genomic regions across different species.\n4. GERP: A software package that uses a hidden Markov model to predict the degree of conservation of a given genomic region.\n5. CAFÉ: A software package that uses a Bayesian approach to infer the evolutionary history of conserved genomic regions.\n6. Prodigal: A software package that can be used to predict the evolutionary history of conserved genomic regions, including the identification of functional regions and the analysis of selection pressure.\n7. HMMER: A software package that uses hidden Markov models to identify and classify conserved genomic regions.\n8. MEME: A software package that can be used to identify and analyze conserved genomic regions, including the identification of functional regions and the analysis of selection pressure.\nThese software packages can be used to analyze conserved genomic loci in different organisms, including bacteria, archaea, and eukaryotes, and can provide information on the evolutionary history, functional annotation, and selection pressure of these regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a Bayesian phylogenetic software package for inferring the evolutionary history of conserved genomic regions.\n2. PhastCons is a program that predicts conservation levels of genomic regions based on phylogenetic relationships among organisms.\n3. CONSER is both a database and software package that provides information on genomic conservation across species.\n4. GERP is a software package that uses a hidden Markov model to predict conservation levels of genomic regions.\n5. CAFÉ utilizes a Bayesian approach to infer evolutionary history of conserved genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a Bayesian phylogenetic software package for inferring the evolutionary history of conserved genomic regions.",
      "PhastCons is a program that predicts conservation levels of genomic regions based on phylogenetic relationships among organisms.",
      "CONSER is both a database and software package that provides information on genomic conservation across species.",
      "GERP is a software package that uses a hidden Markov model to predict conservation levels of genomic regions.",
      "CAFÉ utilizes a Bayesian approach to infer evolutionary history of conserved genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CONSER should likely be a reference to \"Conservation\" databases or tools that track conservation of elements across species, but there isn't a known database or software package specifically named CONSER in the context of genomic conservation. Instead, there's UCSC's \"Conservation\" tracks or ConSurf, among others.\n4. TRUE\n5. FALSE [correction]: CAFÉ (Computational Analysis of gene Family Evolution) uses a probabilistic graphical model to study the evolution of gene families, not specifically for inferring the evolutionary history of conserved genomic regions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Hypohidrosis: Mutations in the PIEZO2 gene can cause hypohidrosis, also known as anhidrosis, a condition characterized by a decreased ability to sweat.\n2. Neuropathic pain: Mutations in the PIEZO2 gene have been linked to neuropathic pain, which is chronic pain that results from damage to the nervous system.\n3. Autism spectrum disorder: Some studies have suggested that mutations in the PIEZO2 gene may be associated with an increased risk of autism spectrum disorder (ASD). However, more research is needed to confirm this association.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene can cause hypohidrosis, a condition characterized by a decreased ability to sweat.\n2. Mutations in the PIEZO2 gene have been linked to neuropathic pain, chronic pain resulting from damage to the nervous system.\n3. Some studies have suggested that mutations in the PIEZO2 gene may be associated with an increased risk of autism spectrum disorder (ASD).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene can cause hypohidrosis, a condition characterized by a decreased ability to sweat.",
      "Mutations in the PIEZO2 gene have been linked to neuropathic pain, chronic pain resulting from damage to the nervous system.",
      "Some studies have suggested that mutations in the PIEZO2 gene may be associated with an increased risk of autism spectrum disorder (ASD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nThe first statement is true because mutations in the PIEZO2 gene can indeed cause various conditions, including those affecting the ability to sweat, though the specific term typically associated with PIEZO2 gene mutations is congenital insensitivity to pain with anhidrosis (CIPA), not just hypohidrosis.\n\nThe second and third statements are more challenging to confirm without specific references to research studies or clinical findings. While the PIEZO2 gene has been studied in the context of mechanosensation and its mutations can lead to various sensory issues, without clear evidence or consensus in the scientific community regarding its link to pain or ASD, these would have to be marked as unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of ubiquitinated proteins. The ERAP1 and ERAP2 proteins are involved in the endoplasmic reticulum (ER) associated degradation (ERAD) pathway, which is a process by which misfolded or damaged proteins are targeted for degradation in the ER. The dimerization of ERAP1 and ERAP2 facilitates the recognition and degradation of these proteins by the ERAD machinery.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of ubiquitinated proteins.\n2. ERAP1 and ERAP2 proteins are involved in the endoplasmic reticulum associated degradation (ERAD) pathway.\n3. The ERAD pathway targets misfolded or damaged proteins for degradation in the endoplasmic reticulum.\n4. The dimerization of ERAP1 and ERAP2 facilitates recognition and degradation of proteins by the ERAD machinery.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of ubiquitinated proteins.",
      "ERAP1 and ERAP2 proteins are involved in the endoplasmic reticulum associated degradation (ERAD) pathway.",
      "The ERAD pathway targets misfolded or damaged proteins for degradation in the endoplasmic reticulum.",
      "The dimerization of ERAP1 and ERAP2 facilitates recognition and degradation of proteins by the ERAD machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ERAP1 and ERAP2 proteins are not primarily involved in the endoplasmic reticulum-associated degradation (ERAD) pathway; they are aminopeptidases involved in trimming peptides for antigen presentation by MHC class I molecules.\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of bone development and homeostasis. In non-damaged gallbladders, R-spondin 1 and Noggin have been shown to have the following functions:\nR-spondin 1:\n* Regulates the expression of genes involved in the maintenance of gallbladder epithelial cell homeostasis and differentiation.\n* Modulates the activity of the Wnt/β-catenin signaling pathway, which is important for gallbladder development and homeostasis.\n* May play a role in the regulation of gallbladder inflammation and fibrosis.\nNoggin:\n* Inhibits the activity of the Wnt/β-catenin signaling pathway, which is important for gallbladder development and homeostasis.\n* Regulates the expression of genes involved in the maintenance of gallbladder epithelial cell homeostasis and differentiation.\n* May play a role in the regulation of gallbladder inflammation and fibrosis.\nOverall, R-spondin 1 and Noggin play important roles in regulating the balance of cell growth, differentiation, and survival in the non-damaged gallbladder, and dysregulation of these proteins has been implicated in the development of gallbladder diseases such as gallbladder cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 regulates gene expression for maintaining gallbladder epithelial cell homeostasis and differentiation in non-damaged gallbladders.\n2. R-spondin 1 modulates the Wnt/β-catenin signaling pathway, which is important for gallbladder development and homeostasis.\n3. Noggin inhibits the activity of the Wnt/β-catenin signaling pathway in non-damaged gallbladders.\n4. Both R-spondin 1 and Noggin may play roles in regulating gallbladder inflammation and fibrosis in non-damaged gallbladders.\n5. Dysregulation of R-spondin 1 and Noggin has been implicated in the development of gallbladder diseases, including gallbladder cancer.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 regulates gene expression for maintaining gallbladder epithelial cell homeostasis and differentiation in non-damaged gallbladders.",
      "R-spondin 1 modulates the Wnt/β-catenin signaling pathway, which is important for gallbladder development and homeostasis.",
      "Noggin inhibits the activity of the Wnt/β-catenin signaling pathway in non-damaged gallbladders.",
      "Both R-spondin 1 and Noggin may play roles in regulating gallbladder inflammation and fibrosis in non-damaged gallbladders.",
      "Dysregulation of R-spondin 1 and Noggin has been implicated in the development of gallbladder diseases, including gallbladder cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific context or evidence, it is unclear if this statement is true or false.\n2. TRUE: R-spondin 1 is known to modulate the Wnt/β-catenin signaling pathway, which is indeed important for development and homeostasis of various organs, including the gallbladder.\n3. FALSE [correction]: Noggin is actually known to inhibit the activity of bone morphogenetic proteins (BMPs), not the Wnt/β-catenin signaling pathway.\n4. UNKNOWN: Without additional context, it is difficult to determine the accuracy of this statement regarding R-spondin 1 and Noggin's roles in gallbladder inflammation and fibrosis.\n5. UNKNOWN: This statement may be true as dysregulation of signaling pathways can lead to disease states, including cancer. However, without specific references to scientific studies or clinical data, the link between R-spondin 1, Noggin, and gallbladder diseases, including cancer, cannot be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that requires four subunits to function: Nox5α, Nox5β, Nox5γ, and p67phox. These subunits work together to generate reactive oxygen species (ROS) in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.\n2. NOX5 requires four subunits to function.\n3. The subunits required for NOX5 function include Nox5α, Nox5β, Nox5γ, and p67phox.\n4. These subunits contribute to the generation of reactive oxygen species (ROS) in the cell.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.",
      "NOX5 requires four subunits to function.",
      "The subunits required for NOX5 function include Nox5α, Nox5β, Nox5γ, and p67phox.",
      "These subunits contribute to the generation of reactive oxygen species (ROS) in the cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is generally regarded as a monomeric enzyme with capability to form multimers.\n2. FALSE [correction]: NOX5 does not require four distinct subunits to function. It has multiple domains but functions as a single protein.\n3. FALSE [correction]: The subunits typically associated with NOX5 are misleading here because Nox5 is self-contained and does not require p67phox, which is associated with other NOX family members like NOX2.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease enzyme that processes several proteins involved in iron metabolism, including hepcidin, a hormone that regulates iron absorption and release from cells. Furin cleaves hepcidin to activate its activity, which in turn inhibits iron absorption in the duodenum and promotes iron release from cells, leading to decreased iron availability in the body. This negative feedback loop helps maintain iron homeostasis and prevent iron overload.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is an enzyme that processes several proteins involved in iron metabolism.\n2. Hepcidin is a hormone that regulates iron absorption and release from cells.\n3. Furin activates hepcidin by cleaving it.\n4. Activated hepcidin inhibits iron absorption in the duodenum.\n5. The interaction between furin and hepcidin helps maintain iron homeostasis and prevent iron overload.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is an enzyme that processes several proteins involved in iron metabolism.",
      "Hepcidin is a hormone that regulates iron absorption and release from cells.",
      "Furin activates hepcidin by cleaving it.",
      "Activated hepcidin inhibits iron absorption in the duodenum.",
      "The interaction between furin and hepcidin helps maintain iron homeostasis and prevent iron overload."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is an enzyme that processes several precursor proteins into their mature forms, including proteins involved in regulating metabolism, not specifically iron metabolism.\n2. TRUE\n3. FALSE [correction]: It is not widely recognized that furin directly activates hepcidin by cleaving it. Such a specific interaction between furin and hepcidin is not well-established in the scientific literature.\n4. TRUE\n5. FALSE [correction]: While the interaction between furin and hepcidin is not clearly established as a mechanism for maintaining iron homeostasis, hepcidin itself is indeed crucial for regulating iron balance and preventing iron overload. It is hepcidin's role in iron metabolism that helps prevent iron overload, but the statement about their interaction is not accurate without further specifying the nature of the interaction.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolytic pathway, also known as the pentose phosphate pathway (PPP). The PPP is a complex network of genes involved in the breakdown of glucose and other sugars to produce energy and building blocks for cell growth and maintenance. The cluster includes over 40 genes that work together to convert glucose-6-phosphate into ribulose-5-phosphate, a key intermediate in the pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The glycolytic pathway is the largest metabolic gene cluster in yeast.\n2. The glycolytic pathway is also known as the pentose phosphate pathway (PPP).\n3. The PPP is involved in the breakdown of glucose and other sugars to produce energy and building blocks for cell growth and maintenance.\n4. There are over 40 genes in the cluster that convert glucose-6-phosphate into ribulose-5-phosphate.",
    "llama-2-7b-chat-hf_fact": [
      "The glycolytic pathway is the largest metabolic gene cluster in yeast.",
      "The glycolytic pathway is also known as the pentose phosphate pathway (PPP).",
      "The PPP is involved in the breakdown of glucose and other sugars to produce energy and building blocks for cell growth and maintenance.",
      "There are over 40 genes in the cluster that convert glucose-6-phosphate into ribulose-5-phosphate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The glycolytic pathway is not necessarily the largest metabolic gene cluster in yeast; however, it is one of the major pathways for energy production.\n2. FALSE [correction]: The glycolytic pathway and the pentose phosphate pathway (PPP) are distinct pathways. The glycolytic pathway breaks down glucose to produce energy in the form of ATP, while the PPP is a parallel pathway that generates NADPH and ribose-5-phosphate for biosynthetic reactions.\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of gene expression in myeloid cells, particularly in the context of hematopoiesis and immune cell development.\nLIMT is known to regulate the expression of genes involved in myeloid cell differentiation, proliferation, and survival, and has been implicated in the development and progression of various hematopoietic malignancies, including leukemia.\nLIMT has been shown to function as a tumor suppressor by inhibiting the expression of oncogenic genes and promoting the expression of tumor suppressor genes in myeloid cells. It has also been shown to regulate the epigenetic landscape of myeloid cells by controlling the expression of histone-modifying enzymes and DNA methyltransferases.\nIn addition, LIMT has been shown to play a role in the regulation of immune cell function, particularly in the context of T cell activation and differentiation. It has been shown to regulate the expression of genes involved in T cell receptor signaling and to modulate the activity of T cells in response to antigen stimulation.\nOverall, the role of LIMT lncRNA is to regulate the expression of genes involved in myeloid cell differentiation, proliferation, and survival, and to play a crucial role in the regulation of hematopoiesis and immune cell function.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) plays a role in the regulation of gene expression in myeloid cells.\n2. LIMT is involved in hematopoiesis and immune cell development.\n3. LIMT has been implicated in the development and progression of hematopoietic malignancies like leukemia.\n4. LIMT functions as a tumor suppressor in myeloid cells by inhibiting oncogenic genes and promoting tumor suppressor genes.\n5. LIMT regulates the epigenetic landscape of myeloid cells by controlling the expression of histone-modifying enzymes and DNA methyltransferases.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) plays a role in the regulation of gene expression in myeloid cells.",
      "LIMT is involved in hematopoiesis and immune cell development.",
      "LIMT has been implicated in the development and progression of hematopoietic malignancies like leukemia.",
      "LIMT functions as a tumor suppressor in myeloid cells by inhibiting oncogenic genes and promoting tumor suppressor genes.",
      "LIMT regulates the epigenetic landscape of myeloid cells by controlling the expression of histone-modifying enzymes and DNA methyltransferases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: LIMT, as a long non-coding RNA, likely plays a role in gene expression regulation, which could include myeloid cells.\n2. TRUE: Given that LIMT is involved in the regulation of gene expression in myeloid cells, it could be involved in hematopoiesis and immune cell development as myeloid cells are key components in these processes.\n3. TRUE: If LIMT is key in regulating genes within myeloid cells, any dysregulation could potentially contribute to the development of hematopoietic malignancies, such as leukemia.\n4. UNKNOWN: Without specific evidence or a source indicating the exact function of LIMT as a tumor suppressor by inhibiting oncogenic genes and promoting tumor suppressor genes, it's impossible to determine the accuracy of this statement.\n5. UNKNOWN: Epigenetic regulation by LIMT as specified, such as control over histone-modifying enzymes and DNA methyltransferases, cannot be confirmed without specific data or references.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor modules that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the popular ones are:\n1. 'SNPfile' package: This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis.\n2. 'SNPsnp' package: This package provides a set of functions for performing various types of SNP analysis, including enrichment analysis.\n3. 'Plink' package: This package is a popular tool for genome-wide association studies (GWAS) and can also be used for SNP enrichment analysis.\n4. 'GSEA' package: This package is a part of the 'Bioconductor' platform and provides a comprehensive set of tools for gene set enrichment analysis (GSEA). It can be used for SNP enrichment analysis by comparing the enrichment of SNPs in different gene sets.\n5. 'Enrichr' package: This package provides a comprehensive set of tools for gene set enrichment analysis (GSEA) and can be used for SNP enrichment analysis. It uses a Bayesian approach to identify overrepresented gene sets in the SNP data.\n6. 'MAS5' package: This package provides a set of tools for genome-wide association studies (GWAS) and can also be used for SNP enrichment analysis. It uses a Bayesian approach to identify overrepresented gene sets in the SNP data.\n7. 'GSEA-SNP' package: This package is a modified version of the 'GSEA' package that is specifically designed for SNP data. It provides a set of tools for performing SNP enrichment analysis using a Bayesian approach.\n8. 'SNP-Set' package: This package provides a set of tools for SNP analysis, including enrichment analysis. It uses a Bayesian approach to identify overrepresented gene sets in the SNP data.\nIt's worth noting that these packages may have different options and methods for performing SNP enrichment analysis, so it's important to consult the documentation and user guides for each package to determine which one is best suited for your specific research question and data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 'SNPfile' package provides tools for SNP analysis, including enrichment analysis.\n2. The 'Plink' package is used for genome-wide association studies and SNP enrichment analysis.\n3. The 'GSEA' package is part of the 'Bioconductor' platform and is used for gene set enrichment analysis, including SNP enrichment analysis.\n4. The 'Enrichr' package uses a Bayesian approach for gene set enrichment analysis and SNP enrichment analysis.\n5. The 'GSEA-SNP' package is a modified version of the 'GSEA' package designed specifically for SNP data.",
    "llama-2-7b-chat-hf_fact": [
      "The 'SNPfile' package provides tools for SNP analysis, including enrichment analysis.",
      "The 'Plink' package is used for genome-wide association studies and SNP enrichment analysis.",
      "The 'GSEA' package is part of the 'Bioconductor' platform and is used for gene set enrichment analysis, including SNP enrichment analysis.",
      "The 'Enrichr' package uses a Bayesian approach for gene set enrichment analysis and SNP enrichment analysis.",
      "The 'GSEA-SNP' package is a modified version of the 'GSEA' package designed specifically for SNP data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While the name 'SNPfile' suggests it might be related to SNP (Single Nucleotide Polymorphisms) analysis, it is not a widely known package and without the context it is unknown if it includes enrichment analysis capabilities.\n\n2. TRUE: 'Plink' is a widely used open-source tool for genome-wide association studies and does perform SNP analysis. It is not specifically known for \"enrichment analysis\" in the common use of the term, but it does handle various forms of association tests which might be interpreted as \"enrichment\" in a broad sense.\n\n3. FALSE [correction]: The 'GSEA' package, which stands for 'Gene Set Enrichment Analysis', is used for gene set enrichment analysis, but it is not specifically designed for SNP enrichment analysis. It is part of the Broad Institute's portfolio of computational tools for bioinformatics.\n\n4. FALSE [correction]: 'Enrichr' is an online tool used for gene set enrichment analysis, but it does not specifically use a Bayesian approach for enrichment analysis. Instead, it uses a variety of statistical methods to determine gene set enrichment.\n\n5. TRUE: The 'GSEA-SNP' package is indeed a modified version of the 'GSEA' tool, which is designed to perform gene set enrichment analysis on SNP data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are the key players in the specification of ependymal cells. Radial glial cells are progenitor cells that line the ventricles of the brain and play a crucial role in the development and maintenance of the central nervous system (CNS). During embryonic development, radial glial cells differentiate into ependymal cells, which are specialized cells that line the ventricles and play a critical role in the production and circulation of cerebrospinal fluid (CSF).\nThe key players in the specification of ependymal cells from radial glial cells include:\n1. Notch signaling pathway: Notch is a transmembrane receptor that plays a crucial role in the regulation of cell fate decisions, including the specification of ependymal cells from radial glial cells. Notch signaling promotes the expression of genes involved in ependymal cell differentiation and inhibits the expression of genes involved in radial glial cell maintenance.\n2. Wnt signaling pathway: Wnt signaling also plays a crucial role in the specification of ependymal cells from radial glial cells. Wnt signaling promotes the expression of genes involved in ependymal cell differentiation and inhibits the expression of genes involved in radial glial cell maintenance.\n3. BMP signaling pathway: BMP (bone morphogenetic protein) signaling also plays a role in the specification of ependymal cells from radial glial cells. BMP signaling promotes the expression of genes involved in ependymal cell differentiation and inhibits the expression of genes involved in radial glial cell maintenance.\n4. Shh signaling pathway: Shh (sonic hedgehog) signaling pathway also plays a role in the specification of ependymal cells from radial glial cells. Shh signaling promotes the expression of genes involved in ependymal cell differentiation and inhibits the expression of genes involved in radial glial cell maintenance.\n5. Ezh2 (Enhancer of zeste homolog 2): Ezh2 is a histone methyltransferase that plays a crucial role in the regulation of gene expression during ependymal cell differentiation. Ezh2 is required for the proper specification of epend",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells differentiate into ependymal cells during embryonic development.\n2. Ependymal cells line the ventricles and are involved in the production and circulation of cerebrospinal fluid.\n3. Notch signaling pathway plays a crucial role in the regulation of cell fate decisions for ependymal cell specification from radial glial cells.\n4. Wnt signaling pathway is involved in the specification of ependymal cells from radial glial cells.\n5. BMP (bone morphogenetic protein) signaling pathway influences the expression of genes involved in the differentiation of ependymal cells from radial glial cells.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells differentiate into ependymal cells during embryonic development.",
      "Ependymal cells line the ventricles and are involved in the production and circulation of cerebrospinal fluid.",
      "Notch signaling pathway plays a crucial role in the regulation of cell fate decisions for ependymal cell specification from radial glial cells.",
      "Wnt signaling pathway is involved in the specification of ependymal cells from radial glial cells.",
      "BMP (bone morphogenetic protein) signaling pathway influences the expression of genes involved in the differentiation of ependymal cells from radial glial cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Radial glial cells are known to differentiate into several cell types during embryonic development, including ependymal cells.\n2. TRUE: Ependymal cells indeed line the ventricles in the brain and play a role in the production and circulation of cerebrospinal fluid.\n3. TRUE: The Notch signaling pathway is critical for the regulation of cell fate decisions, including ependymal cell specification from radial glial cells.\n4. FALSE [correction]: The Wnt signaling pathway is indeed involved in various developmental processes, but it is most commonly associated with the development of cell fate and organization during embryogenesis rather than specifically the specification of ependymal cells from radial glial cells. The role of Wnt in ependymal cell differentiation is not as clearly established as Notch or other signaling pathways, so this statement may not be accurate without additional specific context.\n5. TRUE: The BMP signaling pathway has been implicated in influencing gene expression involved in the differentiation of various cell types, including ependymal cells from radial glial cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a brain tumor that arises from the supporting cells of the brain called glial cells. Triple negative gliomas are characterized by the following features:\n1. Lack of expression of the tumor suppressor proteins TP53, PTEN, and EGFR (epidermal growth factor receptor).\n2. Lack of expression of the estrogen receptor (ER) and progesterone receptor (PR), which are typically found in hormone-sensitive tumors.\n3. Lack of mutations in the HER2 gene, which is commonly amplified in breast cancer.\n4. Lack of expression of the MGMT (O6-methylguanine-DNA methyltransferase) gene, which is involved in the repair of DNA damage.\n5. Presence of a high proliferation rate, as determined by Ki-67 staining.\n6. Presence of a high mitotic rate, as determined by mitotic count.\n7. Presence of necrosis or cystic changes in the tumor.\n8. Tumors are typically located in the cerebral hemispheres, particularly in the frontal and temporal lobes.\n9. Tumors are often large and aggressive, and may infiltrate surrounding brain tissue.\n10. Patients with triple negative gliomas tend to have a poorer prognosis compared to those with other types of gliomas, such as those with TP53 mutations or those with HER2 amplification.\nIt is important to note that these features are not present in all triple negative gliomas and some may have additional characteristics. The diagnosis of triple negative glioma is based on a combination of clinical, radiological, and pathological findings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack expression of the tumor suppressor proteins TP53, PTEN, and EGFR (epidermal growth factor receptor).\n2. Triple negative gliomas do not express the estrogen receptor (ER) and progesterone receptor (PR).\n3. HER2 gene mutations are not present in triple negative gliomas.\n4. The MGMT (O6-methylguanine-DNA methyltransferase) gene is not expressed in triple negative gliomas.\n5. Triple negative gliomas tend to have a high proliferation rate determined by Ki-67 staining.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack expression of the tumor suppressor proteins TP53, PTEN, and EGFR (epidermal growth factor receptor).",
      "Triple negative gliomas do not express the estrogen receptor (ER) and progesterone receptor (PR).",
      "HER2 gene mutations are not present in triple negative gliomas.",
      "The MGMT (O6-methylguanine-DNA methyltransferase) gene is not expressed in triple negative gliomas.",
      "Triple negative gliomas tend to have a high proliferation rate determined by Ki-67 staining."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack expression of the tumor suppressor proteins IDH1, TP53, and ATRX, not EGFR.\n2. TRUE: Triple negative gliomas do not express hormone receptors like estrogen receptor (ER) and progesterone receptor (PR).\n3. TRUE: By definition, triple negative gliomas, which are a subset of triple negative tumors, do not have HER2 overexpression or gene amplification.\n4. UNKNOWN: The expression of MGMT gene varies among gliomas and is not a defining characteristic of triple negative gliomas specifically.\n5. TRUE: Triple negative gliomas, like other high-grade tumors, tend to have a high proliferation rate, and this can be determined by Ki-67 staining.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein AZ1) is a protein that is involved in the regulation of DNA topology and the maintenance of genome stability. It is a subunit of the topoisomerase II complex, which is responsible for relieving topological constraints in DNA and regulating DNA transactions, such as transcriptional elongation, replication, and repair. TOPAZ1 plays a critical role in the regulation of DNA supercoiling and is essential for the proper functioning of the topoisomerase II complex.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is involved in the regulation of DNA topology and the maintenance of genome stability.\n2. TOPAZ1 is a subunit of the topoisomerase II complex.\n3. The topoisomerase II complex is responsible for relieving topological constraints in DNA.\n4. The topoisomerase II complex is involved in regulation of DNA transactions including transcriptional elongation, replication, and repair.\n5. TOPAZ1 plays a critical role in the regulation of DNA supercoiling.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is involved in the regulation of DNA topology and the maintenance of genome stability.",
      "TOPAZ1 is a subunit of the topoisomerase II complex.",
      "The topoisomerase II complex is responsible for relieving topological constraints in DNA.",
      "The topoisomerase II complex is involved in regulation of DNA transactions including transcriptional elongation, replication, and repair.",
      "TOPAZ1 plays a critical role in the regulation of DNA supercoiling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: TOP3A (Topoisomerase III alpha), not TOPAZ1, is a known subunit of the topoisomerase complex. TOPAZ1 does not appear to be a standard nomenclature for a protein involved in topoisomerases.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. GATA-1 is a transcription factor that regulates the expression of genes involved in erythropoiesis, and it exists in multiple isoforms due to alternative splicing of its coding region. The expression of these isoforms is controlled by the GATA-1 gene, which contains enhancers and silencers that regulate the splicing of the gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.\n2. GATA-1 is a transcription factor involved in the regulation of genes associated with erythropoiesis.\n3. GATA-1 exists in multiple isoforms due to alternative splicing.\n4. The GATA-1 gene contains enhancers and silencers that regulate its splicing.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms.",
      "GATA-1 is a transcription factor involved in the regulation of genes associated with erythropoiesis.",
      "GATA-1 exists in multiple isoforms due to alternative splicing.",
      "The GATA-1 gene contains enhancers and silencers that regulate its splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a method for transcriptome analysis that combines the techniques of RNA sequencing (RNA-seq) and microarray analysis. MIRA-seq stands for \"microarray-based RNA sequencing\" and it allows for the simultaneous measurement of gene expression levels and the identification of novel transcripts using a microarray platform.\nIn MIRA-seq, total RNA is first converted into cRNA (complementary RNA) using reverse transcriptase, and then the cRNA is hybridized to a microarray platform. The microarray platform contains thousands of known mRNA sequences, as well as probes for novel transcripts. The cRNA is then detected using a fluorescent label, and the intensity of the signal is proportional to the abundance of the corresponding mRNA transcript.\nThe advantages of MIRA-seq include:\n* High sensitivity and specificity: MIRA-seq can detect low-abundance transcripts that may be missed by RNA-seq.\n* Comprehensive profiling: MIRA-seq can measure the expression levels of thousands of genes in a single experiment, providing a comprehensive view of the transcriptome.\n* Cost-effective: MIRA-seq is less expensive than RNA-seq, making it a more cost-effective option for large-scale transcriptome analysis.\n* Faster turnaround time: MIRA-seq can be performed in a matter of days, while RNA-seq can take several weeks to complete.\nIn summary, MIRA-seq is a powerful tool for transcriptome analysis that offers a combination of high sensitivity, specificity, and cost-effectiveness, making it a valuable tool for researchers studying gene expression at the molecular level.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for \"microarray-based RNA sequencing.\"\n2. MIRA-seq combines techniques of RNA sequencing and microarray analysis.\n3. In MIRA-seq, total RNA is converted into cRNA using reverse transcriptase.\n4. The microarray platform used in MIRA-seq contains thousands of known mRNA sequences, as well as probes for novel transcripts.\n5. MIRA-seq is touted to have a faster turnaround time compared to RNA-seq, with it being able to be performed in a matter of days.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for \"microarray-based RNA sequencing.\"",
      "MIRA-seq combines techniques of RNA sequencing and microarray analysis.",
      "In MIRA-seq, total RNA is converted into cRNA using reverse transcriptase.",
      "The microarray platform used in MIRA-seq contains thousands of known mRNA sequences, as well as probes for novel transcripts.",
      "MIRA-seq is touted to have a faster turnaround time compared to RNA-seq, with it being able to be performed in a matter of days."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"methylation-dependent isoform ratio analysis sequencing.\"\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction provided in statement 1 reflects the accurate expansion of the acronym \"MIRA-seq,\" which is specialized in measuring the ratio of alternatively spliced isoforms of mRNA transcripts depending on their methylation status. Statements 2 through 5 are relevant to various types of sequencing and microarray technologies, but without additional context specifically relating to MIRA-seq, it is not possible to confidently determine their truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medicine used to treat a rare genetic disorder called cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 and older. It is also used to treat a related condition called familial cold autoinflammatory syndrome (FCAS). CAPS and FCAS are characterized by recurring episodes of fever, pain, and swelling, and can lead to joint damage and other complications if left untreated. ARCALYST works by blocking the activity of a protein called interleukin-1 beta (IL-1β) which is involved in the inflammation associated with these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medicine.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 and older.\n3. ARCALYST is also used to treat familial cold autoinflammatory syndrome (FCAS).\n4. CAPS and FCAS episodes typically involve fever, pain, and swelling.\n5. ARCALYST works by blocking the activity of the protein interleukin-1 beta (IL-1β).",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medicine.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 and older.",
      "ARCALYST is also used to treat familial cold autoinflammatory syndrome (FCAS).",
      "CAPS and FCAS episodes typically involve fever, pain, and swelling.",
      "ARCALYST works by blocking the activity of the protein interleukin-1 beta (IL-1β)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE (FCAS is one of the forms of CAPS which ARCALYST is used to treat.)\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes (chromosomes 1, 9, 10, 11, 13, 14, 15, and 21). The specific acrocentric chromosomes involved in Robertsonian translocations can vary, but the following are the most common ones:\n1. Chromosome 14: This is the most common chromosome involved in Robertsonian translocations, occurring in approximately 50% of cases.\n2. Chromosome 15: Chromosome 15 is the second most common chromosome involved in Robertsonian translocations, occurring in approximately 25% of cases.\n3. Chromosome 13: Chromosome 13 is less commonly involved in Robertsonian translocations, occurring in approximately 10% of cases.\n4. Chromosome 21: Chromosome 21 is also less commonly involved in Robertsonian translocations, occurring in approximately 5% of cases.\nIt's worth noting that the specific acrocentric chromosomes involved in Robertsonian translocations can vary depending on the individual and the specific type of translocation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations involve the exchange of genetic material between acrocentric chromosomes.\n2. Chromosomes 1, 9, 10, 11, 13, 14, 15, and 21 in humans are acrocentric chromosomes.\n3. Approximately 50% of Robertsonian translocations involve chromosome 14.\n4. Chromosome 15 is involved in approximately 25% of Robertsonian translocations.\n5. Chromosome 13 and chromosome 21 are involved in Robertsonian translocations, occurring in approximately 10% and 5% of cases, respectively.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations involve the exchange of genetic material between acrocentric chromosomes.",
      "Chromosomes 1, 9, 10, 11, 13, 14, 15, and 21 in humans are acrocentric chromosomes.",
      "Approximately 50% of Robertsonian translocations involve chromosome 14.",
      "Chromosome 15 is involved in approximately 25% of Robertsonian translocations.",
      "Chromosome 13 and chromosome 21 are involved in Robertsonian translocations, occurring in approximately 10% and 5% of cases, respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromosomes 13, 14, 15, 21, and 22 in humans are acrocentric chromosomes. Chromosomes 1, 9, 10, and 11 are not acrocentric.\n3. UNKNOWN [clarification needed]: The statement could be accurate as chromosome 14 is frequently involved in Robertsonian translocations, but without specific data or source, the exact percentage cannot be verified.\n4. UNKNOWN [clarification needed]: As in the previous statement, without specific data on the involvement of chromosome 15 in Robertsonian translocations, the exact percentage cannot be verified.\n5. UNKNOWN [clarification needed]: The involvement of chromosome 13 and chromosome 21 in Robertsonian translocations and their respective percentages cannot be verified without specific data or references. However, it is known that translocations involving these chromosomes can lead to conditions such as Down syndrome for chromosome 21 and Patau syndrome for chromosome 13.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that could be used for the identification of pediatric brain tumors, depending on the specific approach and data available. Here are a few options:\n1. `pediatricBrainTumor`: This package is specifically designed for the analysis of pediatric brain tumor data. It includes functions for identifying tumor subtypes, predicting patient outcomes, and analyzing genomic data.\n2. `brainTumor`: This package provides a comprehensive framework for the analysis of brain tumor data, including functions for identifying tumor subtypes, predicting patient outcomes, and analyzing genomic data.\n3. `survival`: This package is focused on survival analysis, which can be used to model the progression of pediatric brain tumors. It includes functions for estimating survival curves, computing confidence intervals, and testing hypotheses.\n4. `genomicRanges`: This package can be used to identify genomic regions that are associated with pediatric brain tumors. It includes functions for visualizing genomic data, identifying regions of interest, and performing functional enrichment analysis.\n5. `ggplot2`: This package can be used for data visualization, which is an important aspect of analyzing pediatric brain tumor data. It includes functions for creating interactive plots, visualizing genomic data, and exploring correlations between variables.\n6. `ggplot2`: This package can be used for data visualization, which is an important aspect of analyzing pediatric brain tumor data. It includes functions for creating interactive plots, visualizing genomic data, and exploring correlations between variables.\n7. `limma`: This package can be used for the analysis of gene expression data in pediatric brain tumors. It includes functions for identifying differentially expressed genes, visualizing expression data, and performing functional enrichment analysis.\n8. `edgeR`: This package can be used for the analysis of RNA-seq data in pediatric brain tumors. It includes functions for identifying differentially expressed genes, visualizing expression data, and performing functional enrichment analysis.\n9. ` DESeq2`: This package can be used for the analysis of RNA-seq data in pediatric brain tumors. It includes functions for identifying differentially expressed genes, visualizing expression data, and performing functional",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package `pediatricBrainTumor` is designed for the analysis of pediatric brain tumor data.\n2. The `survival` package in R is focused on survival analysis and can be applied to modeling the progression of pediatric brain tumors.\n3. `genomicRanges` is an R package used to identify genomic regions associated with pediatric brain tumors.\n4. `ggplot2` is an R package that allows for data visualization and includes functions for creating interactive plots.\n5. `limma` and `edgeR` are R packages used for the analysis of gene expression and RNA-seq data in pediatric brain tumors respectively.",
    "llama-2-7b-chat-hf_fact": [
      "The R package `pediatricBrainTumor` is designed for the analysis of pediatric brain tumor data.",
      "The `survival` package in R is focused on survival analysis and can be applied to modeling the progression of pediatric brain tumors.",
      "`genomicRanges` is an R package used to identify genomic regions associated with pediatric brain tumors.",
      "`ggplot2` is an R package that allows for data visualization and includes functions for creating interactive plots.",
      "`limma` and `edgeR` are R packages used for the analysis of gene expression and RNA-seq data in pediatric brain tumors respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Assuming the provided context is accurate and there exists an R package named `pediatricBrainTumor`, it would be designed for the analysis of pediatric brain tumor data.\n2. TRUE: The `survival` package in R is indeed focused on survival analysis, which is a relevant method for modeling the progression and prognosis of various diseases, including pediatric brain tumors.\n3. TRUE: `GenomicRanges` is a Bioconductor package in R used to represent and manipulate genomic intervals and variables defined along a genome. While it is not specifically limited to pediatric brain tumors, it can be applied to identify genomic regions associated with any kind of genomic data, including those from pediatric brain tumor studies.\n4. TRUE: `ggplot2` is an R package for data visualization. However, it's important to note that `ggplot2` does not include functions for creating interactive plots by default. Correction: `ggplot2` does not, by itself, allow for the creation of interactive plots; it is geared towards static plot creation. For interactive plots in R, packages like `plotly` or `ggiraph` might be used in combination with `ggplot2`.\n5. TRUE: `limma` and `edgeR` are both Bioconductor R packages used for analyzing gene expression data. `limma` is versatile and can be used for various types of data, including RNA-seq and microarrays, while `edgeR` is specifically designed for the analysis of differential expression in RNA-seq data. They can be used in the context of analyzing pediatric brain tumor data, along with other types of biological data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated Matrix-Organizing protein) is a zinc finger protein. It contains multiple zinc finger domains, which are responsible for its DNA-binding and protein-protein interaction properties.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO stands for Nuclear Envelope-Associated Matrix-Organizing protein.\n2. NEMO is a zinc finger protein.\n3. NEMO contains multiple zinc finger domains.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO stands for Nuclear Envelope-Associated Matrix-Organizing protein.",
      "NEMO is a zinc finger protein.",
      "NEMO contains multiple zinc finger domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO typically stands for NF-kappaB Essential Modulator, a protein that is essential for the activation of the NF-kappaB pathway.\n2. TRUE: NEMO (IKKγ or NF-kappaB Essential Modulator) does contain a ZF (zinc finger) domain, which is a finger-like protrusion that can coordinate zinc ions and participate in protein-DNA or protein-protein interactions.\n3. FALSE [correction]: NEMO contains only one zinc finger domain, not multiple. It specifically possesses a zinc finger domain involved in the linear ubiquitination of NEMO that is important for the activation of NF-kappaB.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcriptional elongation factor that plays a crucial role in the initiation of transcription in eukaryotic cells. It has been shown to interact with nucleosomes and influence their positioning on DNA, thereby affecting transcriptional elongation. TFIIS can either displace or stabilize nucleosomes, depending on the context, and its activity can have a significant impact on gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is a transcriptional elongation factor.\n2. TFIIS plays a role in the initiation of transcription in eukaryotic cells.\n3. TFIIS has been shown to interact with nucleosomes.\n4. TFIIS can influence nucleosome positioning on DNA.\n5. The activity of TFIIS can affect transcriptional elongation and thereby have an impact on gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is a transcriptional elongation factor.",
      "TFIIS plays a role in the initiation of transcription in eukaryotic cells.",
      "TFIIS has been shown to interact with nucleosomes.",
      "TFIIS can influence nucleosome positioning on DNA.",
      "The activity of TFIIS can affect transcriptional elongation and thereby have an impact on gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFIIS plays a role in the elongation phase of transcription, not initiation.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "In yeast, origins of replication located near centromeres typically fire late in the cell cycle. This is because the centromere region is highly compacted and has a unique chromatin structure that inhibits the activity of the origin of replication. As a result, the origin of replication is not able to initiate DNA synthesis until later in the cell cycle, when the chromatin structure has relaxed and the origin is able to interact with the initiation factors necessary for DNA synthesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. In yeast, origins of replication near centromeres typically fire late in the cell cycle.\n2. The centromere region is highly compacted and has a unique chromatin structure.\n3. The unique chromatin structure of the centromere inhibits the activity of the origin of replication.\n4. The origin of replication initiates DNA synthesis later in the cell cycle when the chromatin structure has relaxed.\n5. Timing of DNA synthesis initiation depends on the interaction of the origin with the necessary initiation factors.",
    "llama-2-7b-chat-hf_fact": [
      "In yeast, origins of replication near centromeres typically fire late in the cell cycle.",
      "The centromere region is highly compacted and has a unique chromatin structure.",
      "The unique chromatin structure of the centromere inhibits the activity of the origin of replication.",
      "The origin of replication initiates DNA synthesis later in the cell cycle when the chromatin structure has relaxed.",
      "Timing of DNA synthesis initiation depends on the interaction of the origin with the necessary initiation factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided seem consistent with general knowledge about yeast cell biology and the role of chromatin structure in the regulation of replication timing. Origins of replication are regions of the DNA where replication begins, and their activity can be influenced by their location and chromatin environment. In yeast, as well as in other eukaryotes, the centromere is a specialized region of the chromosome that typically has a unique chromatin structure, which can affect the timing of origin firing. It is known that centromeric regions are often associated with later replication timing within the cell cycle. The availability and interaction of initiation factors with origins are also known to be key determinants of when DNA replication begins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences are characterized by the following properties:\n1. Long-range interactions: Mammalian GA-sequences are known to form long-range interactions with other sequences, which are important for their function.\n2. High stability: Mammalian GA-sequences are highly stable and resistant to degradation, which allows them to maintain their structure and function over time.\n3. Low GC content: Mammalian GA-sequences have a low GC content, which makes them more flexible and prone to forming secondary structures.\n4. High AT-richness: Mammalian GA-sequences are rich in AT bases, which are important for their stability and function.\n5. A-rich motifs: Mammalian GA-sequences often contain A-rich motifs, which are important for their interaction with other sequences and proteins.\n6. Regulatory functions: Mammalian GA-sequences are involved in the regulation of various cellular processes, including gene expression, cell proliferation, and differentiation.\n7. Chromatin structure: Mammalian GA-sequences are important for the organization and structure of chromatin, and play a role in the regulation of chromatin dynamics during cellular processes.\n8. Non-coding RNA function: Mammalian GA-sequences can act as non-coding RNAs, and are involved in the regulation of gene expression, particularly through the formation of RNA-protein complexes.\n9. Cancer-related functions: Mammalian GA-sequences have been implicated in various cancer-related processes, including cancer progression and metastasis.\n10. Evolutionary conservation: Mammalian GA-sequences are highly conserved across species, indicating their importance in mammalian biology and evolution.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are known to form long-range interactions with other sequences.\n2. Mammalian GA-sequences have a high degree of stability and resistance to degradation.\n3. Mammalian GA-sequences have a low GC content.\n4. Mammalian GA-sequences are rich in AT bases. \n5. Mammalian GA-sequences are involved in the regulation of various cellular processes, such as gene expression, cell proliferation, and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are known to form long-range interactions with other sequences.",
      "Mammalian GA-sequences have a high degree of stability and resistance to degradation.",
      "Mammalian GA-sequences have a low GC content.",
      "Mammalian GA-sequences are rich in AT bases.",
      "Mammalian GA-sequences are involved in the regulation of various cellular processes, such as gene expression, cell proliferation, and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE [correction]: Although not explicit in the statement, it implies that since mammalian GA-sequences have a low GC content, they are consequently rich in AT bases because DNA is composed of four bases – adenine (A), thymine (T), guanine (G), and cytosine (C) – and a low GC content suggests a higher AT content.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 10 Groucho-related genes (GRGs), also known as Groucho-like genes (Glg). These genes are:\n1. Groucho (Gro1)\n2. Groucho-like 1 (Glg1)\n3. Groucho-like 2 (Glg2)\n4. Groucho-like 3 (Glg3)\n5. Groucho-like 4 (Glg4)\n6. Groucho-like 5 (Glg5)\n7. Groucho-like 6 (Glg6)\n8. Groucho-like 7 (Glg7)\n9. Groucho-like 8 (Glg8)\n10. Groucho-like 9 (Glg9)\nNote: The number of GRGs may vary slightly depending on the source and method of gene naming.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains a total of 10 Groucho-related genes (GRGs).\n2. These genes are also referred to as Groucho-like genes (Glg).\n3. The names of these genes include Groucho (Gro1), Groucho-like 1 (Glg1), and Groucho-like 2 (Glg2) up to Groucho-like 9 (Glg9).\n\n(Note: The fourth factual statement about the potential variance in the number of GRGs depending on the source and method of gene naming could not be verified without specifying the sources or methods alluded to.)",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains a total of 10 Groucho-related genes (GRGs).",
      "These genes are also referred to as Groucho-like genes (Glg).",
      "The names of these genes include Groucho (Gro1), Groucho-like 1 (Glg1), and Groucho-like 2 (Glg2) up to Groucho-like 9 (Glg9).",
      "ote: The fourth factual statement about the potential variance in the number of GRGs depending on the source and method of gene naming could not be verified without specifying the sources or methods alluded to.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific information or the passage from which these statements are taken, it is not possible to verify the accuracy of these statements related to the mouse genome and the naming of genes within it. Gene naming conventions can be complex and subject to change based on new discoveries and consensus in the scientific community. Additionally, without access to up-to-date genomic databases or scientific literature, it is not feasible to confirm the number of Groucho-related genes or their official nomenclature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is a complex of several subunits, and one of the subunits that carries RNA cleavage activity is the subunit RPA2 (RNA-binding protein 2). RPA2 is responsible for the cleavage of the RNA transcript during the process of mRNA splicing.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II is composed of several subunits.\n2. The subunit RPA2 is part of RNA polymerase II.\n3. RPA2 has RNA cleavage activity.\n4. RPA2 is involved in mRNA splicing through the cleavage of the RNA transcript.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II is composed of several subunits.",
      "The subunit RPA2 is part of RNA polymerase II.",
      "RPA2 has RNA cleavage activity.",
      "RPA2 is involved in mRNA splicing through the cleavage of the RNA transcript."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RPA (Replication Protein A) is not a subunit of RNA polymerase II. It is involved in DNA replication. The correct nomenclature for the subunits of RNA polymerase II would be using \"RPB\" (like RPB1, RPB2, etc.).\n3. FALSE [correction]: RPA2 does not have RNA cleavage activity. RPA2 is part of the RPA protein complex involved in DNA metabolism, not RNA cleavage. It is the RNA polymerase II enzyme itself that has the RNA cleavage activity as part of the transcription process, or specific endonucleases cleave RNA during splicing, not RPA2.\n4. FALSE [correction]: RPA2 is not involved in mRNA splicing through the cleavage of the RNA transcript. It is involved in DNA replication and repair. The process of mRNA splicing is carried out by the spliceosome and other associated proteins, but not by RPA2.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PHLPP1 gene. The PHLPP1 gene provides instructions for making a protein called pleckstrin homology domain-containing protein 1 (PHLPP1), which plays a critical role in regulating the activity of protein kinase B (PKB), also known as Akt. PKB is a key signaling protein that is involved in many cellular processes, including cell survival, metabolism, and growth. Mutations in the PHLPP1 gene can lead to impaired regulation of PKB activity, which can result in a range of developmental and physiological abnormalities, including those characteristic of Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder.\n2. Mutations in the PHLPP1 gene cause Ohdo syndrome.\n3. The PHLPP1 gene provides instructions for making pleckstrin homology domain-containing protein 1 (PHLPP1).\n4. The protein pleckstrin homology domain-containing protein 1 (PHLPP1) is involved in regulating the activity of protein kinase B (PKB), also known as Akt.\n5. Impaired regulation of PKB activity due to mutations in the PHLPP1 gene can result in developmental and physiological abnormalities characteristic of Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder.",
      "Mutations in the PHLPP1 gene cause Ohdo syndrome.",
      "The PHLPP1 gene provides instructions for making pleckstrin homology domain-containing protein 1 (PHLPP1).",
      "The protein pleckstrin homology domain-containing protein 1 (PHLPP1) is involved in regulating the activity of protein kinase B (PKB), also known as Akt.",
      "Impaired regulation of PKB activity due to mutations in the PHLPP1 gene can result in developmental and physiological abnormalities characteristic of Ohdo syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the KAT6B gene or the MED12 gene are known causes of Ohdo syndrome.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychiatricGenomics\" has been developed for the analysis of psychiatric disease genes. This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, including mood disorders, anxiety disorders, and psychotic disorders. It includes tools for genome-wide association studies (GWAS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) data analysis, as well as methods for identifying gene-gene interactions and pathway analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"psychiatricGenomics\" is developed for the analysis of psychiatric disease genes.\n2. The package offers tools for genome-wide association studies (GWAS).\n3. It provides tools for whole-exome sequencing (WES) data analysis.\n4. It includes tools for whole-genome sequencing (WGS) data analysis.\n5. The package has methods for identifying gene-gene interactions and pathway analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"psychiatricGenomics\" is developed for the analysis of psychiatric disease genes.",
      "The package offers tools for genome-wide association studies (GWAS).",
      "It provides tools for whole-exome sequencing (WES) data analysis.",
      "It includes tools for whole-genome sequencing (WGS) data analysis.",
      "The package has methods for identifying gene-gene interactions and pathway analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the \"psychiatricGenomics\" package in R/Bioconductor, it is not possible to definitively determine the truth of these statements. Bioconductor packages often have documentation that details their capabilities and applications, so consulting the official documentation or publication associated with \"psychiatricGenomics\" would be necessary to verify these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a radiological sign that is often seen in patients with intracerebral hemorrhage (ICH). It is characterized by a spiral or swirling pattern of blood in the hemisphere of the brain surrounding the site of the hemorrhage.\nThe swirl sign is thought to occur due to the movement of blood through the damaged blood vessels in the brain, which can create a whirlpool or vortex-like pattern of blood flow. This movement can be caused by a variety of factors, including the pressure of the hemorrhage, the movement of the brain, or the presence of blood clots.\nThe swirl sign can be seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans, and it is often more prominent on the lateral (side) of the brain. It can be an important diagnostic indicator of ICH, as it can help doctors identify the location and extent of the hemorrhage.\nIn addition to its diagnostic value, the swirl sign can also provide information about the severity of the hemorrhage and the potential risk of complications. For example, a larger or more prominent swirl sign may indicate a more severe hemorrhage and a higher risk of neurological deficits or death.\nOverall, the swirl sign is a useful radiological sign that can help doctors diagnose and manage intracerebral hemorrhage. However, it is important to note that it is not specific to ICH and can also be seen in other conditions, such as stroke or cerebral vasculitis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological sign associated with intracerebral hemorrhage.\n2. It is characterized by a spiral or swirling pattern of blood around the hemorrhage site within the brain's hemisphere.\n3. The swirl sign can be caused by the movement of blood through damaged vessels, pressure from the hemorrhage, brain movement, or blood clots.\n4. The swirl sign can be detected on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n5. The presence and appearance of the swirl sign can provide information about the severity of the hemorrhage and the risk of complications.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological sign associated with intracerebral hemorrhage.",
      "It is characterized by a spiral or swirling pattern of blood around the hemorrhage site within the brain's hemisphere.",
      "The swirl sign can be caused by the movement of blood through damaged vessels, pressure from the hemorrhage, brain movement, or blood clots.",
      "The swirl sign can be detected on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "The presence and appearance of the swirl sign can provide information about the severity of the hemorrhage and the risk of complications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by a heterogeneous appearance of blood with mixed-density areas within an intracerebral hematoma, not necessarily a spiral or swirling pattern around the hemorrhage site.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) expression is induced by various factors, including:\n1. Light: Light exposure can induce ROF1 expression in Arabidopsis, suggesting a role in regulating light-responsive gene expression.\n2. Abiotic stressors: ROF1 expression is also induced by abiotic stressors such as drought, high temperature, and salt stress, indicating a role in stress response pathways.\n3. Hormones: ROF1 expression can be induced by various hormones, including auxin, cytokinin, and ethylene, suggesting a role in hormone signaling pathways.\n4. Developmental signals: ROF1 expression is also regulated by developmental signals, such as the transition from the vegetative to reproductive phase, suggesting a role in regulating developmental processes.\n5. Genetic mutations: Mutations in genes involved in RNA polymerase II transcriptional elongation, such as the RNA polymerase II subunit RNAPII, can also induce ROF1 expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Light exposure can induce Arabidopsis ROF1 expression.\n2. Abiotic stressors like drought, high temperature, and salt stress can induce ROF1 expression in Arabidopsis.\n3. Hormones such as auxin, cytokinin, and ethylene can induce Arabidopsis ROF1 expression.\n4. Arabidopsis ROF1 expression is regulated by developmental signals, including the transition from vegetative to reproductive phase.\n5. Genetic mutations in genes involved in RNA polymerase II transcriptional elongation can induce ROF1 expression in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Light exposure can induce Arabidopsis ROF1 expression.",
      "Abiotic stressors like drought, high temperature, and salt stress can induce ROF1 expression in Arabidopsis.",
      "Hormones such as auxin, cytokinin, and ethylene can induce Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 expression is regulated by developmental signals, including the transition from vegetative to reproductive phase.",
      "Genetic mutations in genes involved in RNA polymerase II transcriptional elongation can induce ROF1 expression in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Light exposure is known to impact plant gene expression and can induce the expression of various genes, including ROF1 (ROTAMASE FKBP 1) in Arabidopsis.\n2. TRUE: Abiotic stresses such as drought, high temperature, and salt stress are well-known to induce a wide range of stress-responsive genes, including ROF1 in Arabidopsis, as part of the plant's adaptive response.\n3. UNKNOWN: While hormones like auxin, cytokinin, and ethylene are key regulators of growth and development in plants, and they can induce various gene expressions, without specific literature on ROF1 being regulated by these hormones, the statement remains uncertain.\n4. UNKNOWN: Arabidopsis ROF1 expression may well be influenced by developmental signals, such as the transition from vegetative to reproductive phases. However, without specific information confirming this regulation for ROF1, it is not possible to definitively assess the validity of this statement.\n5. UNKNOWN: Genetic mutations can affect the expression of many genes, including those involved in stress responses. However, without specific details regarding the mutations in genes involved in RNA polymerase II transcriptional elongation and their direct impact on ROF1 expression in Arabidopsis, this statement cannot be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein AL amyloid precursor protein (AP).",
    "llama-2-7b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is commonly caused by the protein AL amyloid precursor protein (AP).",
    "llama-2-7b-chat-hf_fact": [
      "Hereditary renal amyloidosis is commonly caused by the protein AL amyloid precursor protein (AP)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hereditary renal amyloidosis is commonly caused by mutations in the genes encoding fibrinogen A alpha-chain, apolipoprotein AI, lysozyme, or transthyretin (TTR), not the AL amyloid precursor protein (AP). AL amyloidosis is typically associated with a condition called light chain amyloidosis, which is caused by the deposition of abnormal immunoglobulin light chains, and it is not typically hereditary but rather associated with plasma cell disorders like multiple myeloma.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomics techniques, including two-dimensional gel electrophoresis (2DE), mass spectrometry (MS), and label-free quantification. These studies have identified thousands of proteins present in the hippocampus, including proteins involved in synaptic plasticity, neurotransmission, inflammation, and protein degradation.\nSome examples of proteins identified in the hippocampus include:\n1. Synaptic plasticity-related proteins: N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and their associated proteins (e.g., GluR1, GluR2, and AMPA), as well as synaptic scaffolding proteins (e.g., PSD-95 and Homer).\n2. Neurotransmitter release and uptake proteins: Vesicular glutamate transporters (VGluT1 and VGluT2), vesicular GABA transporters (VGAT), and monoamine transporters (e.g., VMAT2 and norepinephrine transporter).\n3. Inflammatory response proteins: Cytokines (e.g., TNF-α and IL-1β), chemokines (e.g., CCL2 and CCL3), and inflammasomes (e.g., NLRC3 and ASC).\n4. Protein degradation proteins: Ubiquitin ligases (e.g., E3 ubiquitin ligases such as MuRF1 and MAFbx), and proteasome subunits (e.g., β5i and β5).\n5. Cytoskeleton and structural proteins: Tubulin, actin, and intermediate filaments (e.g., vimentin and nestin).\nThese proteins are involved in various cellular processes, including synaptic transmission, neuronal excitability, inflammation, and protein turnover. The proteome of the hippocampus is dynamic and can be altered in response to various stimuli, such as exercise, learning, and",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using two-dimensional gel electrophoresis (2DE), mass spectrometry (MS), and label-free quantification.\n2. Studies have identified thousands of proteins present in the mouse hippocampus.\n3. Identified proteins in the hippocampus include N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and proteins like GluR1, GluR2, and PSD-95 related to synaptic plasticity.\n4. Vesicular glutamate transporters (VGluT1 and VGluT2), vesicular GABA transporters (VGAT), and monoamine transporters (e.g., VMAT2 and norepinephrine transporter) are neurotransmitter release and uptake proteins found in the hippocampus.\n5. Proteins related to the inflammatory response in the hippocampus include cytokines such as TNF-α and IL-1β, chemokines like CCL2 and CCL3, and inflammasomes such as NLRC3 and ASC.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using two-dimensional gel electrophoresis (2DE), mass spectrometry (MS), and label-free quantification.",
      "Studies have identified thousands of proteins present in the mouse hippocampus.",
      "Identified proteins in the hippocampus include N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and proteins like GluR1, GluR2, and PSD-95 related to synaptic plasticity.",
      "Vesicular glutamate transporters (VGluT1 and VGluT2), vesicular GABA transporters (VGAT), and monoamine transporters (e.g., VMAT2 and norepinephrine transporter) are neurotransmitter release and uptake proteins found in the hippocampus.",
      "Proteins related to the inflammatory response in the hippocampus include cytokines such as TNF-α and IL-1β, chemokines like CCL2 and CCL3, and inflammasomes such as NLRC3 and ASC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements given all describe factual elements that could plausibly be found in scientific literature concerning the proteome of the mouse hippocampus. Without access to the specific source from which these statements are extracted, there is no contradiction or error apparent within the context provided. The descriptions of protein identification, their functions in synaptic plasticity, neurotransmitter release and uptake, and the inflammatory response align with common scientific understanding of hippocampal neurobiology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a centromere that is located near the center of the chromosome, and mouse chromosomes do not fit this definition. In mammals, including mice, the centromere is typically located near the telomere, the end of the chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "One siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer is ONC201. ONC201 is a small molecule that selectively targets and degrades the oncogenic protein KRAS, which is frequently mutated in pancreatic cancer. ONC201 has shown promising results in early clinical trials, including tumor shrinkage and improvement in progression-free survival in patients with advanced pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC201 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.\n2. ONC201 targets and degrades the oncogenic protein KRAS.\n3. KRAS is frequently mutated in pancreatic cancer.\n4. ONC201 has shown tumor shrinkage in early clinical trials for pancreatic cancer.\n5. ONC201 has shown improvement in progression-free survival in patients with advanced pancreatic cancer in early clinical trials.",
    "llama-2-7b-chat-hf_fact": [
      "ONC201 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.",
      "ONC201 targets and degrades the oncogenic protein KRAS.",
      "KRAS is frequently mutated in pancreatic cancer.",
      "ONC201 has shown tumor shrinkage in early clinical trials for pancreatic cancer.",
      "ONC201 has shown improvement in progression-free survival in patients with advanced pancreatic cancer in early clinical trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ONC201 is not an siRNA-based drug; it is a small molecule that targets and induces the degradation of the protein DRD2.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Hexokinase Pyruvate Glucokinase) pore is a protein complex that plays a key role in regulating glucose metabolism in cells. It is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucokinase (GK), which work together to facilitate the transfer of glucose between different cellular compartments. The HPG pore is a specialized channel in the plasma membrane that allows for the movement of glucose and other sugars into or out of the cell, and it is critical for maintaining proper glucose homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucokinase (GK).\n2. The HPG pore plays a key role in regulating glucose metabolism in cells.\n3. The HPG pore facilitates the transfer of glucose between different cellular compartments.\n4. The HPG pore is a specialized channel in the plasma membrane that allows for the movement of glucose and other sugars into or out of the cell.\n5. Maintaining proper glucose homeostasis in the body is one of the functions of the HPG pore.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucokinase (GK).",
      "The HPG pore plays a key role in regulating glucose metabolism in cells.",
      "The HPG pore facilitates the transfer of glucose between different cellular compartments.",
      "The HPG pore is a specialized channel in the plasma membrane that allows for the movement of glucose and other sugars into or out of the cell.",
      "Maintaining proper glucose homeostasis in the body is one of the functions of the HPG pore."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore does not stand for anything related to Hexokinase (HK), Pyruvate Kinase (PK), and Glucokinase (GK), which are separate enzymes in the glucose metabolism pathway. There is no well-known pore or complex in biology commonly referred to as the \"HPG\" pore involving these enzymes.\n2. FALSE [correction]: Since the \"HPG pore\" as described in statement 1 is incorrect, it does not play a key role in regulating glucose metabolism. Glucose metabolism regulation is indeed a complex process involving many enzymes, but not a structure called the HPG pore.\n3. FALSE [correction]: There is no known HPG pore facilitating the transfer of glucose between different cellular compartments. Glucose transport between cellular compartments is carried out by glucose transporters, not by something called the HPG pore.\n4. FALSE [correction]: The description of the HPG pore as a channel in the plasma membrane for the movement of glucose and other sugars is incorrect. Glucose transport across the plasma membrane is mediated by GLUT (glucose transporter) proteins, not by something known as the HPG pore.\n5. FALSE [correction]: Because the HPG pore as previously described does not exist, maintaining glucose homeostasis is not a function attributed to it. Glucose homeostasis is maintained through various mechanisms and proteins such as insulin, glucagon, glucose transporters, and enzymes involved in glycolysis and gluconeogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes (N959) initiative is a large-scale genomics project focused on the sequencing and analysis of the genomes of all known species of nematode worms, which are a group of microscopic worms that include parasitic and free-living species. The initiative was launched in 2015 and is led by the University of California, Davis, in collaboration with several other institutions and organizations.\nThe goal of the N959 initiative is to generate high-quality genome sequences for over 950 species of nematodes, which will provide a comprehensive understanding of the evolution, diversity, and biology of these organisms. The project also aims to identify genes and genetic mechanisms that are unique to nematodes and could be targeted for the development of new drugs and other therapies.\nThe N959 initiative is using a combination of cutting-edge genomics technologies, including single-cell genomics, to generate detailed genome assemblies for each species. The project is also developing new computational tools and methods for analyzing and interpreting the vast amounts of data generated by the project.\nThe N959 initiative has the potential to make a significant impact on our understanding of nematode biology and disease, as well as on the development of new drugs and therapies for a range of diseases, including parasitic infections and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative was launched in 2015.\n2. The University of California, Davis leads the 959 Nematode Genomes initiative in collaboration with other institutions and organizations.\n3. The aim of the initiative is to sequence and analyze the genomes of all known species of nematode worms.\n4. The goal is to generate high-quality genome sequences for over 950 species of nematodes.\n5. The initiative uses technologies such as single-cell genomics to generate detailed genome assemblies for each species.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative was launched in 2015.",
      "The University of California, Davis leads the 959 Nematode Genomes initiative in collaboration with other institutions and organizations.",
      "The aim of the initiative is to sequence and analyze the genomes of all known species of nematode worms.",
      "The goal is to generate high-quality genome sequences for over 950 species of nematodes.",
      "The initiative uses technologies such as single-cell genomics to generate detailed genome assemblies for each species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative (also known as the 959 Nematode Genomes Project or the 1K Nematode Genomes project) appears to be commonly associated with the name, 1K Nematode Genomes, and detailed launch year was not provided, thus the specific year 2015 cannot be confirmed as true without more context.\n2. TRUE: The University of California, Davis is one of the leading institutions in the 1K Nematode Genomes project, collaborating with other organizations.\n3. FALSE [correction]: The initiative aims to sequence and analyze representative genomes from the phylum Nematoda, not all known species of nematode worms since there are over 25,000 described species, and estimates of total species range up to millions. The 959 figure refers to a representative sample for genomic studies.\n4. TRUE: The goal is to generate high-quality genome sequences for 959 species of nematodes, which is representative of the full diversity of the phylum.\n5. UNKNOWN: Without specific information on the technologies used in the initiative, it is not possible to confirm whether single-cell genomics or other technologies are being used for genome assemblies in the initiative.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data, including:\n1. NIPT: This package provides functions for analyzing NIPT data, including quality control, sample processing, and statistical analysis.\n2. PrenaTest: This package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n3. NIPTkit: This package provides a comprehensive set of tools for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n4. PrenatalTesting: This package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n5. NIPTAnalysis: This package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\nIt's worth noting that these packages are not exclusive to NIPT data analysis and can be used for other types of genomic data analysis as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"NIPT\" R package provides functions for analyzing Non-invasive prenatal testing (NIPT) data, including quality control, sample processing, and statistical analysis.\n2. The \"PrenaTest\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n3. The \"NIPTkit\" R package provides a comprehensive set of tools for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n4. The \"PrenatalTesting\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.\n5. The \"NIPTAnalysis\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The \"NIPT\" R package provides functions for analyzing Non-invasive prenatal testing (NIPT) data, including quality control, sample processing, and statistical analysis.",
      "The \"PrenaTest\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.",
      "The \"NIPTkit\" R package provides a comprehensive set of tools for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.",
      "The \"PrenatalTesting\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis.",
      "The \"NIPTAnalysis\" R package provides functions for analyzing NIPT data, including data preprocessing, sample classification, and statistical analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no R package known as \"PrenaTest\" for analyzing NIPT data. However, there is a commercial test called PrenaTest which is an NIPT test.\n3. UNKNOWN\n4. FALSE [correction]: There is no R package known as \"PrenatalTesting\" specifically for analyzing NIPT data.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach-Sterling syndrome, is a rare genetic disorder that affects the development of the brain and nervous system. It is characterized by a combination of intellectual disability, seizures, and distinctive facial features.\nThe main features of Achenbach's syndrome include:\n1. Intellectual disability: Individuals with Achenbach's syndrome typically have mild to moderate intellectual disability, which can range from mild to moderate.\n2. Seizures: Achenbach's syndrome can cause seizures, which can be a significant problem for individuals with the disorder.\n3. Facial dysmorphism: Achenbach's syndrome is characterized by distinctive facial features, including a small head, narrow eyes, a short nose, and a thin upper lip.\n4. Brain abnormalities: Individuals with Achenbach's syndrome may have abnormalities in the structure and function of the brain, including enlarged ventricles and a smaller cerebellum.\n5. Growth retardation: Achenbach's syndrome can cause growth retardation, which can result in short stature.\n6. Distinctive hand and foot malformations: Some individuals with Achenbach's syndrome may have distinctive hand and foot malformations, including clubfoot and clinodactyly (a condition where the fifth finger is bent backward).\n7. Other symptoms: Achenbach's syndrome can also cause a range of other symptoms, including delayed speech and language development, delayed motor skills, and behavioral problems.\nThe exact cause of Achenbach's syndrome is not fully understood, but it is thought to be related to mutations in the PTK2B gene. This gene is involved in the signaling pathways that control the growth and development of cells in the body. Achenbach's syndrome is a rare disorder, and it is estimated to affect about 1 in 100,000 to 1 in 50,000 individuals worldwide. There is currently no cure for Achenbach's syndrome, but early intervention and management of symptoms can help improve the quality of life for individuals with",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome, also known as Achenbach-Sterling syndrome, is a rare genetic disorder that affects the development of the brain and nervous system.\n2. The disorder is characterized by intellectual disability, seizures, and distinctive facial features.\n3. Distinctive facial features of Achenbach's syndrome include a small head, narrow eyes, a short nose, and a thin upper lip.\n4. Brain abnormalities in individuals with Achenbach's syndrome may include enlarged ventricles and a smaller cerebellum.\n5. Achenbach's syndrome is thought to be related to mutations in the PTK2B gene.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome, also known as Achenbach-Sterling syndrome, is a rare genetic disorder that affects the development of the brain and nervous system.",
      "The disorder is characterized by intellectual disability, seizures, and distinctive facial features.",
      "Distinctive facial features of Achenbach's syndrome include a small head, narrow eyes, a short nose, and a thin upper lip.",
      "Brain abnormalities in individuals with Achenbach's syndrome may include enlarged ventricles and a smaller cerebellum.",
      "Achenbach's syndrome is thought to be related to mutations in the PTK2B gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder; it is a condition that typically presents with spontaneous bruising of the hands or fingers.\n2. FALSE [correction]: Since Achenbach's syndrome is not a genetic disorder affecting brain and nervous system development, it is not characterized by intellectual disability, seizures, and distinctive facial features.\n3. FALSE [correction]: Distinctive facial features are not associated with Achenbach's syndrome, which involves bruising and not developmental issues.\n4. FALSE [correction]: There's no indication that Achenbach's syndrome includes brain abnormalities such as enlarged ventricles or a smaller cerebellum as it's primarily about bruising.\n5. FALSE [correction]: Achenbach's syndrome has no known association with mutations in the PTK2B gene or any other gene, as it is not a genetic disorder in the context described.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions in genomic DNA, including:\n1. RepeatMasker: This is a widely used algorithm that uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome.\n2. GATK (Genome Analysis Toolkit): This software package includes several tools for repeat detection, including the RepeatMasker tool, as well as the GATK Repeat Finder tool, which uses a hidden Markov model to identify repeats.\n3. RepeatScanner: This algorithm uses a probabilistic model to identify repetitive elements in a genome, and can be used to detect both short and long repeat expansions.\n4. LINEFINDER: This algorithm uses a hidden Markov model to identify long repeat elements, including LINE (long interspersed nuclear elements), which are a type of retrotransposon.\n5. Primer3: This is a software tool for designing PCR primers, but it can also be used for repeat detection by analyzing the primer binding sites in a genome.\n6. Repetome: This is a database of repetitive DNA elements, including long repeat expansions, that can be used for detection and analysis.\n7. Dotter: This algorithm uses a probabilistic model to identify repetitive elements in a genome, and can be used to detect both short and long repeat expansions.\n8. REPuter: This is a web-based tool that uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome.\n9. RIP (Repeat Induced Point) PCR: This is a laboratory technique that can be used to detect long repeat expansions by amplifying specific genomic regions using primers that recognize repetitive elements.\n10. Array-based methods: Some microarray platforms, such as the Agilent GoldenGate array, include probes that are specifically designed to detect long repeat expansions.\nIt's worth noting that different algorithms may have different sensitivities and specificities for detecting long repeat expansions, and the choice of algorithm may depend on the specific research question and the characteristics of the genomic DNA being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm that identifies repetitive elements in a genome using sequence similarity and k-mer frequency.\n2. GATK (Genome Analysis Toolkit) includes tools for repeat detection, such as the RepeatMasker tool and GATK Repeat Finder tool.\n3. LINEFINDER uses a hidden Markov model to identify long interspersed nuclear elements (LINEs) in genomic DNA.\n4. Primer3, though mainly a tool for designing PCR primers, can also be used for repeat detection by analyzing primer binding sites in a genome.\n5. The Agilent GoldenGate microarray platform includes probes designed to detect long repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm that identifies repetitive elements in a genome using sequence similarity and k-mer frequency.",
      "GATK (Genome Analysis Toolkit) includes tools for repeat detection, such as the RepeatMasker tool and GATK Repeat Finder tool.",
      "LINEFINDER uses a hidden Markov model to identify long interspersed nuclear elements (LINEs) in genomic DNA.",
      "Primer3, though mainly a tool for designing PCR primers, can also be used for repeat detection by analyzing primer binding sites in a genome.",
      "The Agilent GoldenGate microarray platform includes probes designed to detect long repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GATK (Genome Analysis Toolkit) is known primarily for its tools for variant discovery and genotyping. RepeatMasker is a separate tool not included in GATK, and there is no specific tool called \"GATK Repeat Finder.\"\n3. TRUE\n4. FALSE [correction]: Primer3 is designed for designing PCR primers and does not include functionality for repeat detection.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Glioblastoma: Neuroligin-3 is overexpressed in glioblastoma, the most common and aggressive form of primary brain cancer.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that originates in the cerebellum.\n3. Brain stem gliomas: Neuroligin-3 has been found to be overexpressed in brain stem gliomas, which are tumors that originate in the brain stem and can be malignant or benign.\n4. Pineal parenchymal tumors: Neuroligin-3 has also been found to be overexpressed in pineal parenchymal tumors, which are rare tumors that originate in the pineal gland.\nOverall, the overexpression of neuroligin-3 has been implicated in the development and progression of various types of brain tumors, and targeting this protein with specific inhibitors or immunotherapies may be a promising therapeutic strategy for the treatment of these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in glioblastomas, which are the most common and aggressive form of primary brain cancer.\n2. Neuroligin-3 is overexpressed in medulloblastomas, a type of pediatric brain cancer.\n3. Brain stem gliomas, which can be either malignant or benign, have been found to overexpress neuroligin-3.\n4. Pineal parenchymal tumors overexpress neuroligin-3 and these tumors originate in the pineal gland.\n5. Overexpression of neuroligin-3 has been implicated in the development and progression of various types of brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in glioblastomas, which are the most common and aggressive form of primary brain cancer.",
      "Neuroligin-3 is overexpressed in medulloblastomas, a type of pediatric brain cancer.",
      "Brain stem gliomas, which can be either malignant or benign, have been found to overexpress neuroligin-3.",
      "Pineal parenchymal tumors overexpress neuroligin-3 and these tumors originate in the pineal gland.",
      "Overexpression of neuroligin-3 has been implicated in the development and progression of various types of brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been reported to be overexpressed in glioblastomas, which are indeed among the most common and aggressive forms of primary brain cancer.\n2. UNKNOWN: While neuroligin-3 plays a role in brain development and has been studied in various types of brain tumors, without specific data or studies that confirm its overexpression in medulloblastomas, the truth of this statement cannot be determined from the information available.\n3. UNKNOWN: Again, the overexpression of neuroligin-3 in brain stem gliomas cannot be confirmed as true or false without specific research data provided. Brain stem gliomas can vary widely in their molecular features.\n4. UNKNOWN: Whether neuroligin-3 is overexpressed in pineal parenchymal tumors is not specified without research sources. While these tumors do originate in the pineal gland, neuroligin-3's expression in these tumors would need to be confirmed by scientific studies.\n5. TRUE: The overexpression of neuroligin-3 has indeed been implicated in the development and progression of various types of brain tumors, as it is known to be involved in synaptic function and its dysregulation can contribute to tumorigenesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are typically in the range of 10-100 nanometers (nm) in diameter.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles have diameters in the range of 10-100 nanometers.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles have diameters in the range of 10-100 nanometers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles typically have diameters in the range of 45 to 200 nanometers.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modulating chromatin structure. Here are some of the BET proteins:\n1. BRD2 (Bromodomain and Extra-Terminal Domain Containing Protein 2)\n2. BRD3 (Bromodomain and Extra-Terminal Domain Containing Protein 3)\n3. BRD4 (Bromodomain and Extra-Terminal Domain Containing Protein 4)\n4. BRDT (Bromodomain-Containing Protein T)\n5. BET1 (Bromodomain and Extra-Terminal Domain Containing Protein 1)\n6. BETA (Bromodomain and Extra-Terminal Domain Containing Protein Alpha)\n7. BETB (Bromodomain and Extra-Terminal Domain Containing Protein Beta)\n8. BETC (Bromodomain and Extra-Terminal Domain Containing Protein Gamma)\n9. BETD (Bromodomain and Extra-Terminal Domain Containing Protein Delta)\n10. BETE (Bromodomain and Extra-Terminal Domain Containing Protein Epsilon)\nThese proteins contain a bromodomain, a structural motif that recognizes acetylated lysine residues on histone proteins, and are involved in various cellular processes, including transcriptional activation, gene regulation, and cell signaling. Dysregulation of BET proteins has been implicated in various diseases, including cancer, autoimmune disorders, and neurological conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 2.\n2. BRD3 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 3.\n3. BRD4 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 4.\n4. BRDT is a protein also known as Bromodomain-Containing Protein T.\n5. BET proteins play a role in regulating gene expression by modulating chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 2.",
      "BRD3 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 3.",
      "BRD4 is a protein also known as Bromodomain and Extra-Terminal Domain Containing Protein 4.",
      "BRDT is a protein also known as Bromodomain-Containing Protein T.",
      "BET proteins play a role in regulating gene expression by modulating chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRDT is a protein also known as Bromodomain Testis-Specific Protein.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for prediction of protein subcellular localization using deep learning is the \"Deep Loc\" algorithm. It was proposed by Zhang et al. in 2018 and is based on a deep learning model that uses a combination of sequence features and structural information to predict the subcellular localization of proteins. The model is trained on a large dataset of experimentally validated protein localizations and can predict the localization of both known and novel proteins with high accuracy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"Deep Loc\" algorithm is an algorithm developed for prediction of protein subcellular localization using deep learning.\n2. Zhang et al. proposed the \"Deep Loc\" algorithm in 2018.\n3. The \"Deep Loc\" algorithm combines sequence features and structural information for prediction.\n4. The algorithm is trained on a dataset of experimentally validated protein localizations.\n5. \"Deep Loc\" can predict the localization of both known and novel proteins with high accuracy.",
    "llama-2-7b-chat-hf_fact": [
      "The \"Deep Loc\" algorithm is an algorithm developed for prediction of protein subcellular localization using deep learning.",
      "Zhang et al. proposed the \"Deep Loc\" algorithm in 2018.",
      "The \"Deep Loc\" algorithm combines sequence features and structural information for prediction.",
      "The algorithm is trained on a dataset of experimentally validated protein localizations.",
      "\"Deep Loc\" can predict the localization of both known and novel proteins with high accuracy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGenerally, algorithms like \"Deep Loc\" are designed to predict protein subcellular localization with high accuracy; they often use deep learning, combine sequence features with structural information, and are trained on datasets containing experimental validations. However, the specific details and performance characteristics such as \"high accuracy\" could vary based on definitions and benchmarks used in the field, so that part should ideally be backed by the relevant scientific literature. Without access to the specific paper by Zhang et al. (2018), I cannot fact-check beyond the typical characteristics of such algorithms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is a protein that has not been identified in the scientific literature. It is possible that it is a misspelling or an abbreviation for a protein that is not widely known or used in the scientific community. Can you provide more context or information about the protein you are asking about?",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a protein that has not been identified in the scientific literature.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a protein that has not been identified in the scientific literature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nWithout access to the most current scientific literature or databases, I cannot confirm the existence or non-existence of a protein named MULTOVL. Protein nomenclature is detailed and precise, and new proteins are being discovered and named regularly. To provide an accurate answer, one would need to consult up-to-date scientific literature or databases such as the Protein Data Bank or UniProt.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are altered in response to metformin treatment in patients with type 2 diabetes, and may serve as a useful marker for monitoring treatment response.\nIn one study, GDF15 levels were found to be significantly increased in patients with type 2 diabetes who were treated with metformin compared to those who were not treated with metformin. The study suggested that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin therapy in patients with type 2 diabetes.\nAnother study found that GDF15 levels were inversely correlated with insulin sensitivity in patients with type 2 diabetes, and that the correlation was stronger in those who were treated with metformin. The study suggested that GDF15 may be a useful marker for identifying patients who are likely to benefit from metformin therapy.\nOverall, these studies suggest that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with type 2 diabetes, and may help identify those who are likely to benefit from this therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.\n2. Studies have indicated that GDF15 levels change in response to metformin treatment in patients with type 2 diabetes.\n3. A study showed an increase in GDF15 levels in patients with type 2 diabetes treated with metformin compared to untreated patients.\n4. GDF15 levels were found to be inversely correlated with insulin sensitivity in patients with type 2 diabetes, with a stronger correlation in those treated with metformin.\n5. GDF15 may help identify patients with type 2 diabetes who are likely to benefit from metformin therapy.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.",
      "Studies have indicated that GDF15 levels change in response to metformin treatment in patients with type 2 diabetes.",
      "A study showed an increase in GDF15 levels in patients with type 2 diabetes treated with metformin compared to untreated patients.",
      "GDF15 levels were found to be inversely correlated with insulin sensitivity in patients with type 2 diabetes, with a stronger correlation in those treated with metformin.",
      "GDF15 may help identify patients with type 2 diabetes who are likely to benefit from metformin therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GDF15 levels have been associated with improved insulin sensitivity in patients with type 2 diabetes rather than inversely correlated. The statement about the correlation strength in those treated with metformin cannot be determined from the provided information.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing occurs when a intron is spliced back into the same exon, resulting in a circular splicing pattern. This type of splicing is more likely to occur in shorter introns, as the splicing machinery may have difficulty resolving the intron-exon boundary in longer introns.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing occurs when an intron is spliced back into the same exon.\n3. This mechanism results in a circular splicing pattern.\n4. The splicing machinery may have difficulty resolving the intron-exon boundary in longer introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing occurs when an intron is spliced back into the same exon.",
      "This mechanism results in a circular splicing pattern.",
      "The splicing machinery may have difficulty resolving the intron-exon boundary in longer introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. FALSE [correction]: Recursive splicing occurs when an intron is removed in multiple steps, with a lariat structure forming at an internal branch point within the intron before the intron is fully excised.\n3. FALSE [correction]: Recursive splicing does not result in a circular splicing pattern but rather in a stepwise removal of the intron.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for targeted gene editing, specifically for the precise modification of endogenous genes in living cells. It is used to introduce specific point mutations or insertions/deletions (indels) into a target gene, without leaving footprints or affecting the surrounding genetic material. TALE-iD is a form of homology-directed repair (HDR) gene editing, which allows for the precise modification of the targeted gene sequence.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is used for targeted gene editing.\n2. TALE-iD allows for the precise modification of endogenous genes in living cells.\n3. The method can introduce specific point mutations or insertions/deletions (indels) into a target gene.\n4. TALE-iD does not affect the surrounding genetic material when targeting a gene.\n5. TALE-iD is a form of homology-directed repair (HDR) gene editing.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is used for targeted gene editing.",
      "TALE-iD allows for the precise modification of endogenous genes in living cells.",
      "The method can introduce specific point mutations or insertions/deletions (indels) into a target gene.",
      "TALE-iD does not affect the surrounding genetic material when targeting a gene.",
      "TALE-iD is a form of homology-directed repair (HDR) gene editing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: TALE-iD is not itself a form of homology-directed repair (HDR). TALE-iD involves transcription activator-like effector nucleases (TALENs) for targeted gene editing. HDR is a separate pathway that can be harnessed during gene editing for precise insertion or replacement of DNA sequences, often in conjunction with engineered nucleases like TALENs, CRISPR/Cas, etc.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: A Lisp image processing framework that provides a set of functions for image processing, including filtering, resizing, and feature extraction.\n2. ImageTk: A Lisp package for image processing that provides a simple and intuitive interface for image manipulation and analysis.\n3. Lisp-Image: A Lisp image processing framework that provides a range of functions for image processing, including filtering, resizing, and feature extraction.\n4. DIPS: A Lisp image processing framework that provides a set of functions for image processing, including filtering, resizing, and feature extraction, as well as support for multi-resolution image analysis.\n5. Image-Lisp: A Lisp package for image processing that provides a simple and intuitive interface for image manipulation and analysis, as well as support for multi-resolution image analysis.\n6. Lispy-Image: A Lisp image processing framework that provides a set of functions for image processing, including filtering, resizing, and feature extraction, as well as support for multi-resolution image analysis.\n7. Lisp-Image-J: A Lisp image processing framework that provides a set of functions for image processing, including filtering, resizing, and feature extraction, as well as support for multi-resolution image analysis.\n8. Image-Processing-Lisp: A Lisp package for image processing that provides a set of functions for image processing, including filtering, resizing, and feature extraction, as well as support for multi-resolution image analysis.\nPlease note that this is not an exhaustive list and there may be other Lisp frameworks for image processing available.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp framework for image processing.\n2. ImageTk is a Lisp package designed for image manipulation and analysis.\n3. DIPS is a Lisp framework that supports image processing and multi-resolution image analysis.\n4. Image-Lisp provides a simple interface for image manipulation and analysis in Lisp.\n5. Lisp-Image-J is a Lisp framework that includes support for multi-resolution image analysis.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp framework for image processing.",
      "ImageTk is a Lisp package designed for image manipulation and analysis.",
      "DIPS is a Lisp framework that supports image processing and multi-resolution image analysis.",
      "Image-Lisp provides a simple interface for image manipulation and analysis in Lisp.",
      "Lisp-Image-J is a Lisp framework that includes support for multi-resolution image analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CL-Image is not a known Lisp framework for image processing; a common Lisp library for image processing is Opticl.\n2. FALSE [correction]: ImageTk is not a Lisp package; it is part of the Tk toolkit for the Tcl programming language and is used for displaying images in Tk applications.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections provided are based on commonly known libraries and frameworks as of my knowledge cutoff date in 2023. Statements 3 to 5 refer to frameworks or libraries that are not widely recognized or may not exist, hence the classification as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "In Saccharomyces cerevisiae (baker's yeast), approximately 1,000-1,500 genes are the result of an ancient whole genome duplication. This event, known as the \"yeast whole genome duplication\" (WGD), occurred around 1,000-2,000 million years ago and resulted in the duplication of approximately 30% of the yeast genome. Since then, these duplicated genes have evolved independently and have taken on different functions, leading to the diversity of gene function in the modern yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. In Saccharomyces cerevisiae, approximately 1,000-1,500 genes are the result of an ancient whole genome duplication.\n2. The \"yeast whole genome duplication\" (WGD) occurred around 100-200 million years ago.\n3. The yeast whole genome duplication resulted in the duplication of approximately 30% of the yeast genome.\n4. Since the whole genome duplication, the duplicated genes in Saccharomyces cerevisiae have evolved independently.\n5. The duplicated genes in Saccharomyces cerevisiae have taken on different functions, contributing to the diversity of gene function in the yeast genome.",
    "llama-2-7b-chat-hf_fact": [
      "In Saccharomyces cerevisiae, approximately 1,000-1,500 genes are the result of an ancient whole genome duplication.",
      "The \"yeast whole genome duplication\" (WGD) occurred around 100-200 million years ago.",
      "The yeast whole genome duplication resulted in the duplication of approximately 30% of the yeast genome.",
      "Since the whole genome duplication, the duplicated genes in Saccharomyces cerevisiae have evolved independently.",
      "The duplicated genes in Saccharomyces cerevisiae have taken on different functions, contributing to the diversity of gene function in the yeast genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The yeast whole genome duplication resulted in the duplication of almost the entire yeast genome, not just approximately 30%.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that binds to the complex of estrogen and its cognate response elements (REs) in the DNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb binds to a complex formed by estrogen and response elements (REs) in DNA.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb binds to a complex formed by estrogen and response elements (REs) in DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not known to bind estrogen; it is an orphan receptor that binds directly to specific DNA sequences known as estrogen-related response elements (EREs), which are similar but not identical to estrogen response elements (REs).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein that plays a crucial role in the regulation of chromatin dynamics and gene expression. It is involved in various cellular processes, including transcriptional elongation, chromatin remodeling, and DNA damage response. Specifically, ZCCHC17 has been shown to:\n1. Regulate transcriptional elongation: ZCCHC17 can bind to RNA polymerase II and other transcription factors to facilitate transcriptional elongation and gene expression.\n2. Remodel chromatin structure: ZCCHC17 can interact with other chromatin-remodeling complexes and remodel chromatin structure to create a more accessible chromatin environment for transcriptional activation.\n3. Induce DNA damage response: ZCCHC17 can recognize and respond to DNA damage, leading to the activation of the DNA damage response and the repair of damaged DNA.\nOverall, ZCCHC17 plays a critical role in regulating gene expression and chromatin dynamics, and its dysregulation has been implicated in various diseases, including cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 plays a role in the regulation of chromatin dynamics and gene expression.\n2. ZCCHC17 is involved in transcriptional elongation by binding to RNA polymerase II and other transcription factors.\n3. ZCCHC17 interacts with chromatin-remodeling complexes to impact chromatin structure.\n4. ZCCHC17 recognizes and responds to DNA damage, leading to the activation of the DNA damage response.\n5. Dysregulation of ZCCHC17 has been implicated in various diseases, including cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 plays a role in the regulation of chromatin dynamics and gene expression.",
      "ZCCHC17 is involved in transcriptional elongation by binding to RNA polymerase II and other transcription factors.",
      "ZCCHC17 interacts with chromatin-remodeling complexes to impact chromatin structure.",
      "ZCCHC17 recognizes and responds to DNA damage, leading to the activation of the DNA damage response.",
      "Dysregulation of ZCCHC17 has been implicated in various diseases, including cancer and developmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to the functions and interactions of the protein ZCCHC17. Without access to detailed and current scientific literature or databases specifically confirming these roles, I cannot verify the accuracy of these statements. Moreover, the specifics of molecular biology often require experimental evidence, and these details may not be widely known or available beyond the scope of specialized research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is composed of several proteins in human cells. The main proteins that form the NPC are:\n1. Nucleoporins (Nup107, Nup153, Nup133, etc.): These are the main structural components of the NPC and form the central channel through which DNA, RNA, and proteins can pass.\n2. Nup98: This protein is involved in the assembly and maintenance of the NPC and is also a key regulator of gene expression.\n3. Nup50: This protein is involved in the transport of proteins and RNA through the NPC.\n4. Nup215: This protein is involved in the regulation of the NPC and is required for the proper transport of proteins and RNA.\n5. Nup153: This protein is involved in the regulation of the NPC and is required for the proper transport of proteins and RNA.\n6. Nup107: This protein is involved in the regulation of the NPC and is required for the proper transport of proteins and RNA.\nThese proteins work together to form a complex that spans the nuclear envelope and regulates the transport of molecules between the nucleus and the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is composed of several proteins including Nucleoporins (Nup107, Nup153, Nup133, etc.).\n2. Nup98 is involved in the assembly and maintenance of the nuclear pore complex and acts as a regulator of gene expression.\n3. Nup50 plays a role in the transport of proteins and RNA through the nuclear pore complex.\n4. Nup215 is required for the proper transport of proteins and RNA and has a regulatory role in the NPC.\n5. Nup153 and Nup107 are involved in the regulation of the NPC and are required for the proper transport of proteins and RNA.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is composed of several proteins including Nucleoporins (Nup107, Nup153, Nup133, etc.).",
      "Nup98 is involved in the assembly and maintenance of the nuclear pore complex and acts as a regulator of gene expression.",
      "Nup50 plays a role in the transport of proteins and RNA through the nuclear pore complex.",
      "Nup215 is required for the proper transport of proteins and RNA and has a regulatory role in the NPC.",
      "Nup153 and Nup107 are involved in the regulation of the NPC and are required for the proper transport of proteins and RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Nup214, not Nup215, is required for the proper transport of proteins and RNA and has a regulatory role in the NPC.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a topotype II beta (Topo IIβ) inhibitor. Topo IIβ is a key enzyme involved in the relaxation of supercoiled DNA, and its inhibition can lead to the accumulation of supercoiled DNA and the activation of checkpoint pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Gepotidacin specifically inhibits topoisomerase II beta (Topo IIβ).\n3. Topo IIβ is involved in the relaxation of supercoiled DNA.\n4. Inhibition of Topo IIβ can result in the accumulation of supercoiled DNA.\n5. Inhibition of Topo IIβ can activate checkpoint pathways.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Gepotidacin specifically inhibits topoisomerase II beta (Topo IIβ).",
      "Topo IIβ is involved in the relaxation of supercoiled DNA.",
      "Inhibition of Topo IIβ can result in the accumulation of supercoiled DNA.",
      "Inhibition of Topo IIβ can activate checkpoint pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is not a topoisomerase II inhibitor; it is a novel antibiotic that inhibits bacterial type II topoisomerases, DNA gyrase, and topoisomerase IV.\n2. FALSE [correction]: Since gepotidacin targets bacterial type II topoisomerases and not the human topoisomerase II beta (Topo IIβ), the statement is incorrect as it refers to the specific human enzyme.\n3. TRUE: Topo IIβ is indeed involved in the relaxation of supercoiled DNA in eukaryotic cells.\n4. TRUE: Typically, inhibition of Topo IIβ can result in the accumulation of supercoiled DNA because it stops the enzyme from relieving supercoils effectively.\n5. TRUE: Inhibition of Topo IIβ can indeed activate checkpoint pathways because the cell responds to DNA damage and replication stress by activating these pathways to maintain genomic integrity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Spatially-aware Processing Workflow) is a computational framework for analyzing and modeling complex biological processes, particularly those that involve spatially-resolved data. It is designed to handle large-scale datasets and to incorporate multiple types of data, including imaging, genomics, and proteomics data.\nThe main features of Canvas SPW include:\n1. Spatially-aware data integration: Canvas SPW can integrate data from different sources and at different scales, allowing researchers to analyze and model complex biological processes at the molecular, cellular, and tissue levels.\n2. Scalable processing: Canvas SPW is designed to handle large-scale datasets and to scale up to meet the needs of high-performance computing environments.\n3. Integration of multiple data types: Canvas SPW can incorporate multiple types of data, including imaging, genomics, and proteomics data, allowing researchers to analyze and model complex biological processes from a variety of perspectives.\n4. Modular architecture: Canvas SPW is designed as a modular architecture, allowing researchers to add new tools and modules as needed to support their research.\n5. Flexible workflow management: Canvas SPW provides a flexible workflow management system that allows researchers to define and execute complex workflows, including data processing, analysis, and modeling.\n6. Visualization and analysis tools: Canvas SPW includes a range of visualization and analysis tools, including tools for visualizing and analyzing spatially-resolved data, such as 3D visualization, segmentation, and feature extraction.\n7. Support for multiple programming languages: Canvas SPW supports multiple programming languages, including Python, Java, and C++, allowing researchers to use the language most familiar to them.\n8. Integration with other tools and platforms: Canvas SPW can be integrated with other tools and platforms, such as bioinformatics pipelines, high-performance computing environments, and cloud-based platforms.\nOverall, Canvas SPW is a powerful tool for analyzing and modeling complex biological processes, particularly those that involve spatially-resolved data. Its scalable architecture, modular design, and flexible workflow management system make it a valuable tool for researchers in the life sciences and related fields.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a computational framework designed for analyzing and modeling biological processes that involve spatially-resolved data.\n2. Canvas SPW can integrate data from different sources at the molecular, cellular, and tissue levels.\n3. The framework is capable of handling large-scale datasets and is scalable for high-performance computing environments.\n4. Canvas SPW supports multiple programming languages, including Python, Java, and C++.\n5. It provides tools for 3D visualization, segmentation, and feature extraction of spatially-resolved data.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a computational framework designed for analyzing and modeling biological processes that involve spatially-resolved data.",
      "Canvas SPW can integrate data from different sources at the molecular, cellular, and tissue levels.",
      "The framework is capable of handling large-scale datasets and is scalable for high-performance computing environments.",
      "Canvas SPW supports multiple programming languages, including Python, Java, and C++.",
      "It provides tools for 3D visualization, segmentation, and feature extraction of spatially-resolved data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (STimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are compounds or molecules that activate STING and trigger the production of interferon, a potent antiviral molecule. Here are some examples of STING agonists:\n1. CpG DNA: CpG DNA is a specific type of DNA that contains the dinucleotide sequence CpG, which is found in the genomes of most bacteria and viruses. CpG DNA is a potent STING agonist and is often used as a vaccine adjuvant to enhance the immune response to viral infections.\n2. Poly IC: Poly IC is a synthetic molecule that mimics the structure of double-stranded RNA, which is a common component of viral genomes. Poly IC is a strong STING agonist and has been used to treat viral infections, including HIV and hepatitis B.\n3. DNA-based vaccines: Many DNA-based vaccines contain STING agonists, such as CpG DNA or other synthetic STING agonists, to enhance the immune response to the vaccine.\n4. Small molecule agonists: There are several small molecule agonists of STING that have been developed, including cyclic dinucleotides (CDNs) and 2'-O-methyl-RNA oligonucleotides (2'-OMe RNA). These molecules can be taken up by cells through various mechanisms, including endocytosis and phagocytosis, and activate STING to trigger an immune response.\n5. Viral mimics: Some viral mimics, such as the virus-like particle (VLP) vaccines, can also activate STING and trigger an immune response. VLPs are non-infectious particles that mimic the structure of a virus and can stimulate the immune system in a similar way to a real virus infection.\nOverall, STING agonists can be used to enhance the immune response to viral infections and to develop",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG DNA is a STING agonist that contains the dinucleotide sequence CpG, which is common in bacterial and viral genomes.\n2. Poly IC is a synthetic molecule that acts as a STING agonist by mimicking the structure of double-stranded RNA from viral genomes.\n3. DNA-based vaccines often contain STING agonists to boost the immune response.\n4. Small molecule STING agonists such as cyclic dinucleotides (CDNs) and 2'-O-methyl-RNA oligonucleotides (2'-OMe RNA) have been developed.\n5. Virus-like particle (VLP) vaccines can activate STING, functioning as viral mimics to stimulate the immune system.",
    "llama-2-7b-chat-hf_fact": [
      "CpG DNA is a STING agonist that contains the dinucleotide sequence CpG, which is common in bacterial and viral genomes.",
      "Poly IC is a synthetic molecule that acts as a STING agonist by mimicking the structure of double-stranded RNA from viral genomes.",
      "DNA-based vaccines often contain STING agonists to boost the immune response.",
      "Small molecule STING agonists such as cyclic dinucleotides (CDNs) and 2'-O-methyl-RNA oligonucleotides (2'-OMe RNA) have been developed.",
      "Virus-like particle (VLP) vaccines can activate STING, functioning as viral mimics to stimulate the immune system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Poly IC is not a STING agonist but a TLR3 agonist that mimics double-stranded RNA from viral genomes.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Splicing-dependent Localization of Circular RNA and its Co-regulators in Genomes Everywhere) is a computational method used to identify the subcellular localization of circular RNAs (circRNAs) and their associated protein co-regulators in various organisms.\nSLIC-CAGE uses a combination of computational and experimental approaches to predict the localization of circRNAs and their co-regulators in different cellular compartments, such as the nucleus, cytoplasm, and membranes. The method is based on the observation that the splicing of circRNAs can influence their subcellular localization, and that protein co-regulators can also affect the localization of circRNAs.\nThe SLIC-CAGE method involves the following steps:\n1. RNA sequencing (RNA-seq) analysis: The first step is to perform RNA-seq analysis on the sample of interest to identify the expression levels of circRNAs and their co-regulators.\n2. Splicing event detection: The next step is to detect splicing events in the RNA-seq data using a splicing detection algorithm. This step identifies the splicing junctions in the circRNAs and determines the number of splicing events for each circRNA.\n3. Subcellular localization prediction: The predicted splicing events are then used to predict the subcellular localization of the circRNAs and their co-regulators using a machine learning algorithm. The algorithm takes into account the known subcellular localization of proteins and RNAs, as well as the sequence and structural features of the circRNAs.\n4. Validation by mass spectrometry: The predicted localization of the circRNAs and their co-regulators is validated using mass spectrometry-based methods, such as ribosome profiling or proteomics. This step provides experimental confirmation of the predicted localization and helps to refine the predictions.\n5. Visualization and interpretation: The final step is to visualize and interpret the results using a web-based tool, which provides a comprehensive overview of the subcellular localization of circRNAs and their co-regulators in different cellular compartments.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a computational method used for identifying the subcellular localization of circular RNAs and their protein co-regulators.\n2. SLIC-CAGE incorporates both computational and experimental approaches for its predictions.\n3. RNA sequencing analysis is the first step in the SLIC-CAGE method to identify the expression levels of circRNAs and their co-regulators.\n4. The subcellular localization of circRNAs and their co-regulators is predicted using a machine learning algorithm in the SLIC-CAGE method.\n5. The predicted localizations from SLIC-CAGE are validated using mass spectrometry-based methods like ribosome profiling or proteomics.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a computational method used for identifying the subcellular localization of circular RNAs and their protein co-regulators.",
      "SLIC-CAGE incorporates both computational and experimental approaches for its predictions.",
      "RNA sequencing analysis is the first step in the SLIC-CAGE method to identify the expression levels of circRNAs and their co-regulators.",
      "The subcellular localization of circRNAs and their co-regulators is predicted using a machine learning algorithm in the SLIC-CAGE method.",
      "The predicted localizations from SLIC-CAGE are validated using mass spectrometry-based methods like ribosome profiling or proteomics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mass spectrometry-based methods like ribosome profiling or proteomics are typically used to validate protein expression and interaction, but not specifically for the validation of the subcellular localization predictions of circRNAs and their co-regulators. The validation of localization predictions would more likely involve some form of imaging, such as fluorescence microscopy, or biochemical fractionation methods.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM-domain protein 3) is a protein that plays multiple roles in the regulation of various cellular processes, including:\n1. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin structure, particularly in the regulation of gene expression during cell differentiation and development.\n2. Transcriptional activation: LEM-3 can interact with transcription factors and coactivators to enhance the recruitment of RNA polymerase to promoters and enhance transcriptional activation.\n3. Ubiquitination: LEM-3 can ubiquitinate proteins, which can affect their stability, localization, or interactions with other proteins.\n4. Cell cycle regulation: LEM-3 has been implicated in the regulation of the cell cycle, particularly in the G1/S transition, and may play a role in the regulation of cyclin-dependent kinases (CDKs).\n5. Apoptosis: LEM-3 has been shown to regulate apoptotic pathways, particularly in the context of cancer, where it can promote or inhibit apoptosis depending on the context.\n6. Cellular stress response: LEM-3 can respond to various forms of cellular stress, including DNA damage, oxidative stress, and heat shock, and can activate various stress-response pathways.\n7. Neurodegeneration: LEM-3 has been implicated in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, although the exact mechanisms are not yet fully understood.\nOverall, LEM-3 is a multifunctional protein that plays a complex role in regulating various cellular processes, and its dysregulation has been implicated in a variety of diseases, including cancer, neurodegeneration, and developmental disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in chromatin remodeling, particularly in regulating gene expression during cell differentiation and development.\n2. LEM-3 can interact with transcription factors and coactivators to enhance transcriptional activation.\n3. LEM-3 is capable of ubiquitinating proteins, which can affect their stability, localization, or interactions with other proteins.\n4. LEM-3 has been implicated in the regulation of the cell cycle, especially in the G1/S transition.\n5. LEM-3 has been shown to regulate apoptotic pathways, particularly in the context of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in chromatin remodeling, particularly in regulating gene expression during cell differentiation and development.",
      "LEM-3 can interact with transcription factors and coactivators to enhance transcriptional activation.",
      "LEM-3 is capable of ubiquitinating proteins, which can affect their stability, localization, or interactions with other proteins.",
      "LEM-3 has been implicated in the regulation of the cell cycle, especially in the G1/S transition.",
      "LEM-3 has been shown to regulate apoptotic pathways, particularly in the context of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: LEM-3, as described, is involved in chromatin remodeling and regulation during cell differentiation and development. Ubiquitination is commonly associated with protein degradation rather than chromatin remodeling, and there is no specific information provided to confirm that LEM-3 has ubiquitination activity.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a biomedical scientist, I am familiar with the tmVar package in R, which is a tool for visualizing and analyzing time-series gene expression data. Here are some of the releases of the tmVar package:\n* tmVar 1.0.0 (2015): This was the initial release of the package, which introduced the basic functionality for visualizing and analyzing time-series gene expression data.\n* tmVar 1.2.0 (2016): This release added several new features, including the ability to visualize and analyze gene expression data from multiple samples, and the ability to filter genes based on their expression levels.\n* tmVar 2.0.0 (2018): This release included several major updates, including a new user interface, improved performance, and support for visualizing and analyzing data from multiple time points.\n* tmVar 2.1.0 (2019): This release added several new features, including the ability to visualize and analyze data from single-cell RNA sequencing experiments, and the ability to integrate data from multiple sources.\n* tmVar 2.2.0 (2020): This release included several major updates, including improved performance and stability, and the ability to visualize and analyze data from large-scale gene expression experiments.\nThese are some of the notable releases of the tmVar package, but there may be other releases that are not listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 1.0.0 was released in 2015 as the initial version of the tmVar package.\n2. tmVar 1.2.0, released in 2016, added functionality for analyzing gene expression data from multiple samples.\n3. The tmVar 2.0.0 release in 2018 included a new user interface and improved performance.\n4. In 2019, tmVar version 2.1.0 introduced features for visualizing and analyzing data from single-cell RNA sequencing experiments.\n5. tmVar 2.2.0 was released in 2020, offering improved performance and stability for analyzing large-scale gene expression experiments.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 1.0.0 was released in 2015 as the initial version of the tmVar package.",
      "tmVar 1.2.0, released in 2016, added functionality for analyzing gene expression data from multiple samples.",
      "The tmVar 2.0.0 release in 2018 included a new user interface and improved performance.",
      "In 2019, tmVar version 2.1.0 introduced features for visualizing and analyzing data from single-cell RNA sequencing experiments.",
      "tmVar 2.2.0 was released in 2020, offering improved performance and stability for analyzing large-scale gene expression experiments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The functionality for analyzing gene expression data from multiple samples is not documented as a feature of tmVar 1.2.0. The tmVar tool is developed for extracting variants from biomedical literature, not for analyzing gene expression data.\n3. UNKNOWN: While tmVar 2.0.0 may have included updates, the specific features of a new user interface and improved performance cannot be confirmed without more information about the tool's version history.\n4. UNKNOWN: Similarly, the addition of features for visualizing and analyzing data from single-cell RNA sequencing experiments in tmVar version 2.1.0 cannot be confirmed without additional context or documentation.\n5. UNKNOWN: The release of tmVar 2.2.0 and its improvements are also not verifiable without further details on the version history and documentation of the tmVar package.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There is no comprehensive database of somatic mutations in normal cells. Somatic mutations are mutations that occur in non-reproductive cells in a tissue or organism, and are not present in the reproductive cells (gametes). These mutations can occur spontaneously or as a result of environmental exposures, and can contribute to the development of cancer or other diseases.\nWhile there are many databases that catalogue genetic mutations in cancer cells, there are very few databases that focus on somatic mutations in normal cells. Some examples of databases that include information on somatic mutations include:\n1. The Cancer Genome Atlas (TCGA): This database contains genomic and transcriptomic data from over 10,000 tumor samples across many different cancer types. While the majority of the data is focused on cancer, there are some normal tissue samples included in the database.\n2. The 1000 Genomes Project: This database contains genetic data from over 1,000 individuals, including both normal and diseased tissues.\n3. The ExAC database: This database contains genetic data from over 60,000 individuals, including both normal and diseased tissues.\n4. The GTEx database: This database contains genetic data from over 450,000 individuals, including both normal and diseased tissues.\nIt is important to note that these databases are constantly evolving and new data is being added regularly. Additionally, while these databases can provide valuable insights into the genetic landscape of normal and diseased cells, they are not comprehensive and there may be many somatic mutations that are not represented in these databases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Somatic mutations occur in non-reproductive cells and are not present in the reproductive cells (gametes).\n2. The Cancer Genome Atlas (TCGA) contains genomic and transcriptomic data from over 10,000 tumor samples and includes some normal tissue samples.\n3. The 1000 Genomes Project database contains genetic data from over 1,000 individuals, including both normal and diseased tissues.\n4. The ExAC database contains genetic data from over 60,000 individuals, including both normal and diseased tissues.\n5. The GTEx database contains genetic data from over 450,000 individuals, including both normal and diseased tissues.",
    "llama-2-7b-chat-hf_fact": [
      "Somatic mutations occur in non-reproductive cells and are not present in the reproductive cells (gametes).",
      "The Cancer Genome Atlas (TCGA) contains genomic and transcriptomic data from over 10,000 tumor samples and includes some normal tissue samples.",
      "The 1000 Genomes Project database contains genetic data from over 1,000 individuals, including both normal and diseased tissues.",
      "The ExAC database contains genetic data from over 60,000 individuals, including both normal and diseased tissues.",
      "The GTEx database contains genetic data from over 450,000 individuals, including both normal and diseased tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The 1000 Genomes Project database contains genetic data from over 2,500 individuals from 26 populations around the world, and it is focused on capturing human genetic variation, not specifically on diseased tissues.\n4. UNKNOWN: The Exome Aggregation Consortium (ExAC) database is primarily focused on aggregating and harmonizing exome sequencing data from a wide range of large-scale sequencing projects. However, the exact characterization of the tissues (normal or diseased) in the data is not specified in the statement and such databases usually focus on normal genetic variation, so the specifics would need to be checked within the database itself for accuracy.\n5. FALSE [correction]: The GTEx database (Genotype-Tissue Expression) contains genetic data (both genomic and transcriptomic) from over 17,000 samples across 54 healthy human tissue types from nearly 1000 individuals, not over 450,000 individuals.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are some of them:\n1. GraphKite: GraphKite is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n2. JGraphT: JGraphT is a Java library for graph theory and kernel methods. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n3. GraphSAGE: GraphSAGE is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n4. GraphKernel: GraphKernel is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n5. JGraph: JGraph is a Java library for graph theory and kernel methods. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n6. GraphKernal: GraphKernal is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n7. JGraphKernel: JGraphKernel is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n8. GraphKernel2D: GraphKernel2D is a Java library for graph kernel computation in 2D. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n9. GraphKernel3D: GraphKernel3D is a Java library for graph kernel computation in 3D. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\n10. KernalGraph: KernalGraph is a Java library for graph kernel computation. It provides a simple and efficient implementation of graph kernel algorithms, including the PageRank algorithm.\nPlease note that this is not an exhaustive list and there may be other graph kernel libraries available in Java. It's always a good idea to explore different options and choose the one that best fits your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKite is a Java library designed for graph kernel computation.\n2. JGraphT is a Java library that supports both graph theory and kernel methods.\n3. GraphSAGE is a Java library specializing in graph kernel computation.\n4. GraphKernel3D is a Java library focused on graph kernel computation in 3D.\n5. GraphKernel2D is a Java library tailored for graph kernel computation in 2D.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKite is a Java library designed for graph kernel computation.",
      "JGraphT is a Java library that supports both graph theory and kernel methods.",
      "GraphSAGE is a Java library specializing in graph kernel computation.",
      "GraphKernel3D is a Java library focused on graph kernel computation in 3D.",
      "GraphKernel2D is a Java library tailored for graph kernel computation in 2D."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (Without additional context or information, it is not possible to verify the purpose of \"GraphKite\".)\n2. FALSE [correction]: JGraphT is a Java library that provides mathematical graph-theory objects and algorithms, but there is no explicit evidence that it supports kernel methods, which are typically used in machine learning applications.\n3. FALSE [correction]: GraphSAGE is not a Java library; instead, it is a general inductive framework that leverages node feature information to efficiently generate node embeddings for previously unseen data or for dynamically changing graphs, and it is not specified to specialize in graph kernel computation.\n4. UNKNOWN (There is no well-known Java library named GraphKernel3D that specializes in graph kernel computation in 3D; however, without further context, the existence and purpose of GraphKernel3D cannot be definitively confirmed or denied.)\n5. UNKNOWN (There is no well-known Java library named GraphKernel2D that specializes in graph kernel computation in 2D; however, without further context, the existence and purpose of GraphKernel2D cannot be definitively confirmed or denied.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform integrates four advances in the field of nucleic acid detection:\n1. CRISPR-Cas13: SHERLOCKv2 utilizes the CRISPR-Cas13 system, which is a type of RNA-guided DNA endonuclease, to cleave specific DNA sequences. This allows for the detection of specific nucleic acid targets through the formation of a DNA double-strand break.\n2. Single-molecule FRET: SHERLOCKv2 employs single-molecule FRET (fluorescence resonance energy transfer) to detect the formation of DNA double-strand breaks. This involves the use of two fluorescently labeled probes that are complementary to the target DNA sequence, and the measurement of the FRET efficiency between these probes.\n3. CRISPR-Cas13-based DNA amplification: SHERLOCKv2 uses a CRISPR-Cas13-based DNA amplification mechanism to amplify the target DNA sequence, which allows for the detection of very low concentrations of nucleic acids.\n4. Digital PCR: SHERLOCKv2 utilizes digital PCR (dPCR) to quantify the amount of amplified DNA. dPCR involves the partitioning of the amplified DNA into thousands of nanoliter-sized droplets, followed by PCR amplification of the DNA in each droplet. The resulting data is then analyzed to determine the quantity of the target DNA sequence present in the sample.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses the CRISPR-Cas13 system which cleaves specific DNA sequences for nucleic acid detection.\n2. SHERLOCKv2 incorporates single-molecule FRET to detect the formation of DNA double-strand breaks.\n3. The platform employs a CRISPR-Cas13-based DNA amplification mechanism to detect low concentrations of nucleic acids.\n4. SHERLOCKv2 utilizes digital PCR to quantify the amount of amplified DNA.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses the CRISPR-Cas13 system which cleaves specific DNA sequences for nucleic acid detection.",
      "SHERLOCKv2 incorporates single-molecule FRET to detect the formation of DNA double-strand breaks.",
      "The platform employs a CRISPR-Cas13-based DNA amplification mechanism to detect low concentrations of nucleic acids.",
      "SHERLOCKv2 utilizes digital PCR to quantify the amount of amplified DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SHERLOCKv2 uses the CRISPR-Cas13 system, which cleaves specific RNA sequences for nucleic acid detection.\n2. FALSE [correction]: SHERLOCKv2 incorporates collateral cleavage of RNA triggered by the CRISPR-Cas13 to report the presence of the target nucleic acid, not single-molecule FRET for detecting DNA double-strand breaks.\n3. TRUE\n4. FALSE [correction]: SHERLOCKv2 does not utilize digital PCR. It relies on isothermal amplification and Cas13 detection, rather than digital PCR, to quantify the amount of nucleic acid.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a heuristic algorithm used to solve the traveling salesman problem (TSP), which is a classic problem in computer science and operations research. The algorithm was first proposed by David Goldberg in 1988.\nThe basic idea of the bartender algorithm is to start with an initial random solution and iteratively improve it by exchanging edges between the tour and a set of \"bartender\" vertices. The bartender vertices are chosen based on a set of criteria that favor edges that are close to the current tour and that have not been used recently.\nHere is a high-level description of the bartender algorithm:\n1. Initialize the tour with a random solution.\n2. For each iteration:\na. Choose a bartender vertex: The bartender vertex is chosen based on a set of criteria that favor edges that are close to the current tour and that have not been used recently. One common way to choose the bartender vertex is to select the vertex that is closest to the current tour in terms of distance.\nb. Exchange edges: Swap an edge in the current tour with an edge between the bartender vertex and a vertex in the tour. This step is repeated until no more improvements can be made.\nc. Repeat step b until no more improvements can be made or a stopping criterion is reached.\n3. Return the final tour.\nThe bartender algorithm is a local search algorithm, meaning that it starts with an initial solution and iteratively improves it by exchanging edges between the tour and a set of bartender vertices. The algorithm stops when no more improvements can be made, or when a stopping criterion is reached.\nThe bartender algorithm is simple to implement and has been shown to perform well on many instances of the TSP. However, it is not guaranteed to find the optimal solution, and it may get stuck in local optima. As with other local search algorithms, the performance of the bartender algorithm can be improved by using techniques such as heuristics, diversification, and iterated local search.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm is used to solve the traveling salesman problem (TSP).\n2. The algorithm was first proposed by David Goldberg in 1988.\n3. The bartender algorithm iteratively improves an initial random solution by exchanging edges between the tour and bartender vertices.\n4. The bartender vertices are chosen based on criteria that favor edges close to the current tour and edges not recently used.\n5. The bartender algorithm may not guarantee to find the optimal solution and can get stuck in local optima.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm is used to solve the traveling salesman problem (TSP).",
      "The algorithm was first proposed by David Goldberg in 1988.",
      "The bartender algorithm iteratively improves an initial random solution by exchanging edges between the tour and bartender vertices.",
      "The bartender vertices are chosen based on criteria that favor edges close to the current tour and edges not recently used.",
      "The bartender algorithm may not guarantee to find the optimal solution and can get stuck in local optima."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no such algorithm known as the \"bartender algorithm\" commonly used to solve the traveling salesman problem (TSP). The most known heuristic for solving the TSP is the \"nearest neighbor\" algorithm, among others.\n2. FALSE [correction]: Since the \"bartender algorithm\" does not exist for solving TSP, it's not accurate to attribute its proposal to David Goldberg in 1988. David E. Goldberg is a computer scientist known for his work on genetic algorithms, but not in the context of a \"bartender algorithm.\"\n3. FALSE [correction]: As the \"bartender algorithm\" for TSP does not exist, a statement regarding how it functions is incorrect.\n4. FALSE [correction]: The concept of \"bartender vertices\" is not established in the context of the traveling salesman problem, so this description is not correct.\n5. TRUE: While this statement is generally applicable to many heuristic algorithms for the traveling salesman problem that don't always find the optimal solution, the reference to the \"bartender algorithm\" is incorrect. However, the concept that algorithms may not guarantee to find the optimal solution and can get stuck in local optima is valid for many approximate or heuristic algorithms used in solving TSP.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Online: This is a popular web-based platform that allows users to create and edit family trees, as well as connect with other researchers and share information.\n2. MyHeritage: MyHeritage is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n3. FamilySearch: FamilySearch is a non-profit genealogy organization that offers a web-based pedigree editor, as well as access to historical records and family history research tools.\n4. GenoPro: GenoPro is a web-based genealogy software that allows users to create and edit family trees, as well as add historical records and photos.\n5. Legacy Family Tree: Legacy Family Tree is a web-based genealogy software that allows users to create and edit family trees, as well as add historical records and photos.\n6. FamilyTreeWebinars: FamilyTreeWebinars is a web-based platform that offers live and on-demand genealogy webinars, as well as access to a library of genealogy courses and resources.\n7. GenealogyBank: GenealogyBank is a web-based platform that offers access to historical newspapers, obituaries, and other genealogy resources.\n8. Findmypast: Findmypast is a web-based genealogy research platform that offers access to historical records and family tree building tools.\n9. Ancestry.com: Ancestry.com is a popular web-based genealogy research platform that offers access to historical records and family tree building tools.\n10. BillionGraves: BillionGraves is a web-based platform that allows users to create and edit family trees, as well as add GPS-tagged photos of headstones and cemeteries.\nThese are just a few examples of the many web-based pedigree editors available. Each platform has its own unique features and offerings, so it's important to do some research and choose the one that best fits your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform designed for creating, editing, and sharing family trees.\n2. MyHeritage provides a web-based pedigree editor and access to genealogical records.\n3. FamilySearch is a non-profit organization offering a web-based pedigree editor and historical records for research.\n4. GenoPro is a web-based application that allows users to create and edit family trees and include historical records and photos.\n5. Ancestry.com is a web-based genealogy platform that provides historical records and tools for building family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform designed for creating, editing, and sharing family trees.",
      "MyHeritage provides a web-based pedigree editor and access to genealogical records.",
      "FamilySearch is a non-profit organization offering a web-based pedigree editor and historical records for research.",
      "GenoPro is a web-based application that allows users to create and edit family trees and include historical records and photos.",
      "Ancestry.com is a web-based genealogy platform that provides historical records and tools for building family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (While Pedigree Online could refer to an online service for creating family trees, without more context or specific information about a service with this exact name, the truth value of the statement can't be determined.)\n2. TRUE (MyHeritage is indeed a web-based platform that offers a pedigree editor and access to genealogical records.)\n3. TRUE (FamilySearch is a non-profit organization that provides a platform for editing family trees (pedigree) and accessing historical records for genealogical research.)\n4. FALSE [correction]: GenoPro is a family tree software that requires downloading and is not purely web-based. Users can create and edit family trees and include historical records and photos, but it operates as a downloadable program.\n5. TRUE (Ancestry.com is a well-known web-based genealogy platform offering access to historical records and tools for building family trees.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. SpiderBase: A comprehensive database of spider venom toxins and their components, including their structure, function, and evolution.\n2. Toxinology: A database of venom toxins from various animals, including spiders, snakes, and scorpions, with information on their structure, function, and pharmacology.\n3. Venom-DB: A database of venom peptides and proteins from various organisms, including spiders, snakes, and insects, with information on their structure, function, and evolution.\n4. Natural Products Alert: A database of natural products, including venom peptides and proteins, with information on their structure, function, and pharmacology.\n5. Toxinology Database: A database of toxins from various organisms, including spiders, snakes, and insects, with information on their structure, function, and pharmacology.\n6. Venom Toxin Database: A database of venom toxins from various organisms, including spiders, snakes, and insects, with information on their structure, function, and pharmacology.\n7. Spider Venom Toxin Database: A database of spider venom toxins and their components, including their structure, function, and evolution.\n8. ToxinTox: A database of toxins from various organisms, including spiders, snakes, and insects, with information on their structure, function, and pharmacology.\n9. Venomous Animal Toxin Database: A database of venomous animal toxins, including spider venom toxins, with information on their structure, function, and pharmacology.\n10. Nature's Toxinology Database: A database of toxins from various organisms, including spiders, snakes, and insects, with information on their structure, function, and pharmacology.\nThese databases provide valuable information on the structure, function, and pharmacology of spider-venom toxins, and can be used for research and development of new drugs and therapies.",
    "llama-2-7b-chat-hf_fact_raw": "1. SpiderBase is a database specifically for spider venom toxins, providing information on their structure, function, and evolution.\n2. Toxinology is a database that includes venom toxins from spiders, snakes, and scorpions, focusing on their structure, function, and pharmacology.\n3. Venom-DB encompasses venom peptides and proteins from various organisms, such as spiders, snakes, and insects, detailing their structure, function, and evolution.\n4. Natural Products Alert is a database that covers natural products like venom peptides and proteins, providing information on their structure, function, and pharmacology.\n5. Venomous Animal Toxin Database is a resource for venomous animal toxins, including those from spiders, and covers their structure, function, and pharmacology.",
    "llama-2-7b-chat-hf_fact": [
      "SpiderBase is a database specifically for spider venom toxins, providing information on their structure, function, and evolution.",
      "Toxinology is a database that includes venom toxins from spiders, snakes, and scorpions, focusing on their structure, function, and pharmacology.",
      "Venom-DB encompasses venom peptides and proteins from various organisms, such as spiders, snakes, and insects, detailing their structure, function, and evolution.",
      "Natural Products Alert is a database that covers natural products like venom peptides and proteins, providing information on their structure, function, and pharmacology.",
      "Venomous Animal Toxin Database is a resource for venomous animal toxins, including those from spiders, and covers their structure, function, and pharmacology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "According to the information provided in the question, Axitinib has been shown to prolong the survival of pancreatic cancer patients.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Membrane-Associated Guanylate Kinase-Like Protein) regulates F-actin dynamics through its interaction with the F-actin protein, actin-related protein 2/3 complex (ARP2/3 complex). MLP binds to the ARP2/3 complex and inhibits its activity, thereby reducing the turnover of F-actin and promoting its stability. This leads to the formation of more stable actin filaments and the regulation of cellular processes such as cell migration and cell signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP stands for Membrane-Associated Guanylate Kinase-Like Protein.\n2. MLP regulates F-actin dynamics through interaction with the actin-related protein 2/3 complex (ARP2/3 complex).\n3. MLP binds to the ARP2/3 complex and inhibits its activity.\n4. Inhibition of ARP2/3 by MLP reduces the turnover of F-actin.\n5. This action promotes the stability of actin filaments, which is important for cell migration and cell signaling.",
    "llama-2-7b-chat-hf_fact": [
      "MLP stands for Membrane-Associated Guanylate Kinase-Like Protein.",
      "MLP regulates F-actin dynamics through interaction with the actin-related protein 2/3 complex (ARP2/3 complex).",
      "MLP binds to the ARP2/3 complex and inhibits its activity.",
      "Inhibition of ARP2/3 by MLP reduces the turnover of F-actin.",
      "This action promotes the stability of actin filaments, which is important for cell migration and cell signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP typically stands for Muscle LIM Protein, not Membrane-Associated Guanylate Kinase-Like Protein.\n2. FALSE [correction]: Muscle LIM Protein (MLP) has been implicated in the regulation of mechanical stress responses in muscle cells, not necessarily in regulating F-actin dynamics through interaction with the ARP2/3 complex.\n3. FALSE [correction]: Since MLP is not known to directly interact with the ARP2/3 complex, it does not bind to the ARP2/3 complex to inhibit its activity.\n4. UNKNOWN: Because the previous statement about MLP's interaction with ARP2/3 was incorrect, the effect on F-actin turnover is not clearly established with the information provided.\n5. UNKNOWN: Similarly, due to the incorrect statements regarding MLP's interaction with ARP2/3, the impact on actin filament stability and its implications for cell migration and cell signaling cannot be accurately determined from the given statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Pseudokinases are proteins that have some characteristics of kinases but lack catalytic activity. The exact number of pseudokinases in the human kinome is not well established, as it can vary depending on the source and methodology used to identify them. However, it is estimated that there are approximately 100-150 pseudokinases in the human kinome. These proteins are often involved in various cellular processes, including signal transduction, cytoskeleton organization, and regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pseudokinases are proteins that have some characteristics of kinases but lack catalytic activity.\n2. The exact number of pseudokinases in the human kinome is not well established.\n3. It is estimated that there are approximately 100-150 pseudokinases in the human kinome.\n4. Pseudokinases are involved in various cellular processes including signal transduction, cytoskeleton organization, and regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Pseudokinases are proteins that have some characteristics of kinases but lack catalytic activity.",
      "The exact number of pseudokinases in the human kinome is not well established.",
      "It is estimated that there are approximately 100-150 pseudokinases in the human kinome.",
      "Pseudokinases are involved in various cellular processes including signal transduction, cytoskeleton organization, and regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE, although estimates can vary and the precise number may not be definitive, this statement acknowledges the uncertainty by providing a range.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE (apolipoprotein E) mimetics are small molecules that mimic the structure and function of the apolipoprotein E protein, which plays a crucial role in lipid metabolism and inflammation. Here are three examples of apoE mimetics:\n1. ApoEMimetic-1: This is a synthetic peptide mimic of the apolipoprotein E protein that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of non-alcoholic fatty liver disease (NAFLD).\n2. GW-642440: This is a small molecule inhibitor of the enzyme acetyl-CoA carboxylase (ACC), which is involved in fatty acid synthesis. GW-642440 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.\n3. VX-809: This is a small molecule inhibitor of the enzyme stearoyl-CoA desaturase-1 (SCD1), which is involved in the synthesis of monounsaturated fatty acids. VX-809 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMimetic-1 is a synthetic peptide mimic of apolipoprotein E that reduces liver inflammation and improves insulin sensitivity in animal models of NAFLD.\n2. GW-642440 is a small molecule inhibitor of acetyl-CoA carboxylase (ACC).\n3. GW-642440 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.\n4. VX-809 is a small molecule inhibitor of stearoyl-CoA desaturase-1 (SCD1).\n5. VX-809 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMimetic-1 is a synthetic peptide mimic of apolipoprotein E that reduces liver inflammation and improves insulin sensitivity in animal models of NAFLD.",
      "GW-642440 is a small molecule inhibitor of acetyl-CoA carboxylase (ACC).",
      "GW-642440 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.",
      "VX-809 is a small molecule inhibitor of stearoyl-CoA desaturase-1 (SCD1).",
      "VX-809 has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: VX-809, also known as Lumacaftor, is a corrector of the transmembrane conductance regulator (CFTR) protein defective in cystic fibrosis, not an inhibitor of stearoyl-CoA desaturase-1 (SCD1).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Sperm Associated Mitochondrial DNA-Destroying Enzyme 1) is an enzyme that plays a critical role in regulating the degradation of mitochondrial DNA (mtDNA) in sperm cells. There are sex differences in SAMHD1 activity, with studies showing that:\n1. Female mice have higher levels of SAMHD1 activity compared to males.\n2. SAMHD1 activity is lower in human males compared to females, which may contribute to the higher rates of mtDNA mutations in male sperm.\n3. SAMHD1 activity is regulated by estrogen levels, with estrogen stimulation increasing SAMHD1 activity in female mice.\n4. SAMHD1 activity is also influenced by the presence of paternal mtDNA, with paternal mtDNA mutations reducing SAMHD1 activity in male mice.\nThese sex differences in SAMHD1 activity may have important implications for male reproductive health and the transmission of mtDNA mutations to offspring.",
    "llama-2-7b-chat-hf_fact_raw": "1. Female mice have higher levels of SAMHD1 activity compared to male mice.\n2. SAMHD1 activity in human males is lower than in human females.\n3. Estrogen stimulation increases SAMHD1 activity in female mice.\n4. Paternal mtDNA mutations reduce SAMHD1 activity in male mice.",
    "llama-2-7b-chat-hf_fact": [
      "Female mice have higher levels of SAMHD1 activity compared to male mice.",
      "SAMHD1 activity in human males is lower than in human females.",
      "Estrogen stimulation increases SAMHD1 activity in female mice.",
      "Paternal mtDNA mutations reduce SAMHD1 activity in male mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Paternal mtDNA mutations would not affect SAMHD1 activity because mitochondrial DNA (mtDNA) is inherited maternally, not paternally.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit astrocyte differentiation. RUNX2 is a transcription factor that plays a crucial role in the regulation of cell fate decisions, including the differentiation of neural progenitor cells into astrocytes. Studies have shown that overexpression of RUNX2 inhibits the differentiation of astrocytes, while knockdown of RUNX2 leads to an increase in astrocyte differentiation. This suggests that RUNX2 acts as a negative regulator of astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.\n2. RUNX2 is a transcription factor involved in the regulation of cell fate decisions.\n3. Overexpression of RUNX2 inhibits the differentiation of astrocytes.\n4. Knockdown of RUNX2 leads to an increase in astrocyte differentiation.\n5. RUNX2 acts as a negative regulator of astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.",
      "RUNX2 is a transcription factor involved in the regulation of cell fate decisions.",
      "Overexpression of RUNX2 inhibits the differentiation of astrocytes.",
      "Knockdown of RUNX2 leads to an increase in astrocyte differentiation.",
      "RUNX2 acts as a negative regulator of astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed on the knee joint. It involves removing a portion of the femur (thigh bone) and the tibia (shin bone) and replacing them with an artificial joint. The procedure is typically performed to treat advanced degenerative knee joint disease, such as osteoarthritis, that has not responded to other treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. The procedure involves removing a portion of the femur and the tibia.\n3. An artificial joint replaces the removed portion of the femur and tibia in the Cobb-Stainsby excision arthroplasty.\n4. The Cobb-Stainsby excision arthroplasty is typically used to treat advanced degenerative knee joint disease.\n5. The procedure is usually considered when other treatments for the knee joint disease have not been successful.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "The procedure involves removing a portion of the femur and the tibia.",
      "An artificial joint replaces the removed portion of the femur and tibia in the Cobb-Stainsby excision arthroplasty.",
      "The Cobb-Stainsby excision arthroplasty is typically used to treat advanced degenerative knee joint disease.",
      "The procedure is usually considered when other treatments for the knee joint disease have not been successful."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. TRUE\n3. FALSE [correction]: In the Cobb-Stainsby excision arthroplasty, a portion of the femoral head is removed, and the remaining bone is capped, but an artificial joint does not replace the removed portion. Instead, a prosthetic cap is sometimes used, and muscles and tendons are modified to stabilize the joint.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their epithelial characteristics and acquire mesenchymal properties, such as increased migration and invasiveness, and is a key step in tumor progression. GRHL2 has been shown to promote EMT by suppressing the expression of epithelial markers and increasing the expression of mesenchymal markers, such as vimentin and N-cadherin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. EMT is a process where epithelial cells lose their characteristics and gain mesenchymal properties.\n3. Epithelial-to-mesenchymal transition is a key step in tumor progression.\n4. GRHL2 suppresses the expression of epithelial markers.\n5. GRHL2 increases the expression of mesenchymal markers, including vimentin and N-cadherin.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "EMT is a process where epithelial cells lose their characteristics and gain mesenchymal properties.",
      "Epithelial-to-mesenchymal transition is a key step in tumor progression.",
      "GRHL2 suppresses the expression of epithelial markers.",
      "GRHL2 increases the expression of mesenchymal markers, including vimentin and N-cadherin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GRHL2 actually maintains the expression of epithelial markers.\n5. FALSE [correction]: GRHL2 typically decreases the expression of mesenchymal markers, including vimentin and N-cadherin, since it suppresses EMT.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are T-UCRs that have been implicated in lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.\n2. Eomesodermin (Eomes) is a T-UCR that has been implicated in lung cancer. \n\n(Note: The abbreviations T-UCRs seem to be incorrect in this context, as T-UCRs typically refer to \"transcribed ultraconserved regions,\" while T-bet and Eomes are transcription factors. This indicates that there might be a factual error in the provided information. Nonetheless, the factual statements have been extracted based on the given answer.)",
    "llama-2-7b-chat-hf_fact": [
      "T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.",
      "Eomesodermin (Eomes) is a T-UCR that has been implicated in lung cancer.",
      "ote: The abbreviations T-UCRs seem to be incorrect in this context, as T-UCRs typically refer to \"transcribed ultraconserved regions,\" while T-bet and Eomes are transcription factors. This indicates that there might be a factual error in the provided information. Nonetheless, the factual statements have been extracted based on the given answer.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Eomesodermin (Eomes) is a T-box transcription factor that has been implicated in lung cancer, not a T-UCR (transcribed ultraconserved regions).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, research has shown that GPR151 is involved in a variety of cellular processes, including:\n1. Inflammation: GPR151 has been shown to be involved in the regulation of inflammatory responses, with activation of the receptor leading to the production of pro-inflammatory cytokines.\n2. Cell adhesion and migration: GPR151 has been implicated in the regulation of cell adhesion and migration, with the receptor playing a role in the modulation of cellular responses to extracellular matrix components.\n3. Neuroprotection: GPR151 has been shown to have neuroprotective effects, with the receptor protecting against neuronal damage and death in response to various insults, including oxidative stress and excitotoxicity.\n4. Metabolism: GPR151 has been implicated in the regulation of glucose and lipid metabolism, with the receptor playing a role in the modulation of insulin sensitivity and glucose uptake.\n5. Cancer: GPR151 has been shown to be involved in the progression of certain types of cancer, including breast, lung, and colon cancer, with the receptor promoting tumor growth and metastasis.\nOverall, GPR151 is a complex receptor that is involved in a wide range of cellular processes, and further research is needed to fully understand its role in health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.\n2. GPR151 has been shown to be involved in the regulation of inflammatory responses.\n3. GPR151 has been implicated in the regulation of cell adhesion and migration.\n4. GPR151 has neuroprotective effects, including protection against neuronal damage and death due to oxidative stress and excitotoxicity.\n5. GPR151 has been shown to be involved in the progression of certain types of cancer, such as breast, lung, and colon cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.",
      "GPR151 has been shown to be involved in the regulation of inflammatory responses.",
      "GPR151 has been implicated in the regulation of cell adhesion and migration.",
      "GPR151 has neuroprotective effects, including protection against neuronal damage and death due to oxidative stress and excitotoxicity.",
      "GPR151 has been shown to be involved in the progression of certain types of cancer, such as breast, lung, and colon cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GPR151 is generally referred to as an orphan receptor as it is a G protein-coupled receptor with no known endogenous ligand and unclear physiological role.\n\n2. FALSE [correction]: As an orphan receptor, GPR151 does not have a well-established function, including the regulation of inflammatory responses unless specific recent research has identified such a role which is not indicated in the given statements.\n\n3. FALSE [correction]: GPR151 is not specifically known to be involved in regulating cell adhesion and migration, as its physiological function remains largely unclear, unless defined by new research findings.\n\n4. FALSE [correction]: There is no broadly accepted evidence suggesting that GPR151 has neuroprotective effects. The physiological and biological roles of GPR151 are still not well-defined.\n\n5. UNKNOWN: Without specific references to research studies or findings that indicate GPR151's involvement in cancer progression, it's not possible to confirm or deny this statement. The role of GPR151 in cancer would require citation of specific scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n* H1N1 (A/California/7/2009)\n* H3N2 (A/Perth/1/2009)\n* B/Brisbane/60/2008\n* B/Brisbane/33/2010\nThese viruses are attenuated, meaning they have been weakened or modified so that they can stimulate an immune response without causing disease. The vaccine is administered intradermally, meaning it is injected into the skin rather than into the muscle, and it provides protection against four different types of influenza viruses: two A strains (H1N1 and H3N2) and two B strains (Brisbane/60/2008 and Brisbane/33/2010).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.\n2. The attenuated viruses in the vaccine include H1N1 (A/California/7/2009).\n3. The attenuated viruses in the vaccine include H3N2 (A/Perth/1/2009).\n4. The attenuated viruses in the vaccine include B/Brisbane/60/2008.\n5. The attenuated viruses in the vaccine include B/Brisbane/33/2010.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.",
      "The attenuated viruses in the vaccine include H1N1 (A/California/7/2009).",
      "The attenuated viruses in the vaccine include H3N2 (A/Perth/1/2009).",
      "The attenuated viruses in the vaccine include B/Brisbane/60/2008.",
      "The attenuated viruses in the vaccine include B/Brisbane/33/2010."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not attenuated (live, weakened) viruses.\n2. TRUE\n3. FALSE [correction]: The H3N2 virus included in the Fluzone vaccine would be updated based on the most current recommendations for the flu season and might not be the A/Perth/1/2009 strain. The specific strains included change yearly as recommended by health authorities.\n4. FALSE [correction]: The B/Brisbane/60/2008 virus strain is an example of a past influenza B virus component for flu vaccines, but the strains included in the vaccine are updated annually.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, also known as the Tumor Necrosis Factor Receptor 2 gene, has been genetically associated with Systemic Lupus Erythematosus (SLE). Specifically, mutations in the TNFR2 gene have been identified as a risk factor for the development of SLE. The most well-known genetic variation associated with SLE is a polymorphism in the TNFR2 gene, specifically the -308G/A polymorphism, which results in a glutamine (Q) instead of a glycine (G) at position 308 of the TNFR2 protein. This polymorphism has been shown to increase the risk of developing SLE by altering the signaling pathways involved in the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. Mutations in the TNFR2 gene have been identified as a risk factor for SLE.\n3. A well-known genetic variation associated with SLE in the TNFR2 gene is the -308G/A polymorphism.\n4. The -308G/A polymorphism in the TNFR2 gene leads to a substitution of glutamine (Q) for glycine (G) at position 308 of the TNFR2 protein.\n5. The -308G/A polymorphism in the TNFR2 gene is shown to increase the risk of developing SLE by altering immune response signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "Mutations in the TNFR2 gene have been identified as a risk factor for SLE.",
      "A well-known genetic variation associated with SLE in the TNFR2 gene is the -308G/A polymorphism.",
      "The -308G/A polymorphism in the TNFR2 gene leads to a substitution of glutamine (Q) for glycine (G) at position 308 of the TNFR2 protein.",
      "The -308G/A polymorphism in the TNFR2 gene is shown to increase the risk of developing SLE by altering immune response signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The -308G/A polymorphism is associated with the TNF gene, not the TNFR2 gene.\n4. FALSE [correction]: The -308G/A polymorphism does not result in an amino acid substitution; it is a single nucleotide polymorphism (SNP) in the promoter region of the gene that can affect the level of gene expression.\n5. TRUE (assuming the correction that the -308G/A polymorphism is associated with the TNF gene and not TNFR2)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a vaccine for peanut allergy, and several clinical trials are underway to evaluate the safety and efficacy of these vaccines.\nOne of the most promising approaches is to use a peptide-based vaccine that targets specific proteins found in peanuts. These peptides are designed to stimulate the immune system to produce antibodies that can help neutralize the allergenic properties of the peanut proteins.\nAnother approach is to use a subunit vaccine, which contains only the specific proteins that are responsible for triggering an allergic reaction. This type of vaccine is designed to stimulate an immune response that is specific to the allergenic proteins, without inducing a general immune response.\nWhile these vaccines show promise, it is important to note that they are still in the experimental stages, and more research is needed to determine their safety and efficacy in humans. Additionally, even if a vaccine is developed, it is unlikely to be a cure for peanut allergy, but rather a tool to help manage the condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine currently available for the prevention of peanut allergy.\n2. Researchers are working on developing a vaccine for peanut allergy.\n3. Clinical trials are underway to evaluate the safety and efficacy of peanut allergy vaccines.\n4. One promising approach is a peptide-based vaccine targeting specific proteins in peanuts.\n5. Another approach under investigation is a subunit vaccine containing only the specific proteins that trigger an allergic reaction.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine currently available for the prevention of peanut allergy.",
      "Researchers are working on developing a vaccine for peanut allergy.",
      "Clinical trials are underway to evaluate the safety and efficacy of peanut allergy vaccines.",
      "One promising approach is a peptide-based vaccine targeting specific proteins in peanuts.",
      "Another approach under investigation is a subunit vaccine containing only the specific proteins that trigger an allergic reaction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (As of my knowledge cutoff in March 2023, there was no licensed vaccine available for the prevention of peanut allergy.)\n2. TRUE (Researchers are continuously working on developing new treatments and vaccines for various allergies, including peanut allergies.)\n3. TRUE (It is common for clinical trials to be conducted to evaluate potential new treatments and vaccines, so it is plausible that there are trials for peanut allergy vaccines.)\n4. TRUE (Peptide-based vaccines targeting specific proteins are a known area of research in allergy vaccine development, including for peanut allergy.)\n5. TRUE (Subunit vaccines that contain only specific proteins or allergens are indeed a method under investigation for treating allergies; this approach aims to induce immunity without causing a full allergic reaction.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome. It is one of the few genes on the X chromosome that is expressed in both male and female mice, despite the fact that the X chromosome is typically inactivated in female mice. This is known as X-inactivation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The Fxy gene is expressed in both male and female mice.\n3. X-inactivation typically occurs in female mice, in which the X chromosome is inactivated.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The Fxy gene is expressed in both male and female mice.",
      "X-inactivation typically occurs in female mice, in which the X chromosome is inactivated."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq is a method for sequencing DNA that utilizes the reaction of methidiumpropyl-EDTA (Mpe-EDTA) with DNA to selectively capture and isolate the 5' ends of DNA fragments. The basis of the MPE-seq method is the use of Mpe-EDTA, which reacts with the aldehyde group of the 5' end of DNA fragments to form a covalent complex. This complex can then be isolated and purified, allowing for the capture and sequencing of the 5' ends of the DNA fragments. The resulting sequence data can be used to provide information about the 5' ends of the DNA fragments, such as their length, sequence, and structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq is a method for sequencing DNA.\n2. Methidiumpropyl-EDTA (Mpe-EDTA) is used in MPE-seq to react with DNA.\n3. Mpe-EDTA reacts specifically with the aldehyde group at the 5' end of DNA fragments in MPE-seq.\n4. The reaction of Mpe-EDTA with DNA forms a covalent complex.\n5. The covalent complex can be isolated and purified for the capture and sequencing of the 5' ends of the DNA fragments.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq is a method for sequencing DNA.",
      "Methidiumpropyl-EDTA (Mpe-EDTA) is used in MPE-seq to react with DNA.",
      "Mpe-EDTA reacts specifically with the aldehyde group at the 5' end of DNA fragments in MPE-seq.",
      "The reaction of Mpe-EDTA with DNA forms a covalent complex.",
      "The covalent complex can be isolated and purified for the capture and sequencing of the 5' ends of the DNA fragments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MPE-seq generally refers to Multiplexed Paired-End sequencing, a technique used to sequence DNA, but the term \"MPE-seq\" is not standard. \"MPE\" in the context of DNA typically refers to methidiumpropyl-EDTA, but it is not used for sequencing DNA.\n2. TRUE\n3. FALSE [correction]: Methidiumpropyl-EDTA (Mpe-EDTA) does not specifically react with the aldehyde group at the 5' end of DNA fragments. It is a DNA intercalator and cleaving agent that interacts with DNA but not at a specific site like the aldehyde group at the 5' end.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages, depending on the specific implementation and the research question being addressed. However, some common programming languages used in GWAS analysis include:\n1. R: R is a popular language for statistical computing and graphics, and many GWAS analyses are implemented using R packages such as PLINK, GCTA, and snpStats.\n2. Python: Python is a versatile language that is widely used in bioinformatics and genomics. Popular Python packages for GWAS analysis include scikit-learn, GWASpy, and PLINK.\n3. MATLAB: MATLAB is a programming language and environment specifically designed for numerical computation and data analysis. It is commonly used for GWAS analysis, particularly in the context of genome-wide association studies.\n4. SAS: SAS (Statistical Analysis System) is a software suite that is widely used in bioinformatics and genomics for data analysis and interpretation. GWAS analysis can be implemented using SAS procedures such as PROC GENMOD and PROC GLM.\nIt's worth noting that GWAR can also be implemented using other programming languages such as Java, C++, and Julia, but the above-mentioned languages are the most commonly used ones.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is used for statistical computing and graphics in GWAS analyses with packages like PLINK, GCTA, and snpStats.\n2. Python is widely used in bioinformatics and genomics for GWAS analysis with packages such as scikit-learn, GWASpy, and PLINK.\n3. MATLAB is used for numerical computation and data analysis in GWAS analysis.\n4. SAS is used for data analysis and interpretation in bioinformatics and genomics, including GWAS analysis with procedures like PROC GENMOD and PROC GLM.\n5. Common programming languages used for GWAS analysis also include Java, C++, and Julia, in addition to those mentioned above.",
    "llama-2-7b-chat-hf_fact": [
      "R is used for statistical computing and graphics in GWAS analyses with packages like PLINK, GCTA, and snpStats.",
      "Python is widely used in bioinformatics and genomics for GWAS analysis with packages such as scikit-learn, GWASpy, and PLINK.",
      "MATLAB is used for numerical computation and data analysis in GWAS analysis.",
      "SAS is used for data analysis and interpretation in bioinformatics and genomics, including GWAS analysis with procedures like PROC GENMOD and PROC GLM.",
      "Common programming languages used for GWAS analysis also include Java, C++, and Julia, in addition to those mentioned above."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: R is indeed a popular language for statistical computing and graphics and is used in Genome-Wide Association Studies (GWAS) analysis with packages such as PLINK, GCTA, and snpStats.\n\n2. TRUE: Python is also widely used in bioinformatics and genomics for GWAS analysis and has various packages available for these purposes, including scikit-learn, GWASpy, and it can work with PLINK.\n\n3. FALSE [correction]: While MATLAB is used for numerical computation and data analysis, it is not typically associated with GWAS analysis. GWAS analysis is more commonly performed with programming languages and software packages that are specialized for statistical genetics.\n\n4. TRUE: SAS is utilized in data analysis in various fields including bioinformatics and genomics. It provides procedures such as PROC GENMOD and PROC GLM that can be used for GWAS analysis.\n\n5. TRUE: Java, C++, and Julia are indeed part of the suite of common programming languages that can be used for GWAS analysis, alongside R, Python, SAS, and others. Each language may have specific packages or libraries that facilitate GWAS.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as edaravone) is a drug that has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS). While the results of clinical trials have been mixed, some studies have suggested that xaliproden may have a beneficial effect on the progression of ALS.\nOne phase III clinical trial published in 2017 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS, as measured by the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score, compared to placebo. However, the study did show that xaliproden was associated with a slower decline in forced vital capacity (FVC), a measure of lung function, compared to placebo.\nAnother phase III clinical trial published in 2020 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS, as measured by the change in the ALSFRS-R score, compared to placebo. However, the study did show that xaliproden was associated with a slower decline in FVC and a slower rate of decline in the 6-minute walk distance test, compared to placebo.\nIt is important to note that these clinical trials were small and had limited sample sizes, so more research is needed to confirm these findings and determine the long-term safety and efficacy of xaliproden for the treatment of ALS. Additionally, the FDA has not approved xaliproden for the treatment of ALS, and it is not currently available in the United States.\nIn summary, while the results of clinical trials have been mixed, some studies suggest that xaliproden may have a beneficial effect on the progression of ALS, particularly in terms of slowing the decline in lung function. However, more research is needed to confirm these findings and determine the long-term safety and efficacy of xaliproden for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. A phase III clinical trial published in 2017 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) score, compared to placebo.\n3. The same 2017 trial indicated that xaliproden was associated with a slower decline in forced vital capacity (FVC), a measure of lung function, compared to placebo.\n4. Another phase III clinical trial published in 2020 also found that xaliproden did not meet the primary endpoint of slowing the progression of ALS as measured by the ALSFRS-R score, compared to placebo.\n5. The 2020 trial reported that xaliproden was associated with a slower decline in FVC and a slower rate of decline in the 6-minute walk distance test, compared to placebo.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "A phase III clinical trial published in 2017 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) score, compared to placebo.",
      "The same 2017 trial indicated that xaliproden was associated with a slower decline in forced vital capacity (FVC), a measure of lung function, compared to placebo.",
      "Another phase III clinical trial published in 2020 also found that xaliproden did not meet the primary endpoint of slowing the progression of ALS as measured by the ALSFRS-R score, compared to placebo.",
      "The 2020 trial reported that xaliproden was associated with a slower decline in FVC and a slower rate of decline in the 6-minute walk distance test, compared to placebo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no specific detail available about the phase III clinical trial's results of xaliproden from 2017 concerning the ALSFRS-R score. The statement provided cannot be verified without more context or details about the clinical trial in question.\n3. FALSE [correction]: Similarly, this statement about the association of xaliproden and FVC cannot be confirmed without additional information regarding the cited trial. Given that it refers to the same 2017 trial as the previous point, its accuracy is contingent upon the validity and existence of such a study.\n4. UNKNOWN: Without specific information on clinical trials conducted in 2020 or access to updated databases or scientific literature, the claim about the outcomes of another phase III trial for xaliproden cannot be verified.\n5. UNKNOWN: As with the previous statement, the association of xaliproden with FVC and the 6-minute walk distance test in a 2020 trial cannot be confirmed without additional evidence or context to support the claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line in which the transgene is inserted into chromosome 11.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line.\n2. In the LiPS-A3S line, the transgene is inserted into chromosome 11.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line.",
      "In the LiPS-A3S line, the transgene is inserted into chromosome 11."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n\nWithout specific context or information about the LiPS-A3S line, it is not possible for me to verify where the transgene is inserted. Therefore, the statement regarding the chromosome number is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy, including:\n1. DeepDrug: This is a deep learning model that uses a convolutional neural network (CNN) to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n2. Drug2Drug: This is a deep learning model that uses a multi-layer perceptron (MLP) to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n3. DrugCombinator: This is a deep learning model that uses a combination of CNN and MLP to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n4. Synergizer: This is a deep learning model that uses a CNN to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n5. DrugSynergy: This is a deep learning model that uses a combination of CNN and MLP to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n6. ChEA-Net: This is a deep learning model that uses a combination of CNN and MLP to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n7. Drug-Drug Interaction Predictor (DDIP): This is a deep learning model that uses a combination of CNN and MLP to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n8. Drug-Drug Interaction Predictor 2 (DDIIP2): This is a deep learning model that uses a combination of CNN and MLP to predict drug synergy. It takes as input a set of molecular descriptors for each drug and predicts the synergy score between the drugs.\n9. DeepDrug-",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model that uses a convolutional neural network (CNN) to predict drug synergy.\n2. Drug2Drug uses a multi-layer perceptron (MLP) to predict drug synergy.\n3. DrugCombinator is a deep learning model that combines CNN and MLP to predict the synergy score between drugs.\n4. Synergizer utilizes a CNN to predict drug synergy based on a set of molecular descriptors for each drug.\n5. ChEA-Net is a deep learning model that combines CNN and MLP to predict drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model that uses a convolutional neural network (CNN) to predict drug synergy.",
      "Drug2Drug uses a multi-layer perceptron (MLP) to predict drug synergy.",
      "DrugCombinator is a deep learning model that combines CNN and MLP to predict the synergy score between drugs.",
      "Synergizer utilizes a CNN to predict drug synergy based on a set of molecular descriptors for each drug.",
      "ChEA-Net is a deep learning model that combines CNN and MLP to predict drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the named models (DeepDrug, Drug2Drug, DrugCombinator, Synergizer, ChEA-Net) and how they operate, it is not possible to verify the truth of these statements. The statements could potentially refer to real or hypothetical deep learning models and their strategies for predicting drug synergy, but without additional context or data to reference, their veracity cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS is called \"Meta-Analyst\".",
    "llama-2-7b-chat-hf_fact_raw": "1. \"Meta-Analyst\" is a cloud-based platform.\n2. The platform is developed for comparing GWAS (Genome-Wide Association Studies).",
    "llama-2-7b-chat-hf_fact": [
      "\"Meta-Analyst\" is a cloud-based platform.",
      "The platform is developed for comparing GWAS (Genome-Wide Association Studies)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Yes, CMB305 has been shown to be effective against sarcomas. CMB305 is a bispecific antibody that targets both CD3 and CD138, which are expressed on the surface of multiple myeloma cells, including some sarcomas. Studies have shown that CMB305 can induce apoptosis (cell death) in sarcoma cells and inhibit their growth and proliferation. Additionally, CMB305 has been shown to enhance the activity of chemotherapy drugs in treating sarcomas, and may have potential as a combination therapy for this type of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a bispecific antibody that targets CD3 and CD138.\n2. CD3 and CD138 are expressed on the surface of multiple myeloma cells and some sarcomas.\n3. CMB305 can induce apoptosis in sarcoma cells.\n4. CMB305 has been shown to inhibit the growth and proliferation of sarcoma cells.\n5. CMB305 enhances the activity of chemotherapy drugs in treating sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a bispecific antibody that targets CD3 and CD138.",
      "CD3 and CD138 are expressed on the surface of multiple myeloma cells and some sarcomas.",
      "CMB305 can induce apoptosis in sarcoma cells.",
      "CMB305 has been shown to inhibit the growth and proliferation of sarcoma cells.",
      "CMB305 enhances the activity of chemotherapy drugs in treating sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE, although CD138 is more commonly associated with multiple myeloma cells, some forms of sarcomas can also express CD138.\n3. UNKNOWN: Without specific data or research findings, it is unclear whether CMB305 can induce apoptosis in sarcoma cells.\n4. UNKNOWN: The statement needs supporting evidence from clinical studies or scientific experiments to confirm the inhibitory effect of CMB305 on the growth and proliferation of sarcoma cells.\n5. UNKNOWN: Similar to statement 4, evidence from research is needed to substantiate the claim that CMB305 enhances the activity of chemotherapy drugs in treating sarcomas.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad is a clinical triad that is characterized by the following manifestations:\n1. Developmental delay or intellectual disability: Individuals with the Saint's Triad may have difficulty with cognitive and motor development, and may have intellectual disability or delayed cognitive development.\n2. Distinctive facial features: The Saint's Triad is characterized by distinctive facial features, including a small head, narrow eyes, a short nose, and a thin upper lip.\n3. Congenital anomalies: Individuals with the Saint's Triad may have congenital anomalies, such as heart defects, neural tube defects, and limb abnormalities.\nThese manifestations are often seen together in individuals with the Saint's Triad, but they can vary in severity and frequency from person to person. The Saint's Triad is a rare genetic disorder that is caused by mutations in the MEF2C gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is characterized by developmental delay or intellectual disability.\n2. Distinctive facial features associated with the Saint's Triad include a small head, narrow eyes, a short nose, and a thin upper lip.\n3. Congenital anomalies such as heart defects, neural tube defects, and limb abnormalities may occur in individuals with the Saint's Triad.\n4. The Saint's Triad is caused by mutations in the MEF2C gene.\n5. The manifestations of the Saint's Triad can vary in severity and frequency from person to person.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is characterized by developmental delay or intellectual disability.",
      "Distinctive facial features associated with the Saint's Triad include a small head, narrow eyes, a short nose, and a thin upper lip.",
      "Congenital anomalies such as heart defects, neural tube defects, and limb abnormalities may occur in individuals with the Saint's Triad.",
      "The Saint's Triad is caused by mutations in the MEF2C gene.",
      "The manifestations of the Saint's Triad can vary in severity and frequency from person to person."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is no widely recognized medical condition known as the \"Saint's Triad.\" Thus, it's impossible to ascertain if such a condition is associated with developmental delay or intellectual disability.\n2. UNKNOWN: Since the \"Saint's Triad\" is not identified as a medical condition, there can be no definitive associated facial features such as a small head, narrow eyes, a short nose, and a thin upper lip.\n3. UNKNOWN: Without a recognized medical condition termed the \"Saint's Triad,\" the statement about congenital anomalies such as heart defects, neural tube defects, and limb abnormalities occurring in individuals with this condition cannot be verified.\n4. UNKNOWN: The statement that the \"Saint's Triad\" is caused by mutations in the MEF2C gene cannot be verified because there is no established medical condition by that name. MEF2C gene mutations are, however, associated with a different condition known as MEF2C-related disorders, which include intellectual disability and various other symptoms.\n5. UNKNOWN: Due to the lack of information about a medical condition called the \"Saint's Triad,\" the claim that the manifestations vary in severity and frequency from person to person cannot be substantiated. However, this sentence would be true for many known genetic disorders.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are correlated with longer overall survival, disease-free survival, and progression-free survival in NSCLC patients. This suggests that LY6K may play a protective role in the development and progression of NSCLC, and that high levels of LY6K expression may be associated with a more favorable prognosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are correlated with longer overall survival in NSCLC patients.\n3. High levels of LY6K expression are correlated with longer disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are correlated with longer progression-free survival in NSCLC patients.\n5. LY6K may play a protective role in the development and progression of non-small cell lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are correlated with longer overall survival in NSCLC patients.",
      "High levels of LY6K expression are correlated with longer disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are correlated with longer progression-free survival in NSCLC patients.",
      "LY6K may play a protective role in the development and progression of non-small cell lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is typically associated with a worse prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally correlated with shorter overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are usually correlated with shorter disease-free survival in NSCLC patients.\n4. FALSE [correction]: High levels of LY6K expression are often correlated with shorter progression-free survival in NSCLC patients.\n5. FALSE [correction]: LY6K may play a role in promoting the development and progression of non-small cell lung cancer, rather than a protective role.\n\nNote: These corrections are based on the general understanding that LY6K overexpression is often linked to poor prognosis in cancer. However, the field of cancer research is constantly evolving and there might be context-specific studies that provide different insights. For the most accurate and up-to-date information, a review of the latest research literature would be necessary.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Certainly! Cytokinesis is the process by which a cell divides into two daughter cells, and it is regulated by a variety of signaling pathways, including the CDK (cyclin-dependent kinase) pathway. During cytokinesis, CDKs are inhibited by phosphorylation, leading to the dephosphorylation of their targets. Some of the known CDK targets that are dephosphorylated during cytokinesis include:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the G1/S checkpoint and is inhibited during cytokinesis by phosphorylation.\n2. Cyclin-dependent kinase 2 (CDK2): CDK2 is involved in the G1/S and G2/M transitions and is also inhibited during cytokinesis by phosphorylation.\n3. Cyclin-dependent kinase 5 (CDK5): CDK5 is involved in the regulation of neuronal differentiation and is inhibited during cytokinesis by phosphorylation.\n4. Cyclin-dependent kinase 6 (CDK6): CDK6 is involved in the regulation of G1/S progression and is inhibited during cytokinesis by phosphorylation.\n5. Cyclin-dependent kinase 7 (CDK7): CDK7 is involved in the regulation of RNA polymerase II transcription and is inhibited during cytokinesis by phosphorylation.\n6. Cyclin-dependent kinase 8 (CDK8): CDK8 is involved in the regulation of transcriptional elongation and is inhibited during cytokinesis by phosphorylation.\n7. Cyclin-dependent kinase 9 (CDK9): CDK9 is involved in the regulation of transcriptional elongation and is inhibited during cytokinesis by phosphorylation.\n8. Glycogen synthase kinase 3 (GSK3): GSK3 is involved in the regulation of cell signaling and is inhibited during cytokinesis by phosphorylation.\n9. Polo-like kinase 1 (PLK",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (CDK1) is dephosphorylated and inhibited during cytokinesis.\n2. Cyclin-dependent kinase 2 (CDK2) is involved in the G1/S and G2/M transitions and is inhibited during cytokinesis by phosphorylation.\n3. Cyclin-dependent kinase 5 (CDK5) is involved in neuronal differentiation and is inhibited during cytokinesis by phosphorylation.\n4. Cyclin-dependent kinase 6 (CDK6) is involved in the regulation of G1/S progression and is inhibited during cytokinesis by phosphorylation.\n5. Cyclin-dependent kinase 7 (CDK7) is involved in RNA polymerase II transcription regulation and is inhibited during cytokinesis by phosphorylation.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (CDK1) is dephosphorylated and inhibited during cytokinesis.",
      "Cyclin-dependent kinase 2 (CDK2) is involved in the G1/S and G2/M transitions and is inhibited during cytokinesis by phosphorylation.",
      "Cyclin-dependent kinase 5 (CDK5) is involved in neuronal differentiation and is inhibited during cytokinesis by phosphorylation.",
      "Cyclin-dependent kinase 6 (CDK6) is involved in the regulation of G1/S progression and is inhibited during cytokinesis by phosphorylation.",
      "Cyclin-dependent kinase 7 (CDK7) is involved in RNA polymerase II transcription regulation and is inhibited during cytokinesis by phosphorylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinase 1 (CDK1) is typically activated during mitosis and is not inhibited during cytokinesis; instead, it plays a vital role in initiating mitosis.\n2. TRUE\n3. FALSE [correction]: Cyclin-dependent kinase 5 (CDK5) is involved in neuronal differentiation, but there is no common consensus that it is inhibited during cytokinesis by phosphorylation. CDK5's role is primarily in the nervous system, and it's regulated by its activators p35 and p39, not typically through cytokinesis.\n4. UNKNOWN: While Cyclin-dependent kinase 6 (CDK6) is involved in the regulation of G1/S progression, it is not clear from the statement whether it is inhibited during cytokinesis by phosphorylation.\n5. UNKNOWN: Cyclin-dependent kinase 7 (CDK7) does play a role in RNA polymerase II transcription regulation, but the statement's specifics about its inhibition during cytokinesis by phosphorylation are not clearly established.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that inhibits the activity of the protein kinase CK2 (casein kinase 2), which is involved in various cellular processes, including cell signaling, DNA replication, and RNA transcription. CK2 is a serine/threonine kinase that phosphorylates and regulates various proteins, and its dysregulation has been implicated in various diseases, including cancer and neurodegenerative disorders. Xanamem is being developed as a potential therapeutic agent for the treatment of cancer and other diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that inhibits the activity of the protein kinase CK2 (casein kinase 2).\n2. Protein kinase CK2 is involved in several cellular processes such as cell signaling, DNA replication, and RNA transcription.\n3. CK2 is a serine/threonine kinase that phosphorylates and regulates various proteins.\n4. Dysregulation of CK2 has been implicated in various diseases, including cancer and neurodegenerative disorders.\n5. Xanamem is being developed as a potential therapeutic agent for the treatment of cancer and other diseases.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that inhibits the activity of the protein kinase CK2 (casein kinase 2).",
      "Protein kinase CK2 is involved in several cellular processes such as cell signaling, DNA replication, and RNA transcription.",
      "CK2 is a serine/threonine kinase that phosphorylates and regulates various proteins.",
      "Dysregulation of CK2 has been implicated in various diseases, including cancer and neurodegenerative disorders.",
      "Xanamem is being developed as a potential therapeutic agent for the treatment of cancer and other diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the Hof1-Cyk3 interaction plays a crucial role in regulating the spindle assembly checkpoint (SAC) and ensuring proper chromosome segregation during cell division. Hof1 is a protein that interacts with the Cyk3 protein, which is a key regulator of the SAC. The interaction between Hof1 and Cyk3 helps to activate the SAC and prevent cells from entering mitosis until proper chromosome segregation has occurred. This interaction is essential for maintaining genome stability and preventing errors during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the spindle assembly checkpoint (SAC) in yeast.\n2. Proper chromosome segregation during cell division in yeast is ensured by the Hof1-Cyk3 interaction.\n3. Hof1 is a protein that interacts with Cyk3 protein.\n4. The interaction between Hof1 and Cyk3 activates the SAC.\n5. The Hof1-Cyk3 interaction prevents cells from entering mitosis until proper chromosome segregation has occurred.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the spindle assembly checkpoint (SAC) in yeast.",
      "Proper chromosome segregation during cell division in yeast is ensured by the Hof1-Cyk3 interaction.",
      "Hof1 is a protein that interacts with Cyk3 protein.",
      "The interaction between Hof1 and Cyk3 activates the SAC.",
      "The Hof1-Cyk3 interaction prevents cells from entering mitosis until proper chromosome segregation has occurred."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Hof1-Cyk3 interaction does not regulate the spindle assembly checkpoint (SAC) in yeast. SAC is regulated by several other proteins, such as Mad1, Mad2, Mad3, Bub1, Bub3, Mps1, etc.\n2. UNKNOWN: The Hof1-Cyk3 interaction may play a role in cytokinesis or other processes related to cell division, but without context, it's uncertain if it directly ensures proper chromosome segregation.\n3. TRUE: Hof1 is a protein known to interact with Cyk3 protein in yeast during cytokinesis.\n4. FALSE [correction]: The interaction between Hof1 and Cyk3 is involved in the process of cytokinesis, not the activation of the spindle assembly checkpoint (SAC).\n5. UNKNOWN: While the Hof1-Cyk3 interaction is involved in cytokinesis, without specific context, it's unclear how or if this interaction prevents cells from entering mitosis until proper chromosome segregation has occurred.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are two T-cell transcription factors that have been implicated in gastric cancer. T-bet and Eomes are both transcription factors that play critical roles in the regulation of T-cell function and immune responses, and have been shown to be involved in the development and progression of gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet (T-box transcription factor Eomesodermin) has been implicated in gastric cancer.\n2. Eomesodermin (Eomes) is a T-cell transcription factor implicated in gastric cancer.\n3. T-bet and Eomes play critical roles in the regulation of T-cell function and immune responses.\n4. T-bet and Eomes have been shown to be involved in the development and progression of gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet (T-box transcription factor Eomesodermin) has been implicated in gastric cancer.",
      "Eomesodermin (Eomes) is a T-cell transcription factor implicated in gastric cancer.",
      "T-bet and Eomes play critical roles in the regulation of T-cell function and immune responses.",
      "T-bet and Eomes have been shown to be involved in the development and progression of gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: T-bet (T-bet is actually known as T-box transcription factor TBX21) has been implicated in gastric cancer.\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite measure that takes into account various clinical and laboratory variables, including:\n1. Physical examination findings (e.g., rash, joint swelling, lymphadenopathy)\n2. Laboratory tests (e.g., erythrocyte sedimentation rate, C-reactive protein, anti-nuclear antibody titers)\n3. Organ involvement (e.g., kidney, lung, nervous system)\n4. Disease activity (e.g., pain, fatigue, fever)\n5. Patient's global assessment of disease severity\nThe LSI score ranges from 0 to 100, with higher scores indicating greater disease severity. The LSI has been shown to be a reliable and valid tool for assessing SLE severity in clinical trials and everyday practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems.\n3. The LSI is a composite measure that includes clinical and laboratory variables.\n4. Variables included in the LSI consist of physical examination findings, laboratory tests, organ involvement, disease activity, and the patient's global assessment of disease severity.\n5. The LSI score can range from 0 to 100, with higher scores indicating greater disease severity.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems.",
      "The LSI is a composite measure that includes clinical and laboratory variables.",
      "Variables included in the LSI consist of physical examination findings, laboratory tests, organ involvement, disease activity, and the patient's global assessment of disease severity.",
      "The LSI score can range from 0 to 100, with higher scores indicating greater disease severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement regarding the Lupus Severity Index (LSI) cannot be verified without additional specific information about this particular index. It's worth noting, however, that there are several validated tools for assessing SLE, such as the SLE Disease Activity Index (SLEDAI), but without specific information about the LSI, the validity of the statement cannot be determined.\n2. TRUE: Systemic lupus erythematosus (SLE) is indeed a chronic autoimmune disease that can affect multiple organ systems.\n3. UNKNOWN: Similar to statement 1, without specific information about the LSI, it is not possible to confirm the components of this measure. The SLEDAI and other indices like the British Isles Lupus Assessment Group (BILAG) index do include clinical and laboratory variables, but the statement's reference to the LSI cannot be verified.\n4. UNKNOWN: Again, the variables included in the LSI cannot be confirmed without additional information about this specific measure. In general, indices for SLE do consider factors like physical examination findings, laboratory tests, organ involvement, disease activity, and patient's assessment, but this cannot be confirmed for the LSI without more details.\n5. UNKNOWN: The potential range and interpretation of scores for the LSI cannot be determined to be true or false without specific knowledge of this scoring system.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several rare genetic disorders, including:\n1. Zellweger syndrome with microphthalmia (ZWM): ZSWIM6 mutations are a common cause of ZWM, a rare genetic disorder characterized by severe neonatal hypotonia, microphthalmia, and craniofacial dysmorphism.\n2. Zellweger syndrome: ZSWIM6 mutations are also associated with Zellweger syndrome, a rare and severe neonatal disorder characterized by hypotonia, microphthalmia, and cerebral hypoplasia.\n3. Other rare disorders: ZSWIM6 mutations have also been identified in other rare disorders, including intellectual disability, autism spectrum disorder, and congenital anomalies.\nIt is important to note that these disorders are rare and the frequency of ZSWIM6 mutations in these disorders may vary. Further research is needed to fully understand the role of ZSWIM6 in these disorders and to identify the underlying mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the ZSWIM6 gene are a common cause of Zellweger syndrome with microphthalmia (ZWM).\n2. Zellweger syndrome with microphthalmia is characterized by severe neonatal hypotonia, microphthalmia, and craniofacial dysmorphism.\n3. ZSWIM6 mutations are associated with Zellweger syndrome, which is a severe neonatal disorder.\n4. Zellweger syndrome is characterized by symptoms such as hypotonia, microphthalmia, and cerebral hypoplasia.\n5. ZSWIM6 mutations have been identified in cases of intellectual disability, autism spectrum disorder, and congenital anomalies.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the ZSWIM6 gene are a common cause of Zellweger syndrome with microphthalmia (ZWM).",
      "Zellweger syndrome with microphthalmia is characterized by severe neonatal hypotonia, microphthalmia, and craniofacial dysmorphism.",
      "ZSWIM6 mutations are associated with Zellweger syndrome, which is a severe neonatal disorder.",
      "Zellweger syndrome is characterized by symptoms such as hypotonia, microphthalmia, and cerebral hypoplasia.",
      "ZSWIM6 mutations have been identified in cases of intellectual disability, autism spectrum disorder, and congenital anomalies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in genes such as PEX1, PEX6, PEX10, PEX12, PEX13, PEX16, PEX19, and PEX26 are common causes of Zellweger syndrome. ZSWIM6 gene mutations are associated with acromelic frontonasal dysostosis, not typically with Zellweger syndrome.\n2. TRUE\n3. FALSE [correction]: ZSWIM6 mutations are not typically associated with Zellweger syndrome, which is a peroxisome biogenesis disorder. The syndrome involves a spectrum of disorders known as Zellweger spectrum disorders (ZSD), and is caused by mutations in PEX genes.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify diseases of the nervous system, particularly those affecting the central nervous system (CNS). It is commonly used to classify neurodegenerative diseases, such as:\n1. Alzheimer's disease\n2. Parkinson's disease\n3. Huntington's disease\n4. Progressive supranuclear palsy\n5. Multiple system atrophy\n6. Corticobasal degeneration\n7. Frontotemporal dementia\n8. Primary lateral sclerosis\nEach of these diseases is characterized by a specific set of clinical features, including cognitive, motor, and behavioral changes, and are distinguished from one another based on their distinct pathological features. The Koos Classification provides a useful framework for understanding the different types of neurodegenerative diseases and for developing effective treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify diseases of the central nervous system (CNS).\n2. Neurodegenerative diseases such as Alzheimer's disease can be classified using the Koos Classification.\n3. Parkinson's disease is a disease that can be classified using the Koos Classification.\n4. Huntington's disease is another disease that falls under the Koos Classification system.\n5. The Koos Classification includes diseases like progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, frontotemporal dementia, and primary lateral sclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify diseases of the central nervous system (CNS).",
      "Neurodegenerative diseases such as Alzheimer's disease can be classified using the Koos Classification.",
      "Parkinson's disease is a disease that can be classified using the Koos Classification.",
      "Huntington's disease is another disease that falls under the Koos Classification system.",
      "The Koos Classification includes diseases like progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, frontotemporal dementia, and primary lateral sclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is not used to classify diseases of the central nervous system (CNS); it is used to classify vestibular schwannomas (acoustic neuromas) based on size and location.\n2. FALSE [correction]: Alzheimer's disease, a neurodegenerative disease, is not classified using the Koos Classification, which is specific to vestibular schwannomas.\n3. FALSE [correction]: Parkinson's disease is not classified using the Koos Classification, as it is a neurodegenerative disease and not a vestibular schwannoma.\n4. FALSE [correction]: Huntington's disease is a neurodegenerative disorder and does not fall under the Koos Classification system, which is for vestibular schwannomas.\n5. FALSE [correction]: Diseases like progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, frontotemporal dementia, and primary lateral sclerosis are neurodegenerative diseases and are not classified using the Koos Classification, which is for vestibular schwannomas.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphoinositide 3-kinase). In vivo, AZD8601 has been shown to have a variety of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 can induce programmed cell death (apoptosis) in cancer cells, which can help to slow or stop the growth of tumors.\n3. Inhibition of angiogenesis: AZD8601 can inhibit the formation of new blood vessels, which are necessary for the growth and spread of solid tumors.\n4. Enhancement of chemotherapy: AZD8601 can enhance the effectiveness of certain chemotherapy drugs in treating cancer, by increasing the death of cancer cells and reducing the resistance of cancer cells to chemotherapy.\n5. Immune modulation: AZD8601 can modulate the immune response, which can help to enhance the immune system's ability to recognize and attack cancer cells.\n6. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\n7. Cardiovascular protection: AZD8601 has been shown to have protective effects on the cardiovascular system, including reducing inflammation and improving cardiovascular function.\n8. Metabolic effects: AZD8601 has been shown to have effects on glucose metabolism and insulin sensitivity, which may be beneficial in the treatment of metabolic disorders such as type 2 diabetes.\nIt is important to note that the specific in vivo effects of AZD8601 can vary depending on the specific experimental conditions and the type of cancer or disease being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphoinositide 3-kinase).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in vivo.\n3. AZD8601 can induce programmed cell death (apoptosis) in cancer cells.\n4. AZD8601 can inhibit the formation of new blood vessels necessary for the growth and spread of solid tumors.\n5. AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphoinositide 3-kinase).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in vivo.",
      "AZD8601 can induce programmed cell death (apoptosis) in cancer cells.",
      "AZD8601 can inhibit the formation of new blood vessels necessary for the growth and spread of solid tumors.",
      "AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor, but rather a modified RNA designed to encode for the protein VEGF-A, which is involved in the angiogenesis process.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE: By providing VEGF-A, AZD8601 could indeed promote angiogenesis, but in the context of therapeutic angiogenesis, not inhibiting it. Thus, the statement is true as it relates to the role of VEGF-A. However, AZD8601 itself is designed to promote rather than inhibit angiogenesis.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Organized High-Frequency Fluctuations) are created through a process called \"chromatin remodeling,\" which involves the movement of nucleosomes along DNA strands. This process is mediated by enzymes called \"chromatin remodelers,\" which use energy from ATP hydrolysis to move nucleosomes along DNA strands, creating new higher-order chromatin structures. The creation of SAHFs is thought to be an important mechanism for regulating gene expression and chromatin organization in various cell types.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process called chromatin remodeling.\n2. Chromatin remodeling involves the movement of nucleosomes along DNA strands.\n3. Chromatin remodelers are enzymes that mediate chromatin remodeling.\n4. Chromatin remodelers use energy from ATP hydrolysis to move nucleosomes along DNA strands.\n5. The creation of SAHFs is associated with regulating gene expression and chromatin organization in different cell types.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process called chromatin remodeling.",
      "Chromatin remodeling involves the movement of nucleosomes along DNA strands.",
      "Chromatin remodelers are enzymes that mediate chromatin remodeling.",
      "Chromatin remodelers use energy from ATP hydrolysis to move nucleosomes along DNA strands.",
      "The creation of SAHFs is associated with regulating gene expression and chromatin organization in different cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/Discs-large/ZO-1) domain is a protein-binding domain found in the SATB1 protein. The PDZ domain of SATB1 is involved in the binding of SATB1 to other proteins, including transcription factors and cofactors, and plays a role in regulating the activity of SATB1 in gene expression. The PDZ domain can bind to specific phosphorylated serine/threonine residues on target proteins, leading to the modulation of protein-protein interactions and signaling pathways. In the context of SATB1, the PDZ domain is thought to play a role in recruiting SATB1 to specific genomic loci and regulating its interactions with other transcription factors and coregulators.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein-binding domain found in SATB1.\n2. The PDZ domain of SATB1 is involved in the binding of SATB1 to other proteins, including transcription factors and cofactors.\n3. The PDZ domain plays a role in regulating the activity of SATB1 in gene expression.\n4. It can bind to specific phosphorylated serine/threonine residues on target proteins.\n5. The PDZ domain in SATB1 is thought to play a role in recruiting SATB1 to specific genomic loci.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein-binding domain found in SATB1.",
      "The PDZ domain of SATB1 is involved in the binding of SATB1 to other proteins, including transcription factors and cofactors.",
      "The PDZ domain plays a role in regulating the activity of SATB1 in gene expression.",
      "It can bind to specific phosphorylated serine/threonine residues on target proteins.",
      "The PDZ domain in SATB1 is thought to play a role in recruiting SATB1 to specific genomic loci."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is a common structural domain in proteins but there is no evidence to suggest that SATB1 contains a PDZ domain.\n2. FALSE [correction]: Since SATB1 does not contain a PDZ domain, the statement about its involvement in binding through a PDZ domain is incorrect.\n3. FALSE [correction]: Given that SATB1 does not have a PDZ domain, this domain cannot play a role in regulating SATB1's activity in gene expression.\n4. TRUE: PDZ domains can bind to specific phosphorylated serine/threonine residues at the C-terminus of target proteins; however, this statement is true in the general sense for PDZ domains, but not necessarily related to SATB1.\n5. FALSE [correction]: Because SATB1 does not have a PDZ domain, it is incorrect to say that the PDZ domain plays a role in recruiting SATB1 to specific genomic loci. However, SATB1 does localize to specific genomic loci to regulate gene expression, but it does this through mechanisms that do not involve a PDZ domain.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Bias-Free Linear Iterative Scatter Search) technique is based on the following principles:\n1. Linear Iterative Scatter Search (LISS): BLISS uses a linear iterative scatter search algorithm to find the optimal parameters for the model. This algorithm starts with an initial set of parameters and iteratively updates them to minimize the distance between the observed and predicted data.\n2. Bias-Free: BLISS is designed to be bias-free, meaning that it does not make any assumptions about the distribution of the data. This is in contrast to other optimization methods, such as maximum likelihood estimation, which can be biased towards certain parameter values.\n3. Non-linear least squares: BLISS uses a non-linear least squares optimization method to find the optimal parameters for the model. This method is more flexible than linear least squares and can handle more complex relationships between the observed and predicted data.\n4. Gradient-based optimization: BLISS uses a gradient-based optimization method to search for the optimal parameters. This method is efficient and can converge quickly to the optimal parameters.\n5. Parallel computing: BLISS can be parallelized, which allows it to take advantage of multiple processors or cores to speed up the optimization process.\nOverall, the BLISS technique is a powerful optimization method that can be used to fit complex models to data in a bias-free and efficient manner.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique uses a linear iterative scatter search algorithm to find optimal model parameters.\n2. The BLISS technique is designed to be bias-free and does not make assumptions about the data distribution.\n3. The BLISS technique employs a non-linear least squares optimization method.\n4. A gradient-based optimization method is used in the BLISS technique.\n5. The BLISS technique can utilize parallel computing to speed up the optimization process.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique uses a linear iterative scatter search algorithm to find optimal model parameters.",
      "The BLISS technique is designed to be bias-free and does not make assumptions about the data distribution.",
      "The BLISS technique employs a non-linear least squares optimization method.",
      "A gradient-based optimization method is used in the BLISS technique.",
      "The BLISS technique can utilize parallel computing to speed up the optimization process."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The acronym BLISS has been used for various things, but one known scientific application is the \"Baseline Inference with Least Squares\" technique, which is not necessarily associated with a linear iterative scatter search algorithm. Instead, it's a method used in the field of astronomy for modeling correlated noise in time-series data, particularly from exoplanet transits.\n   \n2. UNKNOWN: Without additional specific context on which BLISS technique this statement is referring to, it's difficult to confirm the statement. If it's related to the aforementioned \"Baseline Inference with Least Squares\" technique in astronomy, it generally aims to minimize bias, but no technique is entirely free from assumptions. Every statistical method has some level of assumption about the data.\n   \n3. TRUE: If we consider the BLISS technique in the context of astronomy, it does use a form of least squares optimization method to infer the systematic trends in data, which is non-linear in the parameters it seeks to estimate.\n   \n4. FALSE [correction]: The BLISS technique as used in astronomy with least squares optimization does not necessarily employ a gradient-based optimization method. It uses the least squares to find the best fit to the data, which may not require the computation of gradients as in gradient-based methods.\n   \n5. UNKNOWN: The ability for the BLISS technique to utilize parallel computing for speeding up the process is not specified here. In high-performance computing, many algorithms can be parallelized to some extent, but without specific details, it's difficult to determine the truth of this statement for the BLISS technique.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Sure! Here are three NK3R (neurokinin 3 receptor) antagonists:\n1. A-83-01: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including migraine, gastrointestinal disorders, and cancer.\n2. L-733,060: A highly selective NK3R antagonist that has been shown to have potential in the treatment of migraine and other neurological disorders.\n3. ML1303: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including migraine, gastrointestinal disorders, and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-83-01 is a potent and selective NK3R antagonist with potential applications in treating migraines, gastrointestinal disorders, and cancer.\n2. L-733,060 is a highly selective NK3R antagonist with potential applications in treating migraines and other neurological disorders.\n3. ML1303 is a potent and selective NK3R antagonist with potential applications in treating migraines, gastrointestinal disorders, and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "A-83-01 is a potent and selective NK3R antagonist with potential applications in treating migraines, gastrointestinal disorders, and cancer.",
      "L-733,060 is a highly selective NK3R antagonist with potential applications in treating migraines and other neurological disorders.",
      "ML1303 is a potent and selective NK3R antagonist with potential applications in treating migraines, gastrointestinal disorders, and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nSince the provided statements contain specific scientific information about chemical compounds (A-83-01, L-733,060, and ML1303) and their applications, without access to the relevant scientific literature or databases, it is not possible for me to confirm the accuracy of these statements. Thus, they remain unknown without further research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, the only approved cholera vaccine in the United States, has been shown to provide protection against moderate to severe cholera in clinical trials.\nThe protective efficacy of Vaxchora against moderate to severe cholera was demonstrated in a phase 3 clinical trial conducted in Bangladesh, where the vaccine was evaluated in over 40,000 participants, including children and adults, over a period of 3 years. The results of the trial showed that Vaxchora provided 80% protection against moderate to severe cholera, including 74% protection against severe cholera, compared to placebo.\nAdditionally, a post-hoc analysis of the trial data suggested that Vaxchora may provide long-term protection against cholera, with continued protection observed for up to 5 years after vaccination.\nIt's important to note that while Vaxchora has been shown to be effective in preventing moderate to severe cholera, it is not 100% effective, and it does not provide complete protection against all cases of cholera. Therefore, it is still important to practice good hygiene and sanitation practices, such as proper handwashing and water treatment, to reduce the risk of cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the only approved cholera vaccine in the United States.\n2. A phase 3 clinical trial in Bangladesh demonstrated that Vaxchora provides protection against moderate to severe cholera.\n3. The phase 3 clinical trial of Vaxchora included over 40,000 participants, both children and adults.\n4. Vaxchora provided 80% protection against moderate to severe cholera and 74% protection against severe cholera compared to placebo.\n5. A post-hoc analysis suggested that Vaxchora may provide protection against cholera for up to 5 years after vaccination.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the only approved cholera vaccine in the United States.",
      "A phase 3 clinical trial in Bangladesh demonstrated that Vaxchora provides protection against moderate to severe cholera.",
      "The phase 3 clinical trial of Vaxchora included over 40,000 participants, both children and adults.",
      "Vaxchora provided 80% protection against moderate to severe cholera and 74% protection against severe cholera compared to placebo.",
      "A post-hoc analysis suggested that Vaxchora may provide protection against cholera for up to 5 years after vaccination."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The available information does not specify the number of participants in the phase 3 clinical trial for Vaxchora; thus, it cannot be confirmed if the trial included over 40,000 participants. Clinical trials for vaccines commonly have thousands of participants; however, 40,000 is a specific figure that requires validation from a reliable source.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine (OCV), also known as the killed oral cholera vaccine, which was approved in 1991.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine (OCV). \n2. The oral cholera vaccine approved in the US is known as the killed oral cholera vaccine. \n3. The oral cholera vaccine was approved in the United States in 1991.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).",
      "The oral cholera vaccine approved in the US is known as the killed oral cholera vaccine.",
      "The oral cholera vaccine was approved in the United States in 1991."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The oral cholera vaccine, known as Vaxchora, was approved in the United States in 2016.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain. These genes are located on the X chromosome and are responsible for the development and function of B cells and T cells, which are important components of the adaptive immune system. Mutations in these genes can lead to a deficiency in the production of functional immunoglobulins and T cells, resulting in the symptoms of CVID.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. The genes responsible for the development and function of B cells and T cells are located on the X chromosome.\n3. Mutations in these X-linked genes can lead to a deficiency in the production of functional immunoglobulins and T cells.\n4. Such mutations can result in the symptoms associated with common variable immunodeficiency (CVID).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "The genes responsible for the development and function of B cells and T cells are located on the X chromosome.",
      "Mutations in these X-linked genes can lead to a deficiency in the production of functional immunoglobulins and T cells.",
      "Such mutations can result in the symptoms associated with common variable immunodeficiency (CVID)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in genes encoding components of the B-cell receptor signaling pathway (like ICOS, TACI, BAFFR) and others are more commonly associated with common variable immunodeficiency (CVID), not the genes for IGH or TCR, which are not typically X-linked.\n2. FALSE [correction]: The genes responsible for the development and function of B cells and T cells are not exclusively located on the X chromosome; they are distributed across various chromosomes, including both autosomes and sex chromosomes.\n3. TRUE: Mutations in genes that affect the function of B cells and T cells can indeed lead to a deficiency in the production of functional immunoglobulins (antibodies) and T cells.\n4. TRUE: Mutations that impair B-cell and T-cell function can result in the symptoms associated with common variable immunodeficiency (CVID), such as recurrent infections due to the deficiency in the immune response.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated in some patients with Systemic Lupus Erythematosus (SLE), an autoimmune disease. The IFIT1 gene encodes a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which plays a role in the regulation of the immune response. Studies have shown that mutations in the IFIT1 gene can lead to an overactive immune response and contribute to the development of SLE. Specifically, IFIT1 mutations can lead to the production of aberrant autoantibodies and the activation of autoreactive T cells, which are thought to be involved in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is associated with Systemic Lupus Erythematosus (SLE), an autoimmune disease.\n2. The IFIT1 gene encodes a protein known as interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).\n3. Mutations in the IFIT1 gene can lead to an overactive immune response.\n4. IFIT1 mutations may result in the production of aberrant autoantibodies.\n5. IFIT1 mutations may activate autoreactive T cells, which are thought to play a role in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is associated with Systemic Lupus Erythematosus (SLE), an autoimmune disease.",
      "The IFIT1 gene encodes a protein known as interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).",
      "Mutations in the IFIT1 gene can lead to an overactive immune response.",
      "IFIT1 mutations may result in the production of aberrant autoantibodies.",
      "IFIT1 mutations may activate autoreactive T cells, which are thought to play a role in the pathogenesis of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE), as it plays a role in the immune response.\n2. TRUE: The IFIT1 gene does indeed encode a protein known as interferon-induced protein with tetratricopeptide repeats 1.\n3. TRUE: Mutations in the IFIT1 gene may lead to an altered or overactive immune response, which is a characteristic observed in autoimmune diseases such as SLE.\n4. TRUE: IFIT1 mutations may potentially result in the production of autoantibodies, which are characteristic of SLE as the immune system mistakenly targets the body's own tissues.\n5. TRUE: Autoreactive T cells are implicated in the pathogenesis of SLE, and genes affecting immune response like IFIT1 may contribute to their activation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow symptoms and disability in patients with elbow conditions such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis). The score assesses the severity of pain, stiffness, and weakness in the elbow, as well as the impact on daily activities. The LES is used to monitor the effectiveness of treatment and to evaluate the progression of the condition over time. It is a useful tool for clinicians to assess the severity of elbow symptoms and to make informed decisions about treatment options.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability.\n2. LES is a patient-reported outcome measure.\n3. The LES is utilized for conditions such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis).\n4. The score evaluates factors like pain, stiffness, and weakness in the elbow, as well as the impact on daily activities.\n5. The LES is used to monitor treatment effectiveness and to evaluate the progression of elbow conditions over time.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability.",
      "LES is a patient-reported outcome measure.",
      "The LES is utilized for conditions such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis).",
      "The score evaluates factors like pain, stiffness, and weakness in the elbow, as well as the impact on daily activities.",
      "The LES is used to monitor treatment effectiveness and to evaluate the progression of elbow conditions over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics initiative launched in the UK in 2012, with the goal of analyzing the genomes of 100,000 patients with rare and/or complex diseases, including sarcoma. Here are some key efforts related to sarcoma from the 100,000 Genomes Project:\n1. Data collection: The 100,000 Genomes Project collected genomic data from a large number of sarcoma patients, including both adult and pediatric cases. The project aimed to collect data from a diverse range of sarcoma subtypes, including soft tissue sarcoma, bone sarcoma, and chondrosarcoma.\n2. Whole-genome sequencing: The project used whole-genome sequencing (WGS) to analyze the genomes of sarcoma patients. WGS involves sequencing the entire DNA molecule of an individual, rather than just a specific gene or region. This approach allows researchers to identify genetic mutations and variations that may be associated with sarcoma development and progression.\n3. Transcriptome analysis: In addition to WGS, the 100,000 Genomes Project also analyzed the transcriptome (the set of RNA molecules present in a cell or tissue) of sarcoma patients. This allowed researchers to identify changes in gene expression that may be associated with sarcoma development and progression.\n4. Identification of novel mutations: The 100,000 Genomes Project identified a number of novel mutations in sarcoma genes, including those that had not been previously reported. These findings have helped to expand our understanding of the genetic landscape of sarcoma and may lead to the development of new diagnostic and therapeutic strategies.\n5. Improved understanding of sarcoma subtypes: The project provided insights into the genetic differences between different subtypes of sarcoma, such as leiomyosarcoma and liposarcoma. This knowledge may help to improve the diagnosis and treatment of these subtypes.\n6. Identification of potential therapeutic targets: The 100,000 Genomes",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2012.\n2. The project aimed to analyze the genomes of 100,000 patients, including those with sarcoma.\n3. The initiative collected genomic data from a diverse range of sarcoma subtypes, including soft tissue sarcoma, bone sarcoma, and chondrosarcoma.\n4. Whole-genome sequencing was used to analyze the genomes of sarcoma patients in the project.\n5. The project identified novel mutations in sarcoma genes that had not been previously reported.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2012.",
      "The project aimed to analyze the genomes of 100,000 patients, including those with sarcoma.",
      "The initiative collected genomic data from a diverse range of sarcoma subtypes, including soft tissue sarcoma, bone sarcoma, and chondrosarcoma.",
      "Whole-genome sequencing was used to analyze the genomes of sarcoma patients in the project.",
      "The project identified novel mutations in sarcoma genes that had not been previously reported."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in the UK in 2013.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, protein ALEX1 (Armadillo-like protein 1) contains multiple armadillo repeats. Armadillo repeats are a structural motif found in proteins that are involved in protein-protein interactions and are characterized by a conserved sequence of about 40-60 amino acids, often found in a repeating pattern. ALEX1 is one of the proteins that contains armadillo repeats, and it is known to be involved in various cellular processes, including cell adhesion, migration, and signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo repeats.\n2. Armadillo repeats are a structural motif involved in protein-protein interactions.\n3. Armadillo repeats are characterized by a conserved sequence of about 40-60 amino acids.\n4. ALEX1 is involved in cellular processes such as cell adhesion, migration, and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo repeats.",
      "Armadillo repeats are a structural motif involved in protein-protein interactions.",
      "Armadillo repeats are characterized by a conserved sequence of about 40-60 amino acids.",
      "ALEX1 is involved in cellular processes such as cell adhesion, migration, and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "There are several enzymes that remove histone modifications, including:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM5A, KDM5B, and JMJD2A.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC6.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from histone H3 lysine 4 (H3K4), leading to changes in chromatin structure and gene expression.\n5. Arginine methyltransferases: These enzymes add methyl groups to histone arginine residues, leading to changes in chromatin structure and gene expression. Examples of arginine methyltransferases include PRMT1 and PRMT5.\n6. Protein arginine methyltransferases (PRMTs): These enzymes add methyl groups to arginine residues on histone proteins, leading to changes in chromatin structure and gene expression. Examples of PRMTs include PRMT1, PRMT5, and PRMT6.\n7. Histone-lysine N-methyltransferases: These enzymes add methyl groups to histone lysine residues, leading to changes in chromatin structure and gene expression. Examples of histone-lysine N-methyltransferases include SETDB1 (also known as EHMT2) and EHMT1.\n8. SUV39H1: This enzyme removes methyl groups from histone H3 lysine 9 (H3K9), leading to",
    "llama-2-7b-chat-hf_fact_raw": "1. KDM5A, KDM5B, and JMJD2A are examples of histone demethylases that remove methyl groups from histone proteins.\n2. p300 and CBP (CREB-binding protein) are examples of histone acetyltransferases (HATs) that add acetyl groups to histone proteins.\n3. HDAC1, HDAC2, and HDAC6 are examples of histone deacetylases (HDACs) that remove acetyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).\n5. SUV39H1 is described as an enzyme that removes methyl groups from histone H3 lysine 9 (H3K9), although this enzyme is recognized for adding methyl groups, not removing them, so this statement is incorrect based on established scientific knowledge.",
    "llama-2-7b-chat-hf_fact": [
      "KDM5A, KDM5B, and JMJD2A are examples of histone demethylases that remove methyl groups from histone proteins.",
      "p300 and CBP (CREB-binding protein) are examples of histone acetyltransferases (HATs) that add acetyl groups to histone proteins.",
      "HDAC1, HDAC2, and HDAC6 are examples of histone deacetylases (HDACs) that remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).",
      "SUV39H1 is described as an enzyme that removes methyl groups from histone H3 lysine 9 (H3K9), although this enzyme is recognized for adding methyl groups, not removing them, so this statement is incorrect based on established scientific knowledge."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: SUV39H1 is an enzyme that adds methyl groups to histone H3 lysine 9 (H3K9), not one that removes them. It is known as a histone methyltransferase (HMT).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Yes, head CT scans have been associated with an increased risk of brain tumors, particularly benign meningioma. This is because head CT scans involve exposure to ionizing radiation, which can increase the risk of cancer. The risk is generally considered to be low, but it is higher in people who have had many head CT scans over time. It is important to weigh the benefits of a head CT scan against the potential risks, particularly for children and young adults, and to discuss the appropriate use of CT scans with a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans have been associated with an increased risk of brain tumors, particularly benign meningioma.\n2. Head CT scans involve exposure to ionizing radiation which can increase the risk of cancer.\n3. The risk of developing brain tumors from head CT scans is generally considered to be low.\n4. The risk of brain tumors increases with the number of head CT scans a person has over time.\n5. The use of CT scans should be discussed with a healthcare provider, especially for children and young adults.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans have been associated with an increased risk of brain tumors, particularly benign meningioma.",
      "Head CT scans involve exposure to ionizing radiation which can increase the risk of cancer.",
      "The risk of developing brain tumors from head CT scans is generally considered to be low.",
      "The risk of brain tumors increases with the number of head CT scans a person has over time.",
      "The use of CT scans should be discussed with a healthcare provider, especially for children and young adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development, but not specifically with neural pluripotency. Otx2 is a homeobox gene that plays a role in the development of the brain and sensory organs. The concept of \"neural pluripotency\" typically refers to the ability of cells to develop into various types of neural cells, a characteristic associated with neural stem cells or induced pluripotent stem cells (iPSCs), rather than with the role of specific genes like Otx2.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region contains several DNase I hypersensitive sites (DHS), which are regions of chromatin that are more accessible to DNase I digestion due to the absence of compact chromatin structure. The exact number of DHS regions in the murine beta globin locus region can vary depending on the specific method used to identify them and the cell type being studied, but generally, there are several DHS regions located throughout the locus.\nSome of the well-characterized DHS regions in the murine beta globin locus include:\n1. DHS1: located at the 5' end of the beta globin gene cluster, spanning the promoter and the first exon.\n2. DHS2: located near the middle of the beta globin gene cluster, spanning the second exon.\n3. DHS3: located at the 3' end of the beta globin gene cluster, spanning the third exon and the 3' untranslated region (UTR).\n4. DHS4: located near the centromere of chromosome 7, which is the location of the beta globin gene cluster.\nThese DHS regions are thought to play important roles in regulating the expression of the beta globin genes, including the recruitment of transcription factors and other regulatory proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. DNase I hypersensitive sites (DHS) are regions of chromatin more accessible to DNase I digestion due to the absence of compact chromatin structure.\n2. The exact number of DHS regions in the murine beta globin locus region can vary depending on the identification method used and the cell type being studied.\n3. DHS1 is located at the 5' end of the beta globin gene cluster, spanning the promoter and the first exon.\n4. DHS2 is located near the middle of the beta globin gene cluster, spanning the second exon.\n5. DHS4 is located near the centromere of chromosome 7, where the beta globin gene cluster is located.",
    "llama-2-7b-chat-hf_fact": [
      "DNase I hypersensitive sites (DHS) are regions of chromatin more accessible to DNase I digestion due to the absence of compact chromatin structure.",
      "The exact number of DHS regions in the murine beta globin locus region can vary depending on the identification method used and the cell type being studied.",
      "DHS1 is located at the 5' end of the beta globin gene cluster, spanning the promoter and the first exon.",
      "DHS2 is located near the middle of the beta globin gene cluster, spanning the second exon.",
      "DHS4 is located near the centromere of chromosome 7, where the beta globin gene cluster is located."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The murine beta globin gene cluster is located on chromosome 11, not chromosome 7. DHS4's location relative to the centromere has not been specified in the given statements, so its exact location in relation to the centromere cannot be confirmed here.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "There are several European influenza vaccines that are approved for use in the European Union (EU) and other countries. Here are some of them:\n1. Fluzone (Sanofi Pasteur): This is a quadrivalent vaccine that protects against four strains of influenza virus: two A strains and two B strains.\n2. Fluarix (GlaxoSmithKline): This is a quadrivalent vaccine that provides protection against the same four strains as Fluzone.\n3. Aggrivax (BioProtection Sciences): This is a quadrivalent vaccine that provides protection against four strains of influenza virus, including two A strains and two B strains.\n4. Vaxigrip (Sanofi Pasteur): This is a trivalent vaccine that protects against three strains of influenza virus: two A strains and one B strain.\n5. FluMist (MedImmune): This is a live, attenuated quadrivalent vaccine that provides protection against four strains of influenza virus: two A strains and two B strains.\n6. Influvac (Bio-Medica): This is a trivalent vaccine that protects against three strains of influenza virus: two A strains and one B strain.\n7. Focetria (GlaxoSmithKline): This is a quadrivalent vaccine that provides protection against four strains of influenza virus: two A strains and two B strains.\n8. Fluad (GlaxoSmithKline): This is a quadrivalent vaccine that provides protection against four strains of influenza virus: two A strains and two B strains.\n9. Vaxchora (Wyeth): This is a trivalent vaccine that protects against three strains of influenza virus: two A strains and one B strain.\nIt's important to note that the availability and composition of these vaccines may vary by country and year, and that this list is not exhaustive. Additionally, there may be other European influenza vaccines available in the market that are not listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluzone is a quadrivalent influenza vaccine approved for use in the European Union.\n2. Fluarix is a quadrivalent influenza vaccine that protects against four strains of the influenza virus.\n3. Vaxigrip is a trivalent influenza vaccine that protects against three strains of the influenza virus.\n4. FluMist is a live, attenuated quadrivalent influenza vaccine approved for use in the European Union.\n5. Fluad is a quadrivalent influenza vaccine that provides protection against four strains of influenza virus.",
    "llama-2-7b-chat-hf_fact": [
      "Fluzone is a quadrivalent influenza vaccine approved for use in the European Union.",
      "Fluarix is a quadrivalent influenza vaccine that protects against four strains of the influenza virus.",
      "Vaxigrip is a trivalent influenza vaccine that protects against three strains of the influenza virus.",
      "FluMist is a live, attenuated quadrivalent influenza vaccine approved for use in the European Union.",
      "Fluad is a quadrivalent influenza vaccine that provides protection against four strains of influenza virus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN: The statement may be true if Vaxigrip hasn't changed their formulation, but there are versions of Vaxigrip that are quadrivalent. The accuracy of this statement would depend on the specific version/formulation of Vaxigrip being referred to.\n4. UNKNOWN: FluMist is a live, attenuated quadrivalent influenza vaccine, but it is primarily known for its approval and use in the United States. The specific approval status in the European Union as of my last knowledge update in 2023 requires verification.\n5. FALSE [correction]: Fluad is not a quadrivalent but a trivalent influenza vaccine with an adjuvant designed to create a stronger immune response. It's intended to protect against three strains of the influenza virus, not four. However, there could be newer formulations that are quadrivalent, and the status should be verified with the most recent information available.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and parainfluenza. Their genome is composed of several segments of negative-sense RNA, which are transcribed in the opposite direction to the direction of transcription. Each segment is called a gene segment, and each segment encodes a different protein. The segments are connected by non-coding regions called introns, and the entire genome is translated into protein through a process called transcription and translation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. Paramyxoviruses include viruses that cause measles, mumps, and parainfluenza.\n3. The genome of Paramyxoviruses is composed of several segments.\n4. Each genome segment of a Paramyxovirus encodes a different protein.\n5. The genome segments are connected by non-coding regions called introns.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "Paramyxoviruses include viruses that cause measles, mumps, and parainfluenza.",
      "The genome of Paramyxoviruses is composed of several segments.",
      "Each genome segment of a Paramyxovirus encodes a different protein.",
      "The genome segments are connected by non-coding regions called introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The genome of Paramyxoviruses is non-segmented.\n4. FALSE [correction]: Since Paramyxoviruses have a non-segmented genome, they do not have genome segments that encode different proteins. Instead, their genome consists of a single strand of RNA that encodes all the viral proteins.\n5. FALSE [correction]: Paramyxoviruses do not have introns in their genome because introns are non-coding regions found within the genes of eukaryotic organisms, not in the RNA genome of negative-sense RNA viruses.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. It is a topical phosphodiesterase 4 (PDE4) inhibitor that helps to reduce inflammation and slow down the growth of skin cells, thereby improving the symptoms of psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. Roflumilast cream acts as a phosphodiesterase 4 (PDE4) inhibitor.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "Roflumilast cream acts as a phosphodiesterase 4 (PDE4) inhibitor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Some of the commonly used tools include:\n1. CpG Island Finder: This tool identifies regions of the genome that are enriched in the dinucleotide CpG dinucleotide, which are often found near ncRNA promoters.\n2. ProbeFinder: This tool identifies putative ncRNA promoters by searching for sequences with high GC content, a high number of CpG dinucleotides, and a high degree of conservation across different species.\n3. RNApromoter: This tool uses a combination of sequence and structural features to predict the location and strength of ncRNA promoters.\n4. PICTAR: This tool uses a machine learning approach to identify ncRNA promoters based on a combination of sequence and structural features.\n5. DeepSEA: This tool uses a deep learning approach to predict ncRNA promoters by analyzing the chromatin structure and the distribution of transcription factors near potential ncRNA transcription start sites.\n6. RNApromoter2: This tool is an updated version of the RNApromoter tool, which uses a more comprehensive set of features to predict ncRNA promoters with improved accuracy.\n7. ncRNA-Pro: This tool predicts ncRNA promoters based on a combination of sequence, structural, and functional features, including the presence of CpG islands, the degree of conservation across different species, and the presence of transcription factor binding sites.\n8. ncRNA-Pro2: This tool is an updated version of the ncRNA-Pro tool, which uses a more comprehensive set of features to predict ncRNA promoters with improved accuracy.\n9. RNApromoter3: This tool is a more recent version of the RNApromoter tool, which uses a more sophisticated machine learning algorithm to predict ncRNA promoters with improved accuracy.\n10. DeepSEA-RNA: This tool is a combination of the DeepSEA tool and the RNApromoter3 tool, which uses a deep learning approach to predict ncRNA promoters with",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies regions enriched in CpG dinucleotides near ncRNA promoters.\n2. ProbeFinder searches for putative ncRNA promoters by examining sequences with high GC content and conservation across species.\n3. RNApromoter predicts ncRNA promoters using sequence and structural features.\n4. PICTAR employs a machine learning approach to identify ncRNA promoters.\n5. DeepSEA uses a deep learning methodology to predict ncRNA promoters by analyzing chromatin structure and transcription factor distribution.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies regions enriched in CpG dinucleotides near ncRNA promoters.",
      "ProbeFinder searches for putative ncRNA promoters by examining sequences with high GC content and conservation across species.",
      "RNApromoter predicts ncRNA promoters using sequence and structural features.",
      "PICTAR employs a machine learning approach to identify ncRNA promoters.",
      "DeepSEA uses a deep learning methodology to predict ncRNA promoters by analyzing chromatin structure and transcription factor distribution."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ProbeFinder does not specifically search for ncRNA promoters based on high GC content and conservation across species. Also, its primary purpose might not be described in the statement provided.\n3. UNKNOWN: The statement may refer to a specific tool or method, but without further details, it's unclear whether \"RNApromoter\" exists and whether it predicts ncRNA promoters using sequence and structural features. This requires validation from a reliable source.\n4. UNKNOWN: PICTAR is known for its role in predicting microRNA targets, not necessarily ncRNA promoters. The method's application might not be accurately described in the statement provided.\n5. UNKNOWN: DeepSEA is known for predicting the effects of noncoding variants on chromatin features and gene expression, but its specific application to ncRNA promoter prediction is not clear from the statement provided. Further details are needed to verify the claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like 1) is a chromatin remodeling gene that has been implicated in various cancers, including glioblastoma. Here are some examples of genes that SWIM tool has identified as down-regulated in glioblastoma:\n1. SWIM1: The gene encoding the SWIM1 protein, which is a chromatin remodeling factor that plays a crucial role in regulating gene expression by altering the chromatin structure.\n2. SNF5: The gene encoding the SNF5 protein, which is a subunit of the SNF complex, a chromatin remodeling complex that plays a key role in regulating gene expression by altering the chromatin structure.\n3. SMAR1: The gene encoding the SMAR1 protein, which is a member of the SWI/SNF chromatin remodeling complex and plays a crucial role in regulating gene expression by altering the chromatin structure.\n4. BRD4: The gene encoding the BRD4 protein, which is a member of the BET (bromodomain and extraterminal) protein family and plays a crucial role in regulating gene expression by altering the chromatin structure.\n5. BRIP1: The gene encoding the BRIP1 protein, which is a member of the BET protein family and plays a crucial role in regulating gene expression by altering the chromatin structure.\n6. ARMC8: The gene encoding the ARMC8 protein, which is a chromatin remodeling factor that plays a crucial role in regulating gene expression by altering the chromatin structure.\n7. CHD4: The gene encoding the CHD4 protein, which is a chromatin remodeling factor that plays a crucial role in regulating gene expression by altering the chromatin structure.\n8. BANF1: The gene encoding the BANF1 protein, which is a chromatin remodeling factor that plays a crucial role in regulating gene expression by altering the chromatin structure.\n9. PHF8: The gene encoding the PHF8 protein, which is a chromatin remodeling factor that plays a crucial role in regulating gene expression by altering the",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool identified the SWIM1 gene as down-regulated in glioblastoma.\n2. The SWIM tool identified the SNF5 gene as down-regulated in glioblastoma.\n3. The SWIM tool identified the SMAR1 gene as down-regulated in glioblastoma.\n4. The SWIM tool identified the BRD4 gene as down-regulated in glioblastoma.\n5. The SWIM tool identified the BRIP1 gene as down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool identified the SWIM1 gene as down-regulated in glioblastoma.",
      "The SWIM tool identified the SNF5 gene as down-regulated in glioblastoma.",
      "The SWIM tool identified the SMAR1 gene as down-regulated in glioblastoma.",
      "The SWIM tool identified the BRD4 gene as down-regulated in glioblastoma.",
      "The SWIM tool identified the BRIP1 gene as down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: The statements provided are very specific and require access to the particular study or scientific literature that mentions the SWIM tool and its findings related to the expression of genes in glioblastoma. Without access to this data or knowledge of the specifics of the SWIM tool and its findings, it is not possible to accurately determine the truthfulness of these statements. Thus, all responses are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Topological Associated Domains (TADs), including:\n1. TADtrack: This package provides a comprehensive framework for the analysis of TADs, including the identification of TAD boundaries, the analysis of TAD size and shape, and the integration of TAD data with other genomic features.\n2. TADseq: This package provides a set of tools for the analysis of TADs in RNA-seq data, including the identification of TADs, the analysis of TAD expression levels, and the integration of TAD data with other genomic features.\n3. TopoRNA: This package provides a set of tools for the analysis of TADs in RNA-seq data, including the identification of TADs, the analysis of TAD expression levels, and the integration of TAD data with other genomic features.\n4. TAD-seq2: This package provides a set of tools for the analysis of TADs in RNA-seq data, including the identification of TADs, the analysis of TAD expression levels, and the integration of TAD data with other genomic features.\n5. TAD-HMM: This package provides a set of tools for the analysis of TADs using hidden Markov models, including the identification of TADs, the analysis of TAD expression levels, and the integration of TAD data with other genomic features.\n6. TAD-clust: This package provides a set of tools for the clustering of TADs based on their genomic location and expression levels, including the identification of TAD clusters, the analysis of TAD cluster properties, and the integration of TAD cluster data with other genomic features.\n7. TAD-diff: This package provides a set of tools for the analysis of TADs in different cell types or conditions, including the identification of TADs, the analysis of TAD expression levels, and the integration of TAD data with other genomic features.\n8. TAD-map: This package provides a set of tools for the visualization and mapping of TADs in a genomic context, including the creation of TAD maps, the visualization of TAD boundaries, and the integration of TAD data with other genomic features.\n9. TAD-seq-tools: This package provides a set of tools for the analysis of T",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package TADtrack is developed for the analysis of Topologically Associated Domains, including identification of TAD boundaries and integration with other genomic features.\n2. TADseq is an R package designed to analyze TADs in RNA-seq data, and it includes tools for identifying TAD expression levels.\n3. TopoRNA is an R package with tools for the analysis of TADs in RNA-seq data, which encompasses TAD identification and expression level analysis.\n4. TAD-HMM is an R package that uses hidden Markov models for the analysis of TADs, including identification and expression level analysis.\n5. TAD-clust is an R package that enables clustering of TADs based on genomic location and expression levels, and includes analysis of TAD cluster properties.",
    "llama-2-7b-chat-hf_fact": [
      "The R package TADtrack is developed for the analysis of Topologically Associated Domains, including identification of TAD boundaries and integration with other genomic features.",
      "TADseq is an R package designed to analyze TADs in RNA-seq data, and it includes tools for identifying TAD expression levels.",
      "TopoRNA is an R package with tools for the analysis of TADs in RNA-seq data, which encompasses TAD identification and expression level analysis.",
      "TAD-HMM is an R package that uses hidden Markov models for the analysis of TADs, including identification and expression level analysis.",
      "TAD-clust is an R package that enables clustering of TADs based on genomic location and expression levels, and includes analysis of TAD cluster properties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TADseq is not an R package designed to analyze TADs in RNA-seq data. TADseq is not a recognized R package for this purpose, and the analysis of TADs is typically not directly relevant to RNA-seq data, which focuses on gene expression.\n3. FALSE [correction]: TopoRNA seems to be a fictitious R package, as there are no known R packages by that name associated with TAD analysis in RNA-seq data. RNA-seq data is generally analyzed for gene expression, and separate techniques and tools are used for TAD analysis.\n4. UNKNOWN: While TAD-HMM appears to be a plausible name for an R package that could use hidden Markov models to analyze TADs, without specific knowledge of every R package available as of the knowledge cutoff, it's not possible to confirm the existence or functionality of TAD-HMM.\n5. UNKNOWN: Similar to statement 4, TAD-clust could be a reasonable name for an R package, but without further information, the existence and features of TAD-clust cannot be confirmed as accurate or part of the R package ecosystem.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor package \"RankReg\" has been developed for accessing bacterial regulatory networks. RankReg is a tool for the analysis of transcriptional regulation in bacteria, and it allows for the inference of regulatory relationships between genes based on the analysis of gene expression data. It uses a Bayesian approach to rank genes based on their potential to be regulated by a given regulatory element, and it can be used to predict the regulatory interactions between genes and their regulatory elements.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bioconductor package \"RankReg\" is designed for accessing bacterial regulatory networks.\n2. RankReg is used for the analysis of transcriptional regulation in bacteria.\n3. The tool enables the inference of regulatory relationships between genes by analyzing gene expression data.\n4. RankReg utilizes a Bayesian approach to rank genes by their potential to be regulated by a regulatory element.\n5. RankReg can predict the regulatory interactions between genes and their regulatory elements.",
    "llama-2-7b-chat-hf_fact": [
      "The Bioconductor package \"RankReg\" is designed for accessing bacterial regulatory networks.",
      "RankReg is used for the analysis of transcriptional regulation in bacteria.",
      "The tool enables the inference of regulatory relationships between genes by analyzing gene expression data.",
      "RankReg utilizes a Bayesian approach to rank genes by their potential to be regulated by a regulatory element.",
      "RankReg can predict the regulatory interactions between genes and their regulatory elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bioconductor package \"RankProd\" is designed for analyzing gene expression data, not \"RankReg\". If \"RankReg\" is assumed to exist and pertain to regulatory networks, additional context is needed as the statement is vague.\n2. UNKNOWN: Without additional context, it is unclear whether \"RankReg\" (assuming it exists) is used for the analysis of transcriptional regulation in bacteria.\n3. UNKNOWN: It cannot be determined from the provided information whether \"RankReg\" enables the inference of regulatory relationships between genes by analyzing gene expression data.\n4. UNKNOWN: It is unclear from the statement whether \"RankReg\" utilizes a Bayesian approach to rank genes by their potential to be regulated by a regulatory element, as no specific details about \"RankReg\" were provided.\n5. UNKNOWN: There is not enough context to determine whether \"RankReg\" can predict the regulatory interactions between genes and their regulatory elements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are:\n1. Aromatic amino acids: phenylalanine, tyrosine, and tryptophan\n2. Quinones: coenzyme Q, menaquinone, and ubiquinone\n3. Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN)\n4. Tryptophan, which is converted into serotonin and melatonin in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. The end products of the shikimate pathway include the aromatic amino acids phenylalanine, tyrosine, and tryptophan.\n2. Coenzyme Q, menaquinone, and ubiquinone are quinones, which are end products of the shikimate pathway.\n3. Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are end products of the shikimate pathway.\n4. Tryptophan is an amino acid that can be converted into serotonin and melatonin in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The end products of the shikimate pathway include the aromatic amino acids phenylalanine, tyrosine, and tryptophan.",
      "Coenzyme Q, menaquinone, and ubiquinone are quinones, which are end products of the shikimate pathway.",
      "Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are end products of the shikimate pathway.",
      "Tryptophan is an amino acid that can be converted into serotonin and melatonin in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Coenzyme Q (also known as ubiquinone) and menaquinone are quinones, but they are not end products of the shikimate pathway. They are synthesized through different metabolic pathways in eukaryotes and prokaryotes, respectively.\n3. FALSE [correction]: Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are not end products of the shikimate pathway. They are coenzymes derived from riboflavin, which is synthesized through a different metabolic pathway.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that occurs after the removal of a pituitary tumor that was causing excessive production of growth hormone. Cabergoline is a dopamine receptor agonist that can help to reduce the excessive growth hormone production and alleviate the symptoms of Nelson's syndrome, such as rapid growth and enlargement of the hands, feet, and face, as well as other symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used in the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the removal of a pituitary tumor.\n3. This pituitary tumor was causing excessive production of growth hormone prior to its removal.\n4. Cabergoline is a dopamine receptor agonist.\n5. Symptoms of Nelson's syndrome may include rapid growth and enlargement of the hands, feet, and face.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used in the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the removal of a pituitary tumor.",
      "This pituitary tumor was causing excessive production of growth hormone prior to its removal.",
      "Cabergoline is a dopamine receptor agonist.",
      "Symptoms of Nelson's syndrome may include rapid growth and enlargement of the hands, feet, and face."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used in the treatment of conditions like prolactinomas and Parkinson's disease, not typically Nelson's syndrome. Nelson's syndrome involves ACTH excess, and treatment might include adrenal enzyme inhibitors or glucocorticoids.\n2. TRUE\n3. FALSE [correction]: The pituitary tumor in Nelson's syndrome typically causes excessive production of ACTH (adrenocorticotropic hormone), not growth hormone.\n4. TRUE\n5. FALSE [correction]: Symptoms of Nelson's syndrome include hyperpigmentation and symptoms associated with cortisol excess if not properly controlled, but the rapid growth and enlargement of the hands, feet, and face are symptoms of acromegaly, related to growth hormone excess, not Nelson's syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the nervous system. The main manifestation of Liebenberg syndrome is a combination of intellectual disability, seizures, and abnormalities in the structure and function of the brain. These abnormalities can include:\n1. Microcephaly: A small head size, which can be evident from birth or develop during early childhood.\n2. Cerebral cortex abnormalities: The outer layer of the brain, known as the cerebral cortex, can be misshapen or have abnormal folding, leading to impaired brain function.\n3. Thalamic hypoplasia: The thalamus is a part of the brain that helps regulate sensory information and motor control. In Liebenberg syndrome, the thalamus can be underdeveloped or abnormally shaped.\n4. Cerebellar hypoplasia: The cerebellum is responsible for coordinating movement and balance. In Liebenberg syndrome, the cerebellum can be underdeveloped or have abnormalities in its structure.\n5. Epilepsy: Seizures are a common feature of Liebenberg syndrome, and can occur in various forms, including generalized seizures, focal seizures, and Lennox-Gastaut syndrome.\n6. Sensory impairments: Individuals with Liebenberg syndrome may experience sensory impairments, including visual, auditory, and tactile deficits.\n7. Speech and language difficulties: Liebenberg syndrome can result in speech and language difficulties, including articulation problems, language impairments, and difficulty with communication.\n8. Autism spectrum disorder: Some individuals with Liebenberg syndrome may also have features of autism spectrum disorder, including social and communication impairments, and repetitive behaviors.\nIt is important to note that the severity and specific manifestations of Liebenberg syndrome can vary widely between individuals, even within the same family. A comprehensive diagnostic evaluation, including clinical examination, imaging studies, and genetic testing, is necessary for accurate diagnosis and appropriate management of the disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the nervous system.\n2. The main manifestation of Liebenberg syndrome includes intellectual disability, seizures, and abnormalities in brain structure and function.\n3. Microcephaly, which is a small head size, can occur in individuals with Liebenberg syndrome.\n4. Individuals with Liebenberg syndrome can exhibit cerebral cortex abnormalities.\n5. Epilepsy, presenting as various forms of seizures, is a common feature of Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the nervous system.",
      "The main manifestation of Liebenberg syndrome includes intellectual disability, seizures, and abnormalities in brain structure and function.",
      "Microcephaly, which is a small head size, can occur in individuals with Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome can exhibit cerebral cortex abnormalities.",
      "Epilepsy, presenting as various forms of seizures, is a common feature of Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no recognized medical condition known as \"Liebenberg syndrome.\" It's possible that the name is fictitious or misspelled.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince \"Liebenberg syndrome\" is not an established medical condition, the details regarding its manifestations and characteristics cannot be confirmed. If the condition is fictional or the name is incorrect, the related statements cannot be properly assessed for validity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Here are some orally bioavailable MPS1 kinase inhibitors:\n1. Vorinostat (Zolinza): Vorinostat is an HDAC (histone deacetylase) inhibitor that has been shown to inhibit MPS1 in various cancer cell lines.\n2. Romidepsin (Istodax): Romidepsin is another HDAC inhibitor that has been shown to inhibit MPS1 in various cancer cell lines.\n3. Panobinostat (Farydak): Panobinostat is a HDAC inhibitor that has been approved for the treatment of multiple myeloma. It has been shown to inhibit MPS1 in various cancer cell lines.\n4. AC253 (MCC950): AC253 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n5. SAR1005 (MCC945): SAR1005 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n6. MLN0128 (GDC-0128): MLN0128 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n7. GDC-0980 (R1626): GDC-0980 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n8. LBH-589 (LBH-02-2885): LBH-589 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n9. BAY-1000394 (GDC-0152): BAY-1000394 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 in various cancer cell lines.\n10. GDC-0159 (BAY-1",
    "llama-2-7b-chat-hf_fact_raw": "1. Vorinostat (Zolinza) is an HDAC inhibitor that is shown to inhibit MPS1 in various cancer cell lines.\n2. Romidepsin (Istodax) is an HDAC inhibitor that is shown to inhibit MPS1 in various cancer cell lines.\n3. Panobinostat (Farydak) is an HDAC inhibitor that has been approved for the treatment of multiple myeloma and is shown to inhibit MPS1 in various cancer cell lines.\n4. AC253 is a small molecule inhibitor of MPS1 that is shown to inhibit MPS1 in various cancer cell lines.\n5. SAR1005 is a small molecule inhibitor of MPS1 that is shown to inhibit MPS1 in various cancer cell lines.",
    "llama-2-7b-chat-hf_fact": [
      "Vorinostat (Zolinza) is an HDAC inhibitor that is shown to inhibit MPS1 in various cancer cell lines.",
      "Romidepsin (Istodax) is an HDAC inhibitor that is shown to inhibit MPS1 in various cancer cell lines.",
      "Panobinostat (Farydak) is an HDAC inhibitor that has been approved for the treatment of multiple myeloma and is shown to inhibit MPS1 in various cancer cell lines.",
      "AC253 is a small molecule inhibitor of MPS1 that is shown to inhibit MPS1 in various cancer cell lines.",
      "SAR1005 is a small molecule inhibitor of MPS1 that is shown to inhibit MPS1 in various cancer cell lines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vorinostat (Zolinza) is an HDAC inhibitor, but there is no specific evidence provided in the context that it inhibits MPS1 in various cancer cell lines.\n2. FALSE [correction]: Romidepsin (Istodax) is an HDAC inhibitor, but there is no specific evidence provided in the context that it inhibits MPS1 in various cancer cell lines.\n3. FALSE [correction]: Panobinostat (Farydak) is an HDAC inhibitor approved for the treatment of multiple myeloma, but there is no specific evidence provided in the context that it inhibits MPS1 in various cancer cell lines.\n4. UNKNOWN: Without context or reference to research, it’s unclear whether AC253 inhibits MPS1 in various cancer cell lines.\n5. UNKNOWN: Without context or reference to research, it’s unclear whether SAR1005 inhibits MPS1 in various cancer cell lines.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been studied for the treatment of diabetes. While it was initially approved by the FDA for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, it has also been investigated for its potential in treating type 2 diabetes.\nGolimumab has been shown to improve glycemic control and reduce inflammation in patients with type 2 diabetes in several clinical trials. For example, a phase IIb study published in The Lancet found that golimumab significantly improved glycemic control and reduced body weight in patients with type 2 diabetes compared to placebo. Another study published in Diabetes, Obesity and Metabolism found that golimumab improved glycemic control and reduced inflammatory markers in patients with type 2 diabetes and obesity.\nHowever, it is important to note that golimumab is not currently approved by the FDA for the treatment of diabetes, and more research is needed to fully understand its efficacy and safety in this population. Additionally, golimumab can have potential side effects, including infections and malignancies, which should be carefully considered when using this drug for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.\n2. The FDA originally approved golimumab for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis.\n3. Golimumab has been studied for the potential treatment of type 2 diabetes.\n4. A phase IIb study published in The Lancet reported that golimumab significantly improved glycemic control and reduced body weight in patients with type 2 diabetes compared to placebo.\n5. Golimumab is not currently approved by the FDA for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.",
      "The FDA originally approved golimumab for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis.",
      "Golimumab has been studied for the potential treatment of type 2 diabetes.",
      "A phase IIb study published in The Lancet reported that golimumab significantly improved glycemic control and reduced body weight in patients with type 2 diabetes compared to placebo.",
      "Golimumab is not currently approved by the FDA for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene. The LMNA gene provides instructions for making a protein called lamin A, which is involved in the structure and function of chromosomes. Mutations in the LMNA gene can lead to the production of a defective lamin A protein, which accumulates in the nucleus of cells and disrupts various cellular processes, including cell division and DNA repair. As a result, progeria is characterized by accelerated aging and a range of physical and developmental abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is caused by a mutation in the LMNA gene.\n3. The LMNA gene is responsible for providing instructions for making the protein lamin A.\n4. Mutations in the LMNA gene can lead to the production of a defective lamin A protein.\n5. Progeria is characterized by accelerated aging and physical and developmental abnormalities.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is responsible for providing instructions for making the protein lamin A.",
      "Mutations in the LMNA gene can lead to the production of a defective lamin A protein.",
      "Progeria is characterized by accelerated aging and physical and developmental abnormalities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Common variants at 12q14 and 12q24 have been associated with various diseases and conditions, including:\n12q14:\n* Type 2 diabetes: Variants at 12q14 are associated with an increased risk of developing type 2 diabetes.\n* Obesity: Some variants at 12q14 have been linked to obesity and body mass index (BMI).\n* Cardiovascular disease: There is evidence that variants at 12q14 may increase the risk of cardiovascular disease, including heart attack and stroke.\n12q24:\n* Breast cancer: Variants at 12q24 are associated with an increased risk of developing breast cancer, particularly in postmenopausal women.\n* Prostate cancer: Some variants at 12q24 have been linked to an increased risk of developing prostate cancer.\n* Other cancers: There is evidence that variants at 12q24 may also be associated with an increased risk of other cancers, such as ovarian and colorectal cancer.\nIt is important to note that the specific variants associated with each disease or condition can vary, and the overall risk of developing these conditions can depend on a complex interplay of multiple genetic and environmental factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 are associated with an increased risk of developing type 2 diabetes.\n2. Some variants at 12q14 have been linked to obesity and body mass index (BMI).\n3. Variants at 12q14 may increase the risk of cardiovascular disease, including heart attack and stroke.\n4. Variants at 12q24 are associated with an increased risk of developing breast cancer, particularly in postmenopausal women.\n5. Some variants at 12q24 have been linked to an increased risk of developing prostate cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 are associated with an increased risk of developing type 2 diabetes.",
      "Some variants at 12q14 have been linked to obesity and body mass index (BMI).",
      "Variants at 12q14 may increase the risk of cardiovascular disease, including heart attack and stroke.",
      "Variants at 12q24 are associated with an increased risk of developing breast cancer, particularly in postmenopausal women.",
      "Some variants at 12q24 have been linked to an increased risk of developing prostate cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truthfulness of these statements hinges on specific scientific evidence and research that discusses the associations between genetic variants at certain loci (like 12q14 and 12q24) and disease risks. Without access to that specific scientific data or the passage from which these statements were extracted, I cannot accurately confirm or deny these statements. They would require referencing current and reliable genetic research to determine their validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are the Robo ligands, which include:\n* Robo1\n* Robo2\n* Robo3\n* Robo4\nThese ligands bind to the extracellular domain of the Robo receptors, triggering intracellular signaling pathways that regulate various cellular processes, including cell migration, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of Roundabout (Robo) receptors include Robo1, Robo2, Robo3, and Robo4.\n2. These ligands bind to the extracellular domain of the Robo receptors.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of Roundabout (Robo) receptors include Robo1, Robo2, Robo3, and Robo4.",
      "These ligands bind to the extracellular domain of the Robo receptors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The ligands of Roundabout (Robo) receptors are not Robo1, Robo2, Robo3, and Robo4. These are the receptors themselves. The ligand known to bind these receptors is Slit.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I has been shown to play a role in megakaryopoiesis, which is the process of developing platelets in the bone marrow. TFII-I is a transcription factor that is involved in the regulation of gene expression, particularly in the context of hematopoiesis. Studies have shown that TFII-I is required for the proper differentiation of megakaryocytes, which are the precursor cells that give rise to platelets, and that it plays a role in regulating the expression of genes involved in platelet function and signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I plays a role in megakaryopoiesis, the process of developing platelets in the bone marrow.\n2. TFII-I is a transcription factor involved in the regulation of gene expression.\n3. TFII-I is required for the proper differentiation of megakaryocytes, the precursor cells to platelets.\n4. TFII-I regulates the expression of genes involved in platelet function and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I plays a role in megakaryopoiesis, the process of developing platelets in the bone marrow.",
      "TFII-I is a transcription factor involved in the regulation of gene expression.",
      "TFII-I is required for the proper differentiation of megakaryocytes, the precursor cells to platelets.",
      "TFII-I regulates the expression of genes involved in platelet function and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: While the statements appear to be reasonable based on the context of TFII-I's role in gene expression and megakaryopoiesis, without specific literature or research data, it's important to acknowledge that the details of these statements should be validated by scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by CYP2D6. CYP2D6 is an enzyme that is responsible for metabolizing a wide range of drugs, including atenolol. Atenolol is metabolized to its active metabolite, carvedilol, by CYP2D6 in the liver. The activity of CYP2D6 can vary greatly between individuals, leading to inter-individual differences in the metabolism and response to atenolol.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. CYP2D6 is an enzyme responsible for metabolizing a wide range of drugs.\n3. Atenolol is metabolized to its active metabolite carvedilol by CYP2D6 in the liver.\n4. The activity of CYP2D6 can vary greatly between individuals.\n5. There are inter-individual differences in the metabolism and response to atenolol due to varying CYP2D6 activity.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "CYP2D6 is an enzyme responsible for metabolizing a wide range of drugs.",
      "Atenolol is metabolized to its active metabolite carvedilol by CYP2D6 in the liver.",
      "The activity of CYP2D6 can vary greatly between individuals.",
      "There are inter-individual differences in the metabolism and response to atenolol due to varying CYP2D6 activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and therefore not by CYP2D6; it is excreted mainly in unchanged form in the urine.\n2. TRUE\n3. FALSE [correction]: Atenolol does not have an active metabolite carvedilol; carvedilol is a separate drug and not a metabolite of atenolol.\n4. TRUE\n5. UNKNOWN (While it's true that the activity of CYP2D6 can vary greatly between individuals and cause inter-individual differences in the metabolism of drugs metabolized by CYP2D6, atenolol is not significantly metabolized by this enzyme, which makes it difficult to determine the validity of the statement in the context of atenolol without additional context.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Expansion Hunter is a software tool used for identifying novel transcripts and splice junctions in RNA-seq data. Here are some versions of Expansion Hunter:\n1. Expansion Hunter 1.0: This is the original version of the software, released in 2012. It can be used to identify novel transcripts and splice junctions in RNA-seq data, and it includes a number of tools for filtering and visualizing the results.\n2. Expansion Hunter 2.0: This version was released in 2016 and includes a number of updates and improvements over the original version. It includes a new algorithm for identifying novel transcripts, as well as improved tools for filtering and visualizing the results.\n3. Expansion Hunter 2.1: This version was released in 2018 and includes a number of additional features, including the ability to identify novel splice junctions and to predict the functional consequences of alternative splicing events.\n4. Expansion Hunter 3.0: This is the latest version of the software, released in 2020. It includes a number of significant updates and improvements over previous versions, including the ability to analyze RNA-seq data with a higher resolution than ever before, and the ability to identify novel transcripts and splice junctions in a more accurate and efficient manner.\n5. Expansion Hunter Cloud: This is a cloud-based version of the software, released in 2020. It allows users to access the software and its features from any device with an internet connection, without the need to install any software on their local computer.\n6. Expansion Hunter Python API: This is a software development kit (SDK) for Expansion Hunter, released in 2020. It allows developers to integrate the functionality of Expansion Hunter into their own software applications, and to automate the analysis of RNA-seq data.",
    "llama-2-7b-chat-hf_fact_raw": "1. Expansion Hunter 1.0 was released in 2012.\n2. Expansion Hunter 2.0 was released in 2016.\n3. Expansion Hunter 2.1 was released in 2018.\n4. Expansion Hunter 3.0 was released in 2020.\n5. Expansion Hunter Cloud was also released in 2020.",
    "llama-2-7b-chat-hf_fact": [
      "Expansion Hunter 1.0 was released in 2012.",
      "Expansion Hunter 2.0 was released in 2016.",
      "Expansion Hunter 2.1 was released in 2018.",
      "Expansion Hunter 3.0 was released in 2020.",
      "Expansion Hunter Cloud was also released in 2020."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or knowledge of \"Expansion Hunter\" software version release history, I'm unable to verify the dates provided. The release dates of software products can be checked through official release notes or announcements by the developers, but such information is not available to me beyond my last update.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) is a secreted protein that plays a role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) activity. Adamts18 functions as a decoy receptor for ER, binding to ER ligands and preventing them from binding to their cognate receptors, thereby reducing the activity of the ER signaling pathway. This can have implications for various physiological processes, including cell growth, differentiation, and survival, and may be relevant in the context of hormone-sensitive cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a secreted protein involved in hormone receptor signaling.\n2. Adamts18 plays a role in the regulation of estrogen receptor (ER) activity.\n3. Adamts18 functions as a decoy receptor for the estrogen receptor by binding to ER ligands.\n4. The binding of Adamts18 to ER ligands prevents them from binding to their cognate receptors.\n5. Adamts18’s interaction with ER ligands can affect cell growth, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a secreted protein involved in hormone receptor signaling.",
      "Adamts18 plays a role in the regulation of estrogen receptor (ER) activity.",
      "Adamts18 functions as a decoy receptor for the estrogen receptor by binding to ER ligands.",
      "The binding of Adamts18 to ER ligands prevents them from binding to their cognate receptors.",
      "Adamts18’s interaction with ER ligands can affect cell growth, differentiation, and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Adamts18 is not known to function as a decoy receptor for the estrogen receptor by binding to ER ligands.\n4. FALSE [correction]: Since Adamts18 does not act as a decoy receptor for the estrogen receptor, it does not bind to ER ligands to prevent them from binding to their cognate receptors.\n5. TRUE, assuming that the interaction between Adamts18 and estrogen receptor signaling, as mentioned in statement 2, can influence these cellular processes. However, without specific evidence linking Adamts18 directly to the modulation of cell growth, differentiation, and survival through ER ligands, this statement's accuracy may vary based on additional context, and could be considered UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme histone deacetylase (HDAC). It works by binding to the HDAC enzyme and preventing it from deacetylating histone proteins, which are important components of chromatin structure. By inhibiting HDAC, thiazovivin can alter chromatin structure and expression of genes, leading to changes in cellular behavior. In particular, thiazovivin has been shown to inhibit the proliferation of cancer cells and induce apoptosis (cell death) in certain types of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an inhibitor of the enzyme histone deacetylase (HDAC).\n2. Thiazovivin operates by binding to the HDAC enzyme and preventing the deacetylation of histone proteins.\n3. Inhibition of HDAC by thiazovivin can change chromatin structure and gene expression.\n4. Thiazovivin has been shown to inhibit cancer cell proliferation.\n5. Thiazovivin can induce apoptosis in certain types of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an inhibitor of the enzyme histone deacetylase (HDAC).",
      "Thiazovivin operates by binding to the HDAC enzyme and preventing the deacetylation of histone proteins.",
      "Inhibition of HDAC by thiazovivin can change chromatin structure and gene expression.",
      "Thiazovivin has been shown to inhibit cancer cell proliferation.",
      "Thiazovivin can induce apoptosis in certain types of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the enzyme histone deacetylase (HDAC); it is a ROCK inhibitor, which inhibits Rho-associated protein kinase.\n2. FALSE [correction]: Thiazovivin does not operate by binding to the HDAC enzyme; since it is not an HDAC inhibitor, thiazovivin does not prevent the deacetylation of histone proteins, but rather affects the cytoskeleton by inhibiting ROCK.\n3. UNKNOWN: While it is true that HDAC inhibitors can change chromatin structure and gene expression, because thiazovivin is not an HDAC inhibitor, this statement's relevance to thiazovivin is unclear without additional context specifying its effects on chromatin structure and gene expression.\n4. UNKNOWN: The statement might be true, as various kinase inhibitors have been shown to inhibit cancer cell proliferation, but without specific evidence regarding thiazovivin's effects on cancer cells, the statement remains undetermined.\n5. UNKNOWN: Similar to the previous statement, without specific evidence regarding thiazovivin inducing apoptosis in cancer cells, the claim remains uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]